Cloning and functional characterization of novel genes expressed preferentially in the human retina by Stojic, Jelena
 
 
 
CLONING AND FUNCTIONAL CHARACTERIZATION OF 
NOVEL GENES EXPRESSED PREFERENTIALLY  
IN THE HUMAN RETINA 
 
 
 
 
 
 
 
DISSERTATION ZUR ERLANGUNG DES 
NATURWISSENSCHAFTLICHEN DOKTORGRADES 
DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG 
 
 
 
 
VORGELEGT VON 
JELENA STOJIC 
AUS BELGRAD 
SERBIEN UND MONTENEGRO 
 
 
 
WÜRZBURG, 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eingereicht am: 21.02.2005. 
Bei der Fakultät für Biologie 
 
Mitglieder der Promotionskommission: 
Vorsitzender:  Prof. Dr. Ulrich Scheer 
Gutachter:  Prof. Dr. Bernhard Weber 
Gutachter:  Prof. Dr. Roy Gross 
 
Tag des Promotionskolloquiums: 08.06.2005. 
Doktorurkunde ausgehändigt am: …………………. 
  
 
 
 
 
 
 
 
 
 
 
Erklärung gemäß §4, Absatz 3 der Promotionsordnung für die Fakultät für Biologie der 
Universität Würzburg: 
 
Hiermit erkläre ich, dass ich die vorliegende Dissertation selbständig durchgeführt und 
verfasst habe. 
Andere Quellen als die angegebenen Hilfsmittel und Quellen wurden nicht verwendet.  
Die Dissertation wurde weder in gleicher noch in ähnlicher Form in einem anderen 
Prüfungsverfahren vorgelegt. 
Es wurde zuvor kein anderer akademischer Grad erworben. 
 
Die vorliegende Arbeit wurde am Institut für Humangenetik der Universität Würzburg unter 
der Leitung von Prof. Bernhard H.F. Weber angefertigt. 
 
 
 
 
Würzburg, 2005  
 
 
Jelena Stojic  
ACKNOWLEDGMENTS 
 
 
First of all, I would like to thank Prof. Dr. Bernhard Weber for giving me the opportunity 
to do my Ph.D. thesis in his group and for his excellent scientific guidance during my studies. I 
would also like to thank Prof. Dr. Roy Gross who accepted to be supervisor of this thesis as a 
member of the Faculty of Biology at the University of Würzburg. 
 
I gladly express my appreciation to Dr. Heidi Stöhr for her support at the beginning of my 
doctorate degree. 
 
In particular, I would like to thank to my lab colleagues, Heidi Schulz for non-selfishly 
sharing her knowledge and being there when necessary to answer all the questions I had, always 
with a smile, and for doing with me virtual Northern blot analysis, Christine Wiedemann for 
helping me with the quantitative real-time PCR analysis, Franziska Krämer for her enthusiasm 
and generous assistance, Vladimir Milenkovic for having a lot of patience to solve the computer 
problems over and beyond the call of duty, Andrea Rivera and Andrea Gehrig for having patience 
and kindness to teach me many technical approaches, Andrea Welcker for the proofreading and 
translation assistance. I would also like to express my thanks to Claudia, Susanne, Ines, Nicole, 
Birgit, Sandra, Peter, Andreas, Johanna and Jürgen for the many social and scientific events we 
have shared during the time I spent in the lab and for friendly atmosphere. And much thanks to 
everybody for being patient to overcome the language barriers at my shaky start and for teaching 
me German. The diversity of the group members, combined with all the new cultural experiences 
gained from living in Würzburg, have furnished me with many fond memories, and have 
certainly broadened my horizons. 
 
I am very grateful to Prof. Dr. med. Holger Höhn, for providing an international 
atmosphere at the Institute of Human Genetics. To the secretary, Ilse Neumann, I would like to 
thank for the smooth running of things. 
 
Very special thanks to my landlady and landlord, Chris and Uwe Berndt, who made me 
feel truly accepted as the member of the family and made my stay in Würzburg wonderful 
experience. 
 
The greatest acknowledgement I reserve for my family in Belgrade, for their support, and 
for giving me the best start in life I could ever have hoped for, to whom I dedicate this 
Dissertation. 
 
 
 
Jelena Stojic  
 
 
 
Table of contents 
TABLE OF CONTENTS 
 
1 SUMMARY................................................................................................................................... 1 
 
2 ZUSAMMENFASSUNG.............................................................................................................. 4 
 
3 INTRODUCTION ........................................................................................................................ 8 
3.1 Organization of the retina ...................................................................................................... 8 
3.1.1 Photoreceptor cells ...................................................................................................... 10 
3.1.2 Phototransduction cascade .......................................................................................... 12 
3.2 Age related macular degeneration........................................................................................ 14 
3.2.1 Disease phenotype....................................................................................................... 14 
3.2.2 Risk factors in AMD ................................................................................................... 16 
3.2.3 The genetics of age-related macular degeneration ...................................................... 17 
3.2.4 Search for the complex disease genes ......................................................................... 20 
3.2.4.1 Genotyping single nucleotide polymorphisms (SNPs) ........................................... 21 
3.3 Goal of the thesis ................................................................................................................. 22 
 
4 MATERIALS AND METHODS ............................................................................................... 24 
4.1 Bioinformatics...................................................................................................................... 24 
4.1.1    Computational analysis of nucleotide sequences.............................................................. 24 
4.1.2 Computational analysis of amino acid sequences ....................................................... 24 
4.2 RNA Methods ...................................................................................................................... 25 
4.2.1 RNA sources ............................................................................................................... 25 
4.2.2  RNA isolation.............................................................................................................. 25 
4.2.2.1 Total RNA............................................................................................................... 25 
4.2.2.2 Cytoplasmic RNA................................................................................................... 26 
4.2.2.3 Poly(A)+ RNA......................................................................................................... 26 
4.2.3  Quantification of RNA................................................................................................ 26 
4.2.4  First-strand cDNA synthesis ....................................................................................... 27 
4.2.5  Northern blot ............................................................................................................... 27 
4.2.5.1      Agarose gel electrophoresis..................................................................................... 27 
4.2.5.2 Transfer to Nylon membrane .................................................................................. 28 
4.2.5.3 Radioactive random-prime probe labelling............................................................. 28 
4.2.5.4      Membrane hybridization ......................................................................................... 28 
4.3 DNA Methods...................................................................................................................... 29 
4.3.1 Phenol / chlorophorm extraction ................................................................................. 29 
4.3.2 Polymerase chain reaction (PCR) ............................................................................... 29 
4.3.2.1      Standard PCR .......................................................................................................... 29 
4.3.2.2      Quantitative Real-time PCR (qRT-PCR) ................................................................ 30 
4.3.3 Agarose gel electrophoresis ........................................................................................ 31 
4.3.4 DNA purification......................................................................................................... 32 
4.3.4.1 Purification of PCR products .................................................................................. 32 
4.3.4.2 Purification of plasmid DNA .................................................................................. 32 
4.3.4.3 Restriction enzyme digestion .................................................................................. 33 
4.3.4.4 Ligation and transformation.................................................................................... 33 
4.3.5 Sequencing .................................................................................................................. 34 
4.3.6 Virtual Northern blot analysis ..................................................................................... 34 
4.4 cDNA libraries ..................................................................................................................... 35 
4.4.1 Generation of a suppression subtracted cDNA library from the human retina ........... 35 
4.4.1.1    Sequencing of the clones from the library................................................................. 35 
Table of contents 
4.4.2 Full-length cDNA library ............................................................................................ 36 
4.4.2.1     Construction ............................................................................................................. 36 
4.4.2.1.1 First strand cDNA synthesis ................................................................................. 36 
4.4.2.1.2 Double strand cDNA synthesis and digestion....................................................... 38 
4.4.2.1.3 Size selection of ds cDNA .................................................................................... 38 
4.4.2.1.4 Ligation to λTriplEx2 vector and packaging......................................................... 39 
4.4.2.2 Determination of library titre .................................................................................. 39 
4.4.2.3 Library amplification .............................................................................................. 40 
4.4.2.4 Plating of phage library and preparation of replicas ............................................... 40 
4.4.2.5 Isolation of positive clones from the phage library................................................. 41 
4.4.2.6 Conversion of λTriplEx2 to pTriplEx2................................................................... 41 
4.5 Mammalian cell lines ........................................................................................................... 42 
4.5.1 ARPE-19 cell line........................................................................................................ 42 
4.5.2 Y79 cell line ................................................................................................................ 42 
4.5.3 EBNA-293 cell line..................................................................................................... 43 
4.5.3.1 Maintenance............................................................................................................ 43 
4.5.3.2 Transfection ............................................................................................................ 43 
4.5.3.3 Purification of recombinant proteins....................................................................... 44 
4.6 Nonsense mediated mRNA decay........................................................................................ 44 
4.6.1 Principle of the decay.................................................................................................. 44 
4.6.2 Inhibition of protein synthesis..................................................................................... 44 
4.7 RNA interference ................................................................................................................. 45 
4.7.1 Principle of RNA interference..................................................................................... 45 
4.7.2 siRNA design and sequences ...................................................................................... 46 
4.7.3 siRNA transfection...................................................................................................... 47 
4.8 Polyclonal antibody production ........................................................................................... 47 
4.8.1 Expression of recombinant fusion proteins ................................................................. 47 
4.8.2 Purification of GST fusion proteins ............................................................................ 48 
4.8.3 Immunization .............................................................................................................. 48 
4.8.4 Analysis of the immune response................................................................................ 49 
4.8.5 Western blot analyses.................................................................................................. 49 
4.8.5.1 SDS - polycrilamide gel electrophoresis (SDS-PAGE) .......................................... 49 
4.8.5.2 Immunoblotting....................................................................................................... 50 
 
5 RESULTS.................................................................................................................................... 51 
5.1 Evaluation of a cDNA library enriched for retinal transcripts by the suppression   
             subtraction hybridization (SSH) technique .......................................................................... 51 
5.1.2 Expression analysis ..................................................................................................... 52 
5.2 Construction of a human retina full-length cDNA library ................................................... 59 
5.2.1 Optimization of the conditions for the full-length cDNA library construction........... 59 
5.2.2 Evaluation of the human retina full-length cDNA library........................................... 62 
5.3 Cloning and characterization of retina specific genes.......................................................... 64 
5.3.1 Cloning and functional characterization of three novel ABCC5 splicing   
                 variants......................................................................................................................... 64 
5.3.1.1 Identification of the full-length cDNA sequences .................................................. 64 
5.3.1.2 Genomic structure................................................................................................... 66 
5.3.1.3 In-silico analysis of cDNA sequences ABCC5_SV1, ABCC5_SV2,   
                ABCC5_SV3............................................................................................................ 66         
5.3.1.4 Expression analysis................................................................................................. 69 
5.3.1.5 Functional characterization of the splice variants................................................... 71 
5.3.1.5.1 Nonsense mediated mRNA decay in isoform SV1 containing a premature   
               termination signal.................................................................................................. 71 
5.3.1.5.2 Silencing of SV1, SV2 and SV3 isoforms with siRNA duplexes......................... 74 
5.3.1.5.3 Characterization of truncated proteins .................................................................. 77 
5.3.1.5.4  Polyclonal antibody production ........................................................................... 78 
Table of contents 
5.3.1.6 Conservation of exons 5a, 5b and 5c of isoforms SV1, SV2 and SV3 ................... 79 
5.3.2 Cloning and characterization of the L33 gene............................................................. 81 
5.3.2.1 Identification of the full-length cDNA sequence .................................................... 81 
5.3.2.2 Genomic structure of L33 ....................................................................................... 82 
5.3.2.3 Expression analysis of L33 ..................................................................................... 83 
5.3.2.4 In-silico analysis of the cDNA sequence ................................................................ 84 
5.3.3 Cloning and characterization of the L35 gene............................................................. 87 
5.3.3.1 Identification of the full-length cDNA sequence .................................................... 87 
5.3.3.2 Genomic structure of L35 ....................................................................................... 89 
5.3.3.3 Expression analysis of L35 ..................................................................................... 90 
5.3.3.4 In-silico analysis of the cDNA sequence ................................................................ 91 
5.3.4 Cloning and characterization of the L37 gene............................................................. 93 
5.3.4.1 Identification of the full-length cDNA sequence .................................................... 93 
5.3.4.2 Genomic structure of L37 ....................................................................................... 95 
5.3.4.3 Expression analysis................................................................................................. 95 
5.3.4.4 Analysis of the L37 cDNA sequence...................................................................... 96 
5.3.5 Cloning and characterization of the L38 gene............................................................. 97 
5.3.5.1 Identification of the full-length cDNA sequence .................................................... 97 
5.3.5.2 Genomic structure of the L38 gene......................................................................... 99 
5.3.5.3 Expression analysis................................................................................................. 99 
5.3.5.4 In-silico analysis of the L38 cDNA sequence....................................................... 100 
5.3.6 Cloning and characterization of the L40 gene........................................................... 102 
5.3.6.1 Identification of the full-length cDNA sequence .................................................. 102 
5.3.6.2 Genomic structure of the L40 gene ............................................................................ 104 
5.3.6.3 Expression analysis............................................................................................... 105 
5.3.6.4 Analysis of the cDNA sequence ........................................................................... 106 
5.3.7 Identification of the single nucleotide polymorphisms (SNPs) in L33, L35 and L38   
         genes .................................................................................................................................. 108 
5.3.7.1 Identification of the single nucleotide polymorphisms (SNPs) in L33 gene.............. 108 
5.3.7.2 SNP analysis of the L35 gene..................................................................................... 109 
5.3.7.3 SNP analysis of the L38 gene..................................................................................... 111 
 
6 DISCUSSION............................................................................................................................ 112 
6.1 Identification of novel retinal transcripts ........................................................................... 112 
6.2 Cloning and characterization of L25 gene ......................................................................... 113 
6.2.1 Evidence for the coupling of alternative splicing and NMD..................................... 121 
6.2.2 RNA interference (RNAi) for gene knockdown ....................................................... 123 
6.3 Cloning and characterization of L33, L35 and L38 genes ................................................. 123 
6.3.1 Non-coding RNA genes ............................................................................................ 126 
6.4 Cloning and characterization of L40 gene ......................................................................... 131 
6.4.1 Overlapping Genes.................................................................................................... 132 
6.5 SNP analysis in candidate genes – search for AMD susceptibility genes ......................... 133 
 
7 REFERENCES ......................................................................................................................... 135 
 
8 APPENDIX................................................................................................................................ 153 
 
9 LIST OF PUBLICATIONS ..................................................................................................... 161 
 
10 CURRICULUM VITAE .......................................................................................................... 162 
 
Summary 
1 
1 SUMMARY 
 
The human retina is a multi-layered neuronal tissue specialized for the reception and 
processing of visual information. The retina is composed of a great diversity of neuronal cell 
types including rod and cone photoreceptors, bipolar cells, ganglion cells, amacrine cells, 
horizontal cells and Müller glia. In response to light, a coordinated series of molecular events, 
the so-called phototransduction cascade, is triggered in photoreceptor cells and the signals 
from the photoreceptors are further processed by the bipolar and ganglion cells to the higher 
centers of the brain. 
The retina as highly complex system may be greatly susceptible to genetic defects 
which can lead to a wide range of disease phenotypes. Therefore, isolation and 
characterisation of the genes active in the human retina will facilitate our deeper 
understanding of retinal physiology and mechanisms underlying retinal degeneration and 
provide novel candidates for the retinal disease genes. To identify novel genes that are 
specifically or predominantly expressed in the human retina, a cDNA library enriched for 
retina specific transcripts was generated using suppression subtractive hybridization (SSH) 
technique. In total, 1113 clones were randomly isolated from the retina SSH cDNA library 
and partially sequenced. On the basis of BLASTN algorithm analysis these clones were 
classified into four categories including those with I) significant homology to known human 
genes (766/1113), II) significant homology to partial transcripts and hypothetical gene 
predictions (162/1113), III) no homology to known mRNAs (149/1113), and IV) vector 
sequences and clones derived from mitochondrial genes (36/1113). After correcting for 
redundancy, category I represented 234 known human genes and category II a total of 92 
unknown transcripts.  
Clones from category I, were selected for expression analysis by RT-PCR in a great 
number of human tissues. This resulted in the identification of 16 genes which were expressed 
exclusively in the retina, 13 which were highly expressed in the retina compared to other 
tissues, 12 genes which were specifically expressed in neuronal tissues and 48 ubiquitously 
expressed genes. Thus, our expression analysis resulted in the identification of 29 genes 
exclusively or abundantly transcribed in the human retina. Of those, retina specific genes L25, 
L33, L35, L37, L38 and L40 were selected for further analysis. To characterize the complete 
mRNA sequences of these transcripts a full-length human retina cDNA library was 
constructed.  
Summary 
2 
The analysis of the L25 gene revealed three splicing variants of the ABCC5 gene, 
consequently named ABCC5_SV1 (SV1), ABCC5_SV2 (SV2) and ABCC5_SV3 (SV3). 
These isoforms comprise the first five exons of ABCC5 and additional novel exons named 5a, 
5b and 5c, generated by differential exon usage. The determined lengths of the three 
transcripts are 2039 bp, 1962 bp, and 1887 bp in size, respectively. RT-PCR, real-time PCR 
and Northern blot analysis of ABCC5 as well as the isoforms SV1, SV2 and SV3 
demonstrated high levels of expression for all transcripts in the retina compared to other 
tissues. Analysis of their nucleotide sequences revealed that inclusion of exon 5a in splicing 
variant SV1 produced a frame shift and premature termination codon (PTC). Our data show 
that this splice variant is the target of nonsense mediated mRNA decay (NMD). This was 
shown by inhibition of protein synthesis with antibiotics puromycin and anisomycin in human 
cell lines A-RPE 19 and Y79. Our analysis resulted in an increase of the PTC containing 
transcript and a decrease of the ABCC5 transcript. Conversely, the amount of both transcripts 
(SV1 and ABCC5) returned to pre-treatment levels after removal of the inhibitors. Together, 
our results suggest that alternative splicing of the ubiquitously expressed ABCC5 gene in 
addition to NMD is involved in retina-specific transcriptional regulation of the mRNA level 
of ABCC5. In contrast, additional experiments demonstrated that the levels of expression of 
SV2 and SV3 isoforms do not appear to influence ABCC5 transcription. 
The analysis of cDNA clones derived from the L33 transcript lead to the identification 
of the full-length cDNA sequence of 1663 bp in size. The L33 gene consists of five exons and 
spans 13 Kb of genomic DNA on chromosome 15q23. Further expression analysis of this 
gene confirmed its predominant transcription in retina with lower levels of expression in 
several other human tissues. The longest putative ORFs in the transcript have the capacity to 
encode peptides ranging from 28 to 42 amino acids.  
The analysis of the L35 gene resulted in the comprehensive identification of two 
isoforms, termed L35_SV1 and L35_SV2, with full-length sizes of 3759 bp and 3618 bp, 
respectively. L35 is a four exon gene located on chromosome 7p21 and spanning 13 Kb of 
genomic sequence. It is located in its entirety in the first intron of the MEOX2 gene, and is 
encoded by the opposite strand. Expression analysis of the L35 gene demonstrated that it is 
highly expressed in the retina, with low levels of expression in skeletal muscle and testis. The 
longest predicted ORF within this cDNA sequence encodes only 44 amino acids.  
The L38 gene was identified as a five exon gene on chromosome 12q21, with 1164 bp 
in size. Virtual Northern blot analysis confirmed its preferential expression in the retina. The 
longest ORFs predicted encode peptides ranging in size from 27 to 34 amino acids. In 
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summary, our data from the analysis of the nucleotide sequences of the genes L33, L35 and 
L38 and their putative coding potential strongly suggest that these transcripts may not 
represent protein-coding genes but rather may function as RNA-encoding transcripts involved 
in transcriptional regulation of gene expression. 
The full-length transcript of L37 is 419 bp in size. The L37 gene consists of two exons 
separated by approximately 30 Kb of intervening sequence. This gene is located within the 36 
Kb long first intron of ATP2C1, with opposite orientation. Virtual Northern blot confirmed its 
exclusive expression in the retina. Analysis of the coding potential of this gene predicts two 
putative proteins consisting of 33 and 35 amino acid residues, respectively, with no homology 
to any known human protein sequences or any known domains. 
The L40 gene transcribes a full-length cDNA sequence with 1.037 bp in size. This 
gene spans approximately 156 Kb of genomic DNA and is divided in seven exons. Three 5’-
terminal exons of L40 (exons 2-4) overlap to 3’-terminal exons (exons 5-7) of the Zona 
pellucida-binding protein (ZPBP) gene. Expression analysis by RT-PCR, with forward 
primers located in the respective unique exons of the two genes and with reverse primers 
located in the first shared exon showed high levels of expression of L40 in the retina with 
minor expression in RPE, whereas expression of ZPBP was specific for the testis. Analysis of 
the L40 nucleotide sequence indicated that its largest open reading frame is 333 bp coding for 
111 amino acid residues by exons 2-5. The L40 overlaps ZPBP between coding sequences 
and both genes share a common stretch of 100 amino acids. This study revealed that two 
major mRNA species of the ZPBP and L40 genes sharing three exons but differing in their 5’-
untranslated regions, can be generated in a tissue-specific manner through the use of tissue-
specific promoters. 
Several of these cloned genes were selected for additional genotyping of single 
nucleotide polymorphisms (SNPs) in order to construct their SNP maps which are going to be 
used for future association studies of complex disease AMD. Thus, identification of novel 
retinal genes and their functional characterization will further our elucidation of retinal 
physiology in general and in the diseased state in particular, by providing candidate retinal 
disease genes. 
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2 ZUSAMMENFASSUNG 
 
 
 Die menschliche Retina ist ein vielschichtiges neuronales Gewebe, das auf die 
Aufnahme und Verarbeitung visueller Informationen spezialisiert ist. Sie besteht aus einer 
großen Vielfalt neuronaler Zelltypen, inklusive der Stäbchen und Zapfen (Photorezeptoren), 
Bipolar- und Ganglionzellen, Amakrinen Zellen sowie Horizontalzellen und Müllerglia. Als 
Antwort auf einen Lichteinfall wird eine koordinierte Serie von molekularen Ereignissen, die 
so genannte Phototransduktionskaskade, in den Photorezeptoren ausgelöst, die von den 
Photorezeptoren kommenden Signale von den Bipolar- und Ganglionzellen weiterverarbeitet 
und an höhere Hirnzentren gesandt.  
 Als äußerst komplexes System kann die Retina hochanfällig für genetische Defekte 
sein, die zu einem breiten Spektrum an Krankheitsphänotypen führen können. Deshalb wird 
die Isolation und Charakterisierung von in der Retina aktiven Genen unser tieferes 
Verständnis für die Physiologie der Netzhaut, sowie den einer Retinadegeneration zu Grunde 
liegenden Mechanismen, erleichtern. Um neue Gene, die spezifisch oder überwiegend in der 
Netzhaut exprimiert werden, identifizieren zu können wurde, unter Nutzung der subtractive 
hybridization technique (SSH) eine cDNA Bibliothek, angereichert mit retinaspezifischen 
Genen, generiert. Insgesamt wurden 1113 Klone zufällig aus der Retina SSH cDNA 
Bibliothek ausgewählt und teilweise sequenziert. Auf der Basis einer BLASTN Algorithmus 
Analyse wurden diese Klone in 4 Kategorien eingeteilt, wobei I) Klone mit signifikanten 
Homologien zu bekannten menschlichen Genen (766/1113) beinhaltet, II) Klone mit 
signifikanten Homologien zu partiellen Transkripten und hypothetischen Genvorhersagen 
(162/1113), III) Klone ohne Homologie zu bekannten mRNAs (149/1113) und IV) 
Vektorsequenzen und Klone, erhalten von mitochondrialen Genen (36/1113). Nach 
Redundanzkorrektur repräsentierte Kategorie I 234 bekannte menschliche Gene und 
Kategorie II insgesamt 92 unbekannte Transkripte.  
 Klone der Kategorie I wurden für eine Expressionsanalyse mittels RT-PCR in einer 
Vielzahl menschlicher Gewebe ausgewählt. Dies führte zur Identifikation von 16 exklusiv in 
der Retina exprimierten Genen, weiteren 13 mit, im Vergleich zu anderen Geweben, hoher 
Expression in der Netzhaut, 12 Genen, die spezifisch in neuronalen Geweben exprimiert 
werden, sowie 48 ubiquitär exprimierten Genen. Somit resultierte unsere Expressionsanalyse  
in der Identifikation von 29 exklusiv oder reichlich in der menschlichen Retina transkribierten 
Genen. Aus diesen wurden die retinaspezifischen Gene L25, L33, L35, L38 und L40 für 
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weitere Analysen ausgewählt. Um die kompletten mRNA Sequenzen dieser Transkripte zu 
charakterisieren wurde eine full-length human retina cDNA Bibliothek konstruiert.  
 Die Analyse des L25 Genes erbrachte 3 Splicevarianten des ABCC5 Genes, die 
konsequent mit ABCC5_SV1 (SV1), ABCC5_SV2 (SV2) und ABCC5_SV3 (SV3) benannt 
wurden. Diese Isoformen bestehen aus den  ersten 5 Exonen von ABCC5 und zusätzlichen 
neuen 5a, 5b und 5c genannten Exonen, die durch unterschiedliche Exonnutzung entstehen. 
Die ermittelten Längen der drei Transkripte sind 2039 bp, 1962 bp, und 1887 bp. RT-PCR, 
real time PCR und Northern Blot Analyse des ABCC5 Genes sowie der Isoformen SV1, SV2 
und SV3, konnten hohe Expressionslevel all dieser Transkripte in der Retina im Vergleich zu 
anderen Geweben zeigen. Die Analyse ihrer Nukleotidsequenzen enthüllte, dass der 
Einschluss von Exon 5a in Splicevariante SV1 eine Leserahmenverschiebung sowie die 
Entstehung eines premature termination Kodons  (PTC) bewirkt. Unsere Daten zeigen, dass 
diese Splicevariante Ziel eines nonsense mediated mRNA decay (NMD) ist. Dies  wurde 
durch Hemmung der Proteinsynthese mittels Gabe der Antibiotika Puromycin und 
Anisomycin in den humanen Zelllinien ARPE-19 und Y79 gezeigt. Es kam bei diesem 
Versuch zu einem Anstieg des PTC enthaltenden Transkripts und einem Abfall des ABCC5 
Transkripts. Umgekehrt ging die Menge beider Transkripte (SV1 und ABCC5) nach 
Wegnahme der Inhibitoren auf die Ausgangswerte vor Antibiotikagabe zurück. 
Zusammengefasst weisen unsere Ergebnisse darauf hin, dass alternatives Splicing des ubiqitär 
exprimierten ABCC5 Genes zusätzlich zu NMD in der retinaspezifischen 
Transkriptionsregulation der mRNA Level des ABCC5 Genes involviert ist. Im Gegensatz 
dazu zeigten zusätzliche Experimente, dass die Expressionslevel der SV2 und SV3 Isoformen 
die ABCC5 Transkription scheinbar nicht beeinflussen.  
 Die Analyse von aus dem L33 Transkript erhaltenen cDNA Klonen führte zur 
Identifikation einer full-length cDNA Sequenz von 1663 bp Größe. Das L33 Gen besteht aus 
5 Exonen und überspannt 13 Kb an genomischer DNA auf Chromosom 15q23. Weitere 
Expressionsanalysen dieses Genes bestätigten dessen dominante Expression in der Netzhaut 
gegenüber geringeren Expressionsleveln in einigen anderen menschlichen Geweben. Die 
längsten vermeintlichen ORFs dieses Transkripts haben die Fähigkeit, Peptide von 28 bis 48 
Aminosäuren Länge zu generieren.  
 Die Analyse des L35 Gens resultierte in der umfassenden Identifizierung zweier 
Isoformen, benannt L35_SV1 und L35_SV2, mit einer Gesamtlänge von 3759 bp bzw. 3618 
bp. L35 ist ein aus vier Exonen bestehendes Gen, lokalisiert auf Chromosom 7p21, und 
überspannt 13 Kb an genomischer Sequenz. Es ist vollständig im ersten Intron des MEOX2 
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Gens lokalisiert und wird auf dem Gegenstrang kodiert. Eine Expressionsanalyse des L35 
Gens zeigte, dass es äußerst stark in der Retina exprimiert wird, sowie in geringer Menge im 
Skelettmuskel und den Hoden. Der längste innerhalb dieser cDNA Sequenz vorhergesagte 
ORF kodiert lediglich 44 Aminosäuren.  
 L38 wurde als ein aus fünf Exonen bestehendes Gen auf Chromosom 12q21 mit 
einer Länge von 1164 bp identifiziert. Northern blot Analyse bestätigte seine bevorzugte 
Expression in der Retina. Die längsten vorhergesagten ORFs kodieren Peptide von 27 bis 34 
Aminosäuren Länge. Zusammengefasst lassen unsere Analysedaten der Nukleotidsequenzen 
der Gene L33, L35 und L38 und ihre mutmaßlichen Kodierungspotentiale stark darauf 
schließen, dass diese Transkripte keine Protein-kodierenden Gene repräsentieren, sondern 
eher als RNA kodierende Transkripte fungieren, die in der Transkriptionsregulation der 
Genexpression involviert sind.  
 Das full-length Transkript von L37 ist 419 bp groß. Das L37 Gen besteht aus zwei 
Exonen, getrennt durch ungefähr 30 Kb intervenierender Sequenz. Dieses Gen ist in 
gegenläufiger Orientierung innerhalb der ersten 36 kb langen Introns von ATP2C1 lokalisiert. 
Virtuelle Northern Blot Analyse bestätigte seine alleinige Expression in der Netzhaut. Die 
Analyse des Kodierungspotentials dieses Gens sagt zwei vermeintliche Proteine vorher, 
bestehend aus 33 bzw. 35 Aminosäureresten ohne Homologie zu bekannten humanen 
Proteinsequenzen oder  Proteindomänen.  
 Das L40 Gen transkribiert eine full-length cDNA mit 1.037 bp Länge. Dieses Gen 
überspannt ungefähr 156 Kb an genomischer DNA und ist in sieben Exone unterteilt. Drei 5´- 
terminale Exone des L40 (Exone 2- 4) überlappen mit 3´-terminalen Exonen (Exone 5- 7) des 
Zona pellucida-binding protein (ZPBP) Gens. Eine Expressionsanlyse mittels RT- PCR, bei 
der die forward Primer in den jeweiligen einzigartigen Exonen der zwei Gene lagen und die 
reversen Primer in den ersten gemeinsamen Exonen, zeigte hohe Expressionslevel des L40 in 
der Retina mit geringerer Expression im RPE, wohingegen die Expression des ZPBP 
spezifische für den Hoden war. Die Analyse der L40 Nukleotidsequenz ließ erkennen, dass 
sein größter offener Leserahmen von 333 bp 111 Aminosäurereste mittels der Exone 2-5 
kodiert. L40 überlappt ZPBP zwischen den kodierenden Sequenzen und beide Gene teilen 
sich einen gemeinsamen Abschnitt von 100 Aminosäuren. Diese Studie deckte auf, dass zwei 
Haupt- mRNAs des ZPBP und L40 Gens, die sich drei Exone teilen, sich aber in ihren 
untranslatierten 5´- Bereichen unterscheiden, durch Nutzung gewebespezifischer Promotoren 
in gewebsspezifischer Weise generiert werden können. 
Zusammenfassung 
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 Einige dieser klonierten Gene wurden zur zusätzliche Genotypisierungen ihrer 
single nucleotide Polymorphismen (SNPs) ausgewählt, mit dem Ziel SNP Karten zu erstellen, 
die für spätere Assoziationsstudien komplexer AMD Erkrankungen verwendet werden sollen. 
Auf diese Weise wird die Identifizierung neuer retinaler Gene sowie deren 
Funktionscharakterisierung die Aufklärung der Netzhautphysiologie im Allgemeinen und 
deren krankhafter Veränderungen  im besonderen fördern, indem sie Kandidatengene für 
Retinaerkrankungen zu Verfügung stellt. 
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3 INTRODUCTION 
3.1 Organization of the retina 
 
           The human retina is a multi-layered neuronal tissue specialized for the reception and 
processing of visual information. Vision begins with the conversion of light from the outside 
world into neural signals which can be processed within the retina and sent through the optic 
nerve to the brain higher centres. Light enters the eye by first passing through the cornea, is 
then focused by the lens, further passes through the vitreous humor and all intervening neural 
layers in the retina, and is finally absorbed by the pigments of the photoreceptor cells (Fig. 1). 
The population of photoreceptors responsible for reading and colour vision is mainly 
concentrated in the fovea (0.35 mm in diameter), which is located in the center of the macula 
(6 mm in diameter) (Tuo et al., 2004). As shown in Figure 1, this highly specific region of the 
macula is located in the central retina temporally to the optic disc.     
 
 
 
 
 
 
Figure 1. Schematic drawing of the human eye  
(figure taken from http://www.brainconnection.com/topics/?main=anat/vision-anat) 
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The retina contains huge diversity of neuronal and non-neuronal cells, like many other 
central nervous system structures. Mammalian retinas have approximately 55 distinct cell 
types and each of them have different function (Masland, 2001). There are seven main classes 
of cells found in the vertebrate retina, including rod and cone photoreceptors, bipolar cells, 
ganglion cells, amacrine cells, horizontal cells and Müller glia (Fig. 2). For example, 
amacrine cells are the most diverse class within the retina with 29 different subtypes 
(Masland, 2001). 
 
 
Retinal pigment epithelium (RPE)
 
Rod 
 
Cone 
 
 
 
 
 
Horizontal cells 
 
Bipolar cells 
Amacrine cells 
 
Ganglion cells 
 
 
Figure 2. Structure of the adult mammalian retina. Main classes of cell types found in the 
vertebrate retina including rod and cone photoreceptors, bipolar cells, ganglion cells, 
amacrine cells and horizontal cells. There are many distinct subtypes within each class of 
neuron. For example, amacrine cells are the most diverse class of the retinal cells with at least 
22 different subtypes in the rabbit retina (figure taken from Livesey and Cepko, 2001). 
 
 
The cell bodies of the neuronal cells are organized in three different layers including 
inner nuclear, outer nuclear and ganglion cell layers (the basic organization of the retinal cell 
layers is shown in Figure 3.). Two synaptic layers, outer and inner plexiform layer, are 
interacting between three cellular layers.  
The outer nuclear layer of the retina is composed of photoreceptor cell bodies (Fig. 3). 
When stimulated, rods and cones transmit their signals through bipolar cells, whose cell 
bodies are found in the inner nuclear layer, to the ganglion cells. From the ganglion cell layer, 
these signals make their way along the optic nerve to the brain. Horizontal and amacrine cells 
in the inner nuclear layer make lateral connections and modulate the direct signalling pathway 
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from photoreceptors to ganglion cells. Amacrine cells also make up a significant proportion of 
the cells in the ganglion cell layer and are referred to as displaced amacrine cells. Müller glial 
cell bodies lie in the centre of the inner nuclear layer and their processes span all three cellular 
layers of the retina. These specialized glial cells are believed to be involved in the protection 
and/or repair of retinal neurons. 
 
 
 
 
Figure 3. Vertical section through the human retina. Main layers of the retina including 
photoreceptors rods and cones, outer nuclear layer (ONL), outer plexiform layer (OPL), inner 
nuclear layer (INL), inner plexiform layer (IPL) and ganglion cell layer (GCL). The vitreous 
is at the bottom and the sclera is at the top. Figure taken from http://webvision.med.utah.edu/ 
sretina.html. 
 
 
3.1.1 Photoreceptor cells 
 
Most vertebrates have two types of photoreceptor cells, rods and cones, in the retina. 
Rods are highly sensitive to light and operate under dim lighting conditions while cones 
function in bright light and are less sensitive and responsible for colour vision. In most 
vertebrates, there is only one rod but 2-4 types of cone photoreceptor cells containing 
different cone pigments (Baylor, 1996). Only 5% of photoreceptor cells are cones and 95% 
are rods (Rattner et al., 1999). In primates, cones are found throughout the retina but are most 
concentrated within a small central region, the fovea (Fig. 1). A somewhat larger zone, called 
 
ONL 
OPL 
INL 
IPL 
GCL  
Amacrine cells 
Ganglion cells, axons 
Rods and cones 
Horizontal / bipolar cells 
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the macula (Fig. 1), is centered in the fovea and also includes the immediately surrounding 
rod-rich retina. Both photoreceptors are highly specialized cells consisting of several 
morphologically and functionally distinct regions. The photoreceptor outer segment (Fig. 4), 
located adjacent to the retinal pigment epithelium (RPE) cell layer, is a specialized 
compartment uniquely designed for light reception and phototransduction. The outer segment 
is filled with flattened membrane sacs called discs and is constantly renewed by new synthesis 
and assembly at its base, and by shedding of older material from its tip. A thin, nonmotile 
cilium links the outer segment to the inner segment, a cellular compartment where subcellular 
organelles are located. This region further extends to the synaptic region where the electrical 
signal generated in the photoreceptor cells is transmitted to other neurons of the retina. 
 
 
 
 
 
 
 
Figure 4. Structure of a rod and cone photoreceptor outer segment. A. In the rod cells, 
the outer segment appears as a cylindrical structure. B. The cone outer segment is generally 
shorter and often is tapered or conical. The outer segment of both photoreceptors consists of 
hundreds of flattened disc membranes assembled in an ordered axial array.  
 
Introduction 
 12
3.1.2 Phototransduction cascade 
 
In response to light, a coordinated series of molecular events, the so-called 
phototransduction cascade, is triggered in photoreceptor cells. Photons excite pigment-
containing proteins called rhodopsins, which then switch on the protein transducin by loading 
it with the small molecule guanosine triphosphate (GTP). When bound to GTP, transducin 
turns on a phosphodiesterase, an enzyme that breaks down cyclic guanosine monophosphate 
(cGMP). High concentrations of cGMP open specialized ion channels in the outer cell 
membrane. Thus, by reducing the concentration of cGMP, light changes the flow of ions 
across the membrane of photoreceptive neurons, resulting in hyperpolarization of the rods 
producing an electrical signal that is necessary for communicating with the brain (Arshavsky 
et al., 2002). In darkness Ca2+ and Na+ enter the cell through the open channel, partially 
depolarizing the membrane. Once the concentration of cGMP decrease, membrane is 
hyperpolyrized by closing the channel and Na+ is extruded by a pump in the inner segment, 
while Ca2+ is extruded by an exchanger who is driven by entry of Na+ and efflux of K+. 
Continued operation of the exchanger at the onset of light produces a fall in the intracellular 
concentration of Ca2+ (for reviews see Burns and Baylor, 2001; Arshavsky et al., 2002). 
The cationic channel in the surface membrane is held open in darkness by the binding 
of cGMP, which is synthesized from the precursor GTP by guanylate cyclase. Once light-
activated switch is on, the cells turn it off by limiting the amount of time that GTP-bound 
transducin can keep the phosphodiesterase enzyme active. Transducin can accomplish this 
task by converting - hydrolysing its bound GTP molecule into guanosine diphosphate, GDP 
(Burns and Baylor, 2001; Arshavsky et al., 2002; Blumer, 2004). Because transducin-bound 
GDP has a low affinity for phosphodiesterase, it releases the enzyme in an inactive form, 
allowing cGMP levels to rise again and return the flow of ions across the cell membrane to 
the ‘dark’ state. In this molecular cascade, then, the conversion of GTP to GDP by transducin 
is rate-limiting and defines the amount of time for which a photoreceptor responds to a light 
pulse. 
 
 
Figure 5. Phototransduction in photoreceptor cells (see next page). In the rod class of 
photoreceptors, the pigment containing protein rhodopsin absorbs light (a) and activates 
transducin (b) by causing it to release GDP and bind GTP. GTP-bound transducin binds to 
and activates a phosphodiesterase (PDE), which converts cGMP to GMP (c). The 
concentration of cGMP decreases below what is required to open cGMP-gated ion channels, 
reducing the flow of ions across the cellular membrane. RGS9 bound to R9AP turns off the 
light-induced response by accelerating the rate of GTP hydrolysis by transducin, releasing 
phosphate, P(d). (picture taken from Blumer, 2004). 
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All vertebrate visual pigments consist of an apoprotein opsin, linked covalently to a 
chromophore 11-cis retinal (an aldehyde derivative of vitamin A). The opsin is different in 
different photopigments and its particular interaction with the retinal determines the 
wavelength that is absorbed. As a photon of light hits a molecule of vision pigment, the 11-
cis-retinal chromophore undergoes isomerization to all-trans-retinal, after which all-trans 
retinal dissociates from opsin, to be replaced by a new molecule of 11-cis retinal (Fig. 6) 
(Arshavsky et al., 2002). This conversion, called the retinoid (or visual) cycle requires 
participation of the retinal pigment epithelium, RPE. In this cycle, the all-trans retinal 
chromophore dissociating from opsin is reduced to all-trans retinol (the corresponding 
alcohol derivative of vitamin A) within photoreceptors. All-trans retinol is then released into 
the extracellular space, where it is absorbed by cells of the pigment epithelium. There, all-
trans-retinol is esterified to form all-trans-retinyl ester by the transfer of a fatty acid from 
phosphatidylcholine. The next reaction, perhaps the most important for the whole cycle, 
couples hydrolysis of the retinyl ester with all-trans to 11-cis isomerization of retinol. Finally, 
11-cis-retinol is oxidized to 11-cis-retinal, which is released from the RPE and taken up by 
photoreceptors to regenerate opsin. An alternative retinoid cycle based on the interaction 
between Müller cells and cones is responsible for the regeneration of the cone opsins (Mata et 
al., 2002). 
The flux through the visual cycle is extremely high. Looking at the blue sky on a 
sunny day produces 20,000 photoisomerizations per rod per second. Under these viewing 
conditions, the visual cycle in each RPE cell therefore processes approximately 1,000,000 
chromophores per second (Rattner et al., 1999). 
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Figure 6. Two Retinoid Cycles in Vertebrate Retina (figure taken from Arshavsky et al., 
2002) 
 
The retina as highly complex system might be greatly susceptible to genetic defects 
leading to a wide range of retinal disease phenotypes. Hereditary eye diseases that cause the 
photoreceptor cells of the retina to degenerate, thus resulting in partial or total blindness, are 
affecting 1 in 3.000 people (Sullivan and Daiger, 1996). Hereditary retinal diseases are 
characterized by age of onset, severity and topographic pattern of visual loss, family history 
and ophthalmoscopic findings (Rattner et al., 1999). They can be caused by defects in single 
gene (monogenic), two genes (digenic) or they can be even more complex (Sullivan and 
Daiger, 1996). The monogenic forms can be autosomal dominant, autosomal recessive or X-
linked, whereas complex or multifactorial forms are caused by defects in multiple genes or by 
combination of genetic and environmental factors (Sullivan and Daiger, 1996). 
 
 
3.2 Age related macular degeneration 
3.2.1 Disease phenotype 
 
Age-related macular degeneration (AMD) is an example of the complex disease 
characterized by a progressive degeneration of the photoreceptors, the underlying retinal 
pigment epithelium, Bruch’s membrane and possibly the choriocapillaries in the macular 
region (Fine et al., 2000; Hageman et al., 2001; Lutty et al., 1999). In industrialized countries, 
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AMD is a major cause of visual impairment in people aged 65 and older (Stöhr et al., 2000). 
Clinical and pathological features of AMD include drusen formation, hypo- and/or 
hyperpigmentation, loss of photoreceptors, choroidal neovascularization, subretinal fibrous 
and/or neovascular tissue in the macula, and alterations of Bruch’s membrane and RPE cells 
(Tuo et al., 2004).  
In the normal eye throughout life there is a regular turnover of the photoreceptor outer 
segments, which contain the photosensitive visual pigments. Material shed from the outer 
segments is engulfed and digested by the underlying retinal pigment epithelium and 
ultimately cleared by the capillaries of the choroid (the choriocapillaris). The RPE is 
separated from the choriocapillaris by a multilayered structure called Bruch membrane. It is 
known that this membrane thickens with age and that in the early stages of AMD there is 
accumulation of acellular debris in the membrane which contributes to the development of 
drusen, one of the characteristic clinical features of early AMD, and pigmentary abnormalities 
in the macular region (John et al., 2000). It is likely that this debris is derived from the 
cytoplasmic material being continually discharged into the inner portion of Bruch membrane 
from the RPE. Although small drusen are commonly observed in the aging macula, the 
presence of large drusen is considered diagnostic for AMD (Bird et al. 1995). Late stages of 
AMD are typically grouped in two forms: (1) a “dry” form associated with the loss of RPE 
and photoreceptors and diminished retinal function, known as “geographic atrophy” (GA); 
and (2) a “wet” exudative form, which is associated with the formation of choroidal 
neovascularization (CNV) (Fig. 7). The new vessels are fragile and often bleed leading to the 
formation of fibrovascular scars and irreversible visual loss. CNV is responsible for the 
majority of cases of severe loss of central vision. These alterations result in the loss of central 
visual activity (Ambati et al., 2003a). Although GA and CNV together account for only 10% 
of patients with AMD (Smith et al. 2001), they are responsible for most cases of associated 
blindness.  
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Figure 7. Range of ophthalmoscopic phenotypes consistent with the diagnosis of AMD. 
A. Normal fundus (for comparison); B. RPE hyperpigmentation; C. large and small drusen 
confined to the macula; D. subretinal hemorrhage secondary to a choroidal neovascular 
membrane; E. geographic atrophy; F. RPE hyperpigmentation and subretinal fibrosis 
secondary to a choroidal neovascular membrane (figure taken from Stone et al., 2001). 
 
 
Laser photocoagulation targeting the choroidal feeding vessels, photodynamic therapy, 
surgical macular translocation, and antiangiogenesis agents are reported to reduce the risk of 
moderate to severe vision loss in some patients with the neovascular, or wet, form of the 
disease, but so far there is no proven treatment of advanced AMD to date (Ciardella et al., 
2002; Fujii et al., 2003; Lim, 2002; McBee et al., 2003; Rechtman et al., 2002). 
 
 
3.2.2 Risk factors in AMD 
 
There are external, individual risk factors that contribute to AMD. For example, a 
number of lifestyle factors may influence disease manifestations (Evans, 2001). Recognized 
risk factors include smoking and diet (Husain et al., 2002; Hyman and Neborsky, 2002; 
Seddon et al., 2001). Oxidative stress may promote neovascularization via deposition of 
extracellular matrix along Bruch’s membrane and increased levels of angiogenic factors in 
RPE cells (Mousa et al., 1999). Different opinions are held concerning the association 
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between AMD and hypertension (Delcourt et al., 2001; Hyman and Neborsky, 2002; Snow 
and Seddon, 1999). Among all potential environmental factors identified, the strongest risk 
factors are ageing, diet and smoking. Many investigators have speculated that dietary 
antioxidants such as carotenoids, zinc, and mineral cofactors confer protection against AMD 
but the evidence is not conclusive and further studies are needed (Frank, 1998; Frank et al., 
1999).  
Pathogenesis in AMD involves environmental factors as well as varying 
susceptibilities to these external factors based upon different genetic backgrounds (Guymer, 
2001). Ethnicity, for example, is a component of genetic background. AMD is more prevalent 
in people with less pigmentation, although little difference in the occurrences of smaller-sized 
drusen in individuals with light and dark skin has been reported (Friedman et al., 1999). A 
possible explanation for this observed trend suggests an enhanced protective role for the 
melanin in RPE cells and choroidal melanocytes. There has been compelling evidence that 
heredity plays a role in AMD (Yoshida et al., 2000). The tendency for familial aggregation in 
AMD cases further supports a genetic context in disease development. Approximately 20% of 
AMD patients have a positive family history (de Jong et al., 1997; Klaver et al., 1998b; 
Meyers et al., 1995). Furthermore, there is higher prevalence of AMD among monozygotic 
twins as compared to their spouses and first-degree relatives Gottfredsdottir et al., 1999; 
Klaver et al., 1998b). 
 
 
3.2.3 The genetics of age-related macular degeneration 
 
There are several limitations in causative gene mapping by linkage studies in late-
onset diseases such as AMD. First, many individuals in the affected families are young and 
have not yet developed the disease. Second, it is likely that many older family members have 
passed away making informative pedigree situations rarely available; and third, the 
heterogeneity of AMD requires the estimation of multiple genetic risks as this disease is 
thought to result from polygenic interactions rather than from single gene effects (Tuo et al., 
2004). Furthermore, the variable presentation of AMD may lead to problems with the 
classification of affected individuals (Seddon et al., 2003). For these reasons, the study of 
hereditary monogenic retinal dystrophies that share clinical and pathological similarities with 
AMD may offer some insightful clues as to identify the AMD-related genes. 
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Several hereditary retinopathies have overlapping phenotypes with AMD, but the 
extent to which they are related to AMD remains unclear (Gorin et al., 1999). For example, 
similar to AMD Stargardt disease and Best vitelliform macular dystrophies commonly result 
in atrophy of the central retina. Drusen are a prominent feature of Doyne honeycomb retinal 
dystrophy (also known as autosomal dominant radial drusen, Malattia Leventinese) which is 
followed at later stages by the development of CNV. The latter feature is also shared by 
Sorsby fundus dystrophy, a rare late onset macular dystrophy. The genes responsible for these 
conditions are attractive candidates for AMD susceptibility genes.  
VMD2 has been identified as the causal gene of dominant juvenile onset vitelliform 
macular dystrophy, commonly known as Best disease. Best disease affects the central retina 
and is characterized clinically by the classical abnormal electrooculogram and the presence of 
round or oval yellow subretinal macular deposits (Fig. 8A). The yellow material gradually 
reabsorbs over time, leaving an area of RPE atrophy and often subretinal fibrosis (Kramer et 
al., 2003; Michaelides et al., 2003; Petrukhin et al., 1998; Weber et al., 1994b). Affected 
individuals carry mutations in the VMD2 gene (Kramer et al., 2003) which has been localized 
to 11q13.2–13.3 (Stone et al. 1992, Weber et al., 1994b). The gene encodes a 585-amino-acid 
protein known as bestrophin, which is selectively expressed in the RPE of the eye (Marquardt 
et al., 1998; Petrukhin et al., 1998).   
Sorsby fundus dystrophy (SFD) is an autosomal dominant disease clinically 
characterized by choroidal neovascularization and irregularities in the extracellular matrix of 
Bruch’s membrane (Fig. 8 B and C). SFD leads to an onset of night blindness in the third or 
fourth decade of life and a loss of central vision from macular atrophy by the fifth (Gregory-
Evans, 2000; Weber et al., 1994a). The SFD locus was mapped to 22q13-qter, containing the 
gene for tissue inhibitor of matrix metalloproteinases-3 (TIMP3). TIMP3 is known to play a 
pivotal role in the regulation of proteases such as the matrix metalloproteinases including the 
collagenases and gelatinases. Recently, TIMP3 was also shown to inhibit several members of 
the ADAM (a disintegrin and a metalloprotein domain) family. TIMP3 thereby greatly 
determines the extent of matrix degradation/regeneration during normal tissue remodeling and 
regulates the homeostasis of the extracellular matrix (Jomary et al., 1995). Reported point 
mutations in TIMP3 (Weber et al., 1994a; Felbor et al., 1995; Carrero-Valenzuela et al., 1996; 
Felbor et al., 1996; Felbor et al., 1997; Tabata et al., 1998; Langton et al. 2000; Jacobson et 
al., 2002) are predicted to disrupt the tertiary structure and consequently the functional 
properties of the mature protein.  
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Stargardt disease (STGD1) is the most frequent of the juvenile macular dystrophies. It 
is characterised by early onset and leads to progressive atrophy of the macular RPE and 
overlying photoreceptors (Fig. 8D). The condition is caused by mutations in the ABCA4 gene 
located in 1p21, a member of the ATP binding cassette (ABC) transporter superfamily 
(Allikmets et al., 1997). PROML1 in 4p15 has been identified as another causative gene for 
STGD (Maw et al., 2000) (autosomal dominant or recessive; you need to specify). The gene 
belongs to the prominin family of five-transmembrane domain proteins.  
The disruption of EFEMP1 (EGF containing fibrillin-like extracellular matrix protein 
1) at 2p16-21, which is encoding a protein homologous to a family of extracellular matrix 
glycoproteins known as fibulins, has been linked to Doyne honeycomb retinal dystrophy 
(DHRD), a dominant macular dystrophy. This disorder is characterised by a confluent drusen 
accumulation beneath the RPE (Fig. 8E) in early adult life (Stone et al., 1999).  
Disruptions in the peripherin/RDS gene (Lith-Verhoeven et al., 2003a) on 
chromosome 6p21 have been identified in patients with pattern dystrophies characterized by a 
bilateral accumulation of lipofuscin-like material at the level of the RPE (Nichols et al., 
1993a, b) (Fig. 8F). The peripherin/RDS protein is a membrane-associated glycoprotein 
restricted to photoreceptor outer-segment discs in a complex with ROM1 (Rod outer segment 
membrane protein 1). This protein may function as an adhesion molecule involved in the 
stabilization and maintenance of a compact arrangement of outer-segment discs (Travis et al., 
1991). Peripherin has also been shown to interact with the GARP domain (glutamic acid- and 
proline-rich region) of the beta-subunit of rod cGMP-gated channels in a complex including 
the Na/Ca–K exchanger (Poetsch et al., 2001).  
CTRP5 has recently been reported as the causal gene of late-onset retinal degeneration 
(L-ORD), an autosomal dominant disorder the retina (Hayward et al., 2003). Clinically, L-
ORD is characterized by onset in the fifth to sixth decade of life with night blindness as the 
main clinical feature. Pathological features include thick punctuate yellow-white deposit 
between the basal lamina of the RPE and Bruch’s membrane, progression to severe central 
and peripheral degeneration, and choroidal neovascularization and chorioretinal atrophy 
(Kuntz et al., 1996; Milam et al., 2000). CTRP5 is secreted by the RPE and is a potential 
constituent of Bruch’s membrane. This protein most likely functions in the facilitation of 
basal RPE adhesion to Bruch’s membrane by forming an extracellular hexagonal lattice. 
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Figure 8. Ophthalmoscopic phenotypes of patients affected with molecularly confirmed 
early-onset heritable macular dystrophies. A. Best disease; B. Sorsby fundus dystrophy; C. 
Sorsby fundus dystrophy; D. Stargardt disease; E. Malattia Leventinese; F. RDS-associated 
pattern dystrophy (figure taken from Stone et al., 2001).  
 
 
3.2.4 Search for the complex disease genes 
 
Age-related macular degeneration has been recognized as a complex genetic disorder 
in which multiple genes may contribute to an individual’s susceptibility for developing the 
condition. These factors are causing disease only when a threshold of susceptibility is reached 
and most of the susceptibility alleles are neither necessary nor sufficient to cause disease, but 
only confer a slight increase in risk (Johnson and Todd, 2000). Methods, based on 
associations between marker and disease, provide powerful tool for localization of disease 
loci. The single nucleotide polymorphisms (SNPs)  became “markers of choice” for disease 
mapping (Johnson and Todd., 2000), allowing analyses for association between a phenotype 
and a functional variant, directly. Genetic association studies with a large sample size analyse 
weather a SNP is enriched in affected cases compared to unaffected controls from the same 
population (Taylor et al., 2001).   
The SNPs are highly abundant, stable genetic markers in the human genome, and are 
estimated to occur at 1 out of every 1,000 bases (Sachidanandam et al., 2001; Venter et al., 
2001). Depending on where a SNP occurs, it might have different consequences at the 
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phenotypic level. SNPs in the coding region of a gene may alter the function or structure of 
the encoded protein by amino acid substitution. Such a functional SNP is a necessary and 
sufficient cause of most of the known recessively or dominantly inherited monogenic 
disorders (Syvänen, 2001). These SNPs are routinely analysed for diagnostic purposes. 
However, restricting the search to cDNA sequences may fail to detect a predisposing variant 
located in a non-coding regulatory region of the gene, which may affect its expression 
(Johnson and Todd, 2000). 
The reason for the current interest in large-scale SNP characterisation is the hope that 
they could be used as markers to identify genes that predispose individuals to common, 
multifactorial disorders by using linkage disequilibrium (LD) mapping (Risch & Merikangas, 
1996; Schork et al., 1998). For example, such studies analyse SNP alleles in population-based 
analyses to identify loci that are associated with a particular disease or phenotype. With the 
advent of new molecular tools, in particular high-density SNP-typing, it has been argued that, 
while linkage analysis may retain some role, genome-wide association studies with SNPs 
offer a superior strategy for unravelling genetic complexity (Baron, 2001).  
 
 
3.2.4.1 Genotyping single nucleotide polymorphisms (SNPs) 
 
As a result of the efforts of the SNP Consortium - a collaboration of 14 major 
pharmaceutical companies and the Wellcome Trust, as well as members of the Human 
Genome Project (Sachidanandam et al., 2001) there were almost 2 million SNPs in public 
databases by the end of year 2001, and perhaps twice that number of SNPs in commercial 
databases, such as that of Celera Genomics (Venter et al., 2001). Genotyping a collection of 
SNPs that occur randomly distributed throughout the whole genome would be a preferred 
approach to detect genomic regions in which the frequencies of the SNP alleles may differ 
between patients and controls. Due to inefficient SNP genotyping capabilities and the 
immense costs involved, such endeavours are still infeasible at present but may be in reach in 
the not too far future.  
Following the completion of the genetic, physical, and SNP maps, the next step is the 
generation of "haplotype" maps of the human genome. Such "haplotype" maps consist of a 
high density of SNPs defining the relatively small number of ancestral haplotypes (blocks of 
tightly correlated genetic variants) in each region of the human genome. Knowledge of these 
haplotypes will allow comprehensive and efficient testing of the association of human genes 
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with disease. Currently, the SNPs are now being verified experimentally and their distribution 
between and within populations are being assessed (Marth et al., 2001; Katsanis et al., 2001). 
The hope that SNPs will allow to pinpoint genes that underlie complex disease, is the driving 
force for establishing the technology for large-scale analysis of SNPs. 
In summary, from the available data it appears that AMD is caused by environmental 
factors triggering disease in genetically susceptible subjects. Identification of AMD’s genetic 
causes will allow characterizations of the disease phenotypes and better understanding of the 
pathogenesis of this disease. If a genetic predisposition is known at an early age, behavioural 
modifications may prevent disease or decrease disease severity later in life. Current evidence 
shows that it is unlikely that a single gene variant is responsible for the development of AMD, 
at least not in the common forms of the disease. Perhaps focusing on the dynamic interaction 
between multiple genes, gene-environmental components and their comprehensive effects 
will provide new insights in the search for the genetic risks, pathogenesis and treatment of 
AMD. 
 
 
3.3 Goal of the thesis 
  
The highly specialized function of the retina requires a large number of specifically 
expressed genes involved in performance and control of phototransduction process. These 
genes might be highly susceptible to the genetic defects. Therefore, isolation and 
characterization of novel retinal genes should further our understanding of the tissue structure 
and physiology, should provide novel candidates for the disease genes and contribute to 
understanding the pathogenesis of the retinal diseases.  
The goal of this project was identification of the novel genes that are specifically or 
predominantly expressed in the human retina. For this purpose cDNA library enriched for 
differentially expressed retina specific transcripts of both high and low abundance was 
generated using suppression subtractive hybridization (SSH) technique (Diatchenko et al., 
1996).  
At the beginning of this project 1113 clones from the retina SSH cDNA library were 
sequenced and obtained sequences were subjected to homology searches against public 
databases. Expression profiling of the clones that derived from the transcripts which sequence 
didn’t show homology to known human genes were performed by RT-PCR, standard and 
virtual Northern blot and real-time PCR. In this way, the transcripts with abundant or 
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exclusive expression in the human retina were identified and selected for additional analysis. 
Further efforts were directed towards identification of the full-length cDNA sequence of the 
several genes of interest (for this purpose full-length retinal cDNA library was constructed 
and screened for the homologue clones) and their functional characterization.  
Identified genes with retina restricted expression could be candidates for the retina 
disease genes. Therefore, a few of them were subjected to the single nucleotide polymorphism 
(SNP) analysis and generated SNP maps will be used for the future association studies of the 
AMD as complex retinal disorder. 
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4 MATERIALS AND METHODS 
4.1 Bioinformatics 
 
Computational analyses of the nucleotide and protein sequences investigated in this 
doctoral thesis were performed using a number of bioinformatics tools. 
 
 
4.1.1    Computational analysis of nucleotide sequences 
 
Nucleotide sequence homology searches in public databases were performed using the 
BLASTN program at National Center for Biotechnology Information - NCBI 
(http://www.ncbi.nlm.nih.gov/), whereas BLAT searches were performed at the Human 
Genome Browser at the University of California, Santa Cruz (USCS Genome Browser at 
http://genome.ucsc.edu/). Repeats in the nucleotide sequences were identified using the 
Repeat Masker Web Server (http://repeatmasker.genome.washington.edu/). Putative ORFs 
within cDNA sequences were predicted using ORF finder 
(http://www.ncbi.nlm.nih.gov/gorf/gorf.html). ClustalW program, provided by the BCM 
Search Launcher (http://www.ebi.ac.uk/clustalw/) was used to generate multiple alignments 
of nucleotide sequences and visualization of the sequence alignments was done using 
BOXSHADE algorithms (http://www.ch.embnet.org/software/BOX_form.html) which shade 
the aligned sequences.  
Information about partial and full-length cDNA sequences investigated in the course 
of this project was acquired from GeneCards (http://bioinfo.weizmann.ac.il/cards/index.shtml) 
and LocusLink (http://www.ncbi.nlm.nih.gov/projects/LocusLink/). 
 
  
4.1.2 Computational analysis of amino acid sequences 
 
The BLASTP program, available at NCBI (http://www.ncbi.nlm.nih.gov/BLAST/), 
was used for amino acid sequence homology searches in public databases. The analyses of 
putative protein sequences for structural and functional motifs were carried out using different 
tools available at ExPASy Web server (http://www.expasy.org/) including TMHMM 
(http://www.cbs.dtu.dk/services/TMHMM) and SWISS-PROT 
(http://www.expasy.org/sprot/).  
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4.2 RNA Methods 
4.2.1 RNA sources 
 
Human retina and RPE were dissected from eyes obtained from the University Eye 
Clinic in Würzburg (eyes were donated for the purpose of cornea transplantion, post mortem, 
approval of local ethics committee were given) and were used for isolation of RNA. 
Commercially obtained mice (Harlan & Winkelmann, Borchen, Germany) were used as 
sources of murine total retina and eye RNA. After dissection of the eyes the isolated tissues 
were immediately subjected to RNA extraction or were frozen in liquid nitrogen and stored at 
-80°C. Total RNA from human brain, fetal brain, spinal cord, bone marrow, retina, heart, 
kidney, liver, fetal liver, lung, trachea, spleen, thymus, skeletal muscle, colon, testis, uterus, 
placenta, adrenal gland, salivary gland and bladder was purchased from Clontech (Heidelberg, 
Germany) and Ambion (Austin, TX, USA) and stored at -80°C.  
 
 
4.2.2  RNA isolation 
4.2.2.1 Total RNA 
 
Total RNA from fresh / frozen tissue or cell culture was isolated with the Rneasy® 
Mini Kit (Qiagen, Hilden, Germany). Samples were first lysed and homogenized in the 
presence of the denaturing guanidine isothiocyanate (GITC) – containing buffer, which 
immediately inactivates RNases to ensure isolation of intact RNA. Homogenization was done 
on ice while subsequent steps were performed at room temperature. Briefly, 75% ethanol was 
added to the lysate to provide appropriate binding conditions and the sample was loaded on an 
Rneasy® mini column where the total RNA binds to the silica-gel based membrane. 
Subsequent washing steps were performed according to the manufacturer’s protocol. Total 
RNA was eluted from the column with 40 µl RNase free water and stored at -80°C.  
The quality and quantity of the purified RNA was analysed by loading 3 µl aliquot on 
a 1.2 % agarose-formaldehyde gel. Intact eukaryotic RNAs reveal a sharp 28S band that is 
approximately twice as intense as the 18S rRNA band. Partially degraded RNA is 
characterized by a smear, lacks the sharp rRNA bands, or is not exhibiting the 2:1 ratio 
whereas completely degraded RNA will appear as a very low molecular weight smear.  
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4.2.2.2 Cytoplasmic RNA 
 
Cytoplasmic RNA was extracted from 30 mg of fresh tissue. In order to keep nuclear 
membrane intact a teflon homogenizer was used (Das et al., 2001). Cell membranes were 
lysed with a precooled lysis buffer (50mM Tris-Cl, pH 8.0; 140mM NaCl; 1.5mM MgCl2; 
0.5% nonident; 1000U/ml RNase inhibitor and 1mM DTT). Cell lysis was done on ice and 
following centrifugation, for pelleting the nuclei at 6.000g for 2 minutes, at 4°C. In order to 
pellet the intact nuclei the supernatant was then mixed with precooled 75% ethanol and all 
subsequent steps were performed at room temperature with Rneasy® Mini Kit  (Qiagen, 
Hilden, Germany), following the manufacturers instructions. RNA was eluted from the 
column with 40µl RNase free water and stored at -80°C. The purity of the cytoplasmic RNA 
was tested by PCR amplification of the XIST gene using XISTF and XISTR primers (Table 
19, Appendix). 
 
 
4.2.2.3 Poly(A)+ RNA  
 
Poly(A)+ RNA was purified using the OligotexTM Kit (Qiagen, Hilden, Germany). 
Following this procedure poly(A)+ containing RNA is hybridized to a dT oligomer which is 
covalently linked to the solid phase matrix of the provided polystyrene-latex Oligotex 
particles. Total RNA diluted in a volume of 100µl was mixed with 10µl Oligotex suspension 
preheated at 37°C. Afterwards, the secondary structure of the RNA was disrupted by heating 
the sample to 70°C for 3 minutes. An incubation step at room temperature for 10 minutes was 
followed by centrifugation at 14.000 rpm for 2 minutes. In order to obtain high-salt 
concentration required for hybridization, the Oligotex/RNA pellet was resuspended in 400µl 
of the provided binding buffer and the sample was transferred to the spin column. 
Subsequently, poly(A)+ mRNA was released by lowering the ionic strength and destabilizing 
the dT:A hybrids with 30µl eluting buffer which was preheated on 75°C.  
 
 
4.2.3  Quantification of RNA   
 
The concentration of RNA was determined by spectrophotometer measurement of the 
absorbance at 260 nm (A260). An absorbance of 1 unit at 260 nm corresponds to 40 µg of 
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RNA per ml of water. Therefore, 100 µl of RNA was diluted in RNase free water (1:50 
dilution) and the concentration of the sample was calculated according to the formula: 
 
Concentration (µg/µl)   =   40µg  X A260 X dilution factor 
Total yield (µg)   =   concentration X volume of sample (µl) 
 
 
4.2.4  First-strand cDNA synthesis 
 
First-strand cDNA synthesis was carried out with reverse transcriptase Superscript 
IITM (Invitrogen, Karlsruhe, Germany) under RNase free conditions. In the first step, 1-2µg 
poly(A)+ RNA were mixed with 10 pmol 3’-RACE AP primer (Table 19, Appendix), 1µl 
dNTPs (10mM of dATP, dTTP, dGTP, dCTP) and RNase free water. RNA was denatured at 
70°C for 10 min and the mixture was immediately transferred to ice. In the second step, 4µl of 
5 X First strand buffer (250mM Tris-HCl, pH 8.3; 30 mM MgCl2; 375mM KCl), 2 µl of 0.1M 
DTT and 1µl of SuperscriptIITM (200 U/µl) were added. The reverse transcription was done at 
42°C for 50 min in 20 µl final volume. Afterwards the mixture was incubated at 70°C for 15 
min, in order to inactivate the enzyme. Synthesized cDNA was stored at -20°C. PCR 
amplification of the GUSB and G3PDH genes was performed using GUS B3/ GUS B5 or 
G3PDH F/ G3PDH R primers in order to test the quality of synthesized cDNAs (Table 19, 
Appendix). 
 
 
4.2.5  Northern blot 
4.2.5.1 Agarose gel electrophoresis 
 
An aliquot of 10 µl of total RNA was electrophoretically separated on an 1.2% 
denaturing agarose gel. The gel was prepared by dissolving 1.2 g agarose in 87 ml DEPC 
treated water, cooling down to 60°C and adding 10 ml 10 X MOPS running buffer (0.2M 
MOPS, 50mM NaOAc, 10mM Na2EDTA – pH 7.0) and 3ml 37% formaldehyde. Previous to 
loading, RNA was denatured at 65°C for 10 min in the presence of 1 vol of RNA loading 
buffer (1 X MOPS, 50% deionised formamide, 18.5% formaldehyde, 0.04% bromphenol blue, 
10 µg ethidiumbromide, 5% glycerin, 0.1 mM EDTA). An RNA size marker (Promega, 
Mannheim, Germany) was run in parallel with RNA samples at 60-80V for 3-4 hrs. Gel was 
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examined on an UV transilluminator to visualize the RNA and photographed with a ruler so 
that the size of the transcript could be determined after blotting and hybridization.  
 
 
4.2.5.2 Transfer to Nylon membrane  
 
Total RNA was transferred to the Nylon Hybond N+ membrane with the VacuGeneTM 
(Amersham Bioscience, Freiburg, Germany). Prior to vacuum blotting, the gel was rinsed for 
10 min in 20 X SSC (3M NaCl, 0.3M NaCitrate, pH 7.0) and the nylon membrane was 
moistured with 2 X SSC. Vacuum transfer was performed at -60 mbar for 3-4 hrs and gel was 
kept permanently covered with 20 X SSC. Afterwards, RNA was immobilized by UV 
crosslinking and the membrane was stored between two sheets of Whattman paper at -20°C. 
 
 
4.2.5.3 Radioactive random-prime probe labelling   
 
DNA fragments were labelled by random-priming with [α32P] dCTP (Hartmann, 
Braunschweig, Germany). Probes were generated by PCR amplification, purified from 
agarose gel by using Nucleospin® Extract Kit (Macherey-Nagel, Düren, Germany) and 20-50 
ng were denatured at 100°C for 5 min in 50 µl final volume. Subsequently,  10µl 5 X OLB-
buffer (250mM Tris-HCl, pH 8.0; 25mM MgCl2; 50mM β-Mercaptoethanol; 2mM of each 
dATP, dTTP, dGTP; 1M Hepes, pH 6.6; 50 U (A260) pd(N)6), 2 mg BSA, 4U Klenow 
fragment and 3µg [α32P] dCTP (3000 Ci/mmol) were added and the mixture was incubated at 
37°C for 3 hrs or overnight at RT. The radioactive labelled DNA probe was then separated 
from unincorporated [α32P] dCTP using a G-25 Sephadex column (Amersham Biosciences, 
Freiburg, Germany) and denatured for 5 min at 100°C prior to hybridization.    
 
 
4.2.5.4 Membrane hybridization 
 
The RNA containing membrane was prepared for hybridization in 25 ml prewarmed 
Church buffer (0.5 M Na2HPO4, pH 7.2; 1 mM EDTA, pH 8.0; 1% BSA; 7% SDS) by 
rotating at 60°C for 1-2 hrs. The purified and denatured radioactive DNA probe was then 
added to the buffer and incubated overnight at 60°C, with rotation. Afterwards the incubation 
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solution was removed and the filter was washed once with SSPE/0.1% SDS buffer (20 X 
SSPE: 3 M NaCl, 200mM NaH2PO4, 20 mM Na2EDTA) at 60°C. The increasing stringency 
of the washing solution was obtained by decreasing concentration of the SSPE starting from 2 
X SSPE to 0.5 X SSPE. Membrane was rinsed by shaking in 50 ml prewarmed SSPE/SDS 
buffer at 60°C and background radiation was checked with Geiger counter in between. The 
membrane was then exposed to an X-ray film (RETINA, Fotochemische Werke, Berlin, 
Germany) at -80°C or to a Storage Phosphor screen (Amerscham Bioscience, Freiburg, 
Germany), for a minimum of 3 days. 
 
 
 
4.3 DNA Methods 
4.3.1 Phenol / chlorophorm extraction 
 
For genomic DNA purification, 1 volume of phenol:chlorophorm:isoamylalcohol 
(25:24:1) mixture was added to the aqueous sample, mixed by continuous gentle inversion for 
1 to 2 min and centrifuged on 14.000 rpm for 5 min. The upper aqueous phase was transferred 
to a fresh tube and 1 volume chlorophorm:isoamylalcohol (24:1) was added to the DNA 
solution, mixed by continuous gentle inversion for 1 to 2 min and again centrifuged at 14.000 
rpm for 5 min. The upper layer was mixed with 1/10 volume 3 M sodium acetate (pH 4.8), 2.5 
volume 95% ethanol and 100 µg glycogen which is important for precipitation of low 
concentrated DNA, centrifuged at 14.000 rpm for 20 min. The pellet was then washed with 
80% ethanol, air dried for 10 min and resuspended with dH2O.   
 
 
4.3.2 Polymerase chain reaction (PCR) 
4.3.2.1 Standard PCR 
 
Primer sequences were designed using the OLIGO version 2.0 tool (Rychlik and 
Rhoads 1989) and Primer3 software (available online at http://www-genome.wi.mit.edu/cgi-
bin/primer/primer3_www.cgi). Primers with length ranging from 18 to 22 bp and having a 
G/C content of 45-55% were chosen as optimal, avoiding self-complementarity within a 
primer and formation of primer dimers. The lyophilized oligonucleotides synthesized by 
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MWG Biotech (Ebersberg, Germany) and Sigma-Aldrich Chemie GmbH (Münich, Germany) 
were dissolved in ddH2O to a final concentration of 100 pmol/µl and stored at -20°C.  
PCR optimization was done at a temperature 3°C below the primers' melting 
temperature (Tm) which was calculated according to the Wallace formula [(A/T) x 2 + (G/C) x 
4] (McConlogue et al., 1988). Amplification of complex genomic DNA templates was done 
using a “touch down” PCR method in order to avoid generation of nonspecific PCR products. 
Specifically, annealing took place at 6°C above the calculated Tm. During the following six 
cycles, temperature was gradually reduced by 3°C until the calculated Tm was reached, which 
was followed by additional 26 cycles of amplification, on obtained Tm temperature. 
Amplification of genomic DNA or cDNA was carried out on the Thermocycler T3 
(Biometra, Goettingen, Germany). Template DNA was mixed together with 1 X PCR buffer 
(50 mM KCl; 10 mM Tris-HCl, pH 8.3; 1.0 or 1.5 mM MgCl2; 0.01% gelatine), 100 µM of 
each dNTPs (Peqlab, Erlangen, Germany), 0.4 µM of both forward (F) and reverse (R) 
primer, 1 U Taq DNA polymerase and formamide (used optionally at a final concentration of 
4%) in 25 µl final volume. PCR consisted of an initial denaturation step at 94°C for 5 min, 
followed by 33 cycles of denaturation at 94°C for 30 sec, annealing at the optimal temperature 
for 30 sec and an elongation step at 72°C. Elongation time was 30 sec for templates up to 1 
Kb long template and for larger PCR products an additional 1 min per Kb was added. 
Reaction was terminated with a synthesis step at 72°C for 5 min.  
 
 
4.3.2.2 Quantitative Real-time PCR (qRT-PCR) 
 
Real-time quantitative PCR amplification reactions were carried out on a BIORAD 
iCycler iQTM Detection System (Münich, Germany) using SYBR® Green I as a fluorescent 
reporter (Sigma-Aldrich Chemie GmbH, Münich, Germany). Quantification is achieved by 
measuring the increase in fluorescence at the start of the exponential phase of PCR.  
Primers, specific for each transcript, were designed to amplify 75 bp to 160 bp long 
PCR fragments. For chosen sequences, formation of primer dimers was not predicted with 
NetPrimer software (http://www.premierbiosoft.com/netprimer/netprlaunch/netprlaunch.html) 
(PREMIER Biosoft International, Palo Alto, USA). Either the forward or the reverse primer 
was designed to anneal to two flanking exons and oligonucleotides were synthetized by MWG 
Biotech (Ebersberg, Germany). In order to obtain maximum efficiency and specificity, PCR 
conditions were optimized using the gradient function of the iCycler IQ using annealing 
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temperature ranging from 57 to 66°C and different MgCl2 concentrations (1.5 mM, 2 mM or 3 
mM). Primer sequences and optimized conditions are listed in Table 22). The iCycle iQ 
software automatically chose threshold limits and threshold cycles (CT value), at which the 
fluorescence rises above background. This was reported for all samples and used for all 
subsequent quantifications. In order to determine the efficiency of each PCR reaction, a 
standard curve was generated using serial dilutions of retina cDNA as template. The slope 
(log of the concentration of a dilution series of the template DNA plotted versus CT value), 
automatically calculated by iCycle iQ system software and used to estimate the efficiency by 
the formula E = 10(-1/slope). 
One to two µg of total RNA were used for the first strand cDNA synthesis in a 20 µl 
reverse transcription reaction mixture as described (see RNA methods 4.4). Template DNA 
was diluted 1:5, 1 X PCR buffer (50 mM KCl; 10 mM Tris-HCl, pH 8.3; 1.5, 2.0 or 3.0 mM 
MgCl2), 100 µM of each dNTPs, 0.5 µl Taq DNA polymerase, 10 nM FITC (Bio-Rad, 
Münich, Germany), 0.5 X SYBR® Green I and 0.2 µM of each primer in a 25 µl final volume. 
The PCR consisted of an initial activation step at 95°C for 1.5 min, followed by 40 cycles of 
denaturation at 95°C for 30 sec, annealing for 30 sec at the optimized temperature and 
measurement of the fluorescence optimized temperature for 10 sec. Subsequently, a melting 
curve analysis was carried out. It consisted of a 1 min incubation at 95°C, followed by the 
reduction of the temperature to the annealing temperature and an increasing of the 
temperature in 0.5°C steps that were held for 10 sec. All qRT-PCR reactions were done in 
triplicates for each template. 
Amplification of the expected PCR product was confirmed by 2% agarose gel 
electrophoresis (see 4.3.3). The Ct values were exported to a Microsoft Excel worksheet, and 
converted according to a model published by Vandesompele et al. (2002). The amount of each 
transcript was calculated by normalization to housekeeping genes beta-2-microglobulin 
(B2M), TATA box binding protein (TBP), succinate dehydrogenase complex, subunit A 
(SDHA) and hypoxantine phosphoribosyl-transferase I (HPRTI) (primers listed in Table 22, 
Appendix). 
 
 
4.3.3 Agarose gel electrophoresis 
 
To prepare a 1% agarose gel, 1 g ultra pure agarose (Roth, Karlsruhe, Germany) was 
dissolved in 100 ml 1 X TBE buffer (10 X TBE: 89 mM Tris-HCl; 89 mM borate acid; 2 mM 
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Na2EDTA, pH 8.3) or 1 X TAE buffer (50 X TAE: 2 M Tris-acetate; 0.05 M EDTA, pH 8.3). 
After cooling to 60°C, ethidium bromide (EtBr) was added to a final concentration of 0.5 
µg/ml and the mixture was poured into an appropriate gel tray. DNA samples were mixed 
with 6 X loading buffer (0.25% bromophenol blue, 40% sucrose) prior to loading and gel was 
run in 1 X TBE or TAE buffer at 100-120 V. As a reference the 1 Kb+ DNA ladder 
(Invitrogen, Karlsruhe, Germany) was size fractionated by electrophoresis on the same gel so 
that fragment size could be determined by comparison. After electrophoresis, fluorescent 
ethidium bromide-stained samples were visualized on the UV illuminator. The gel 
concentration varied, depending on the fragment size being analysed. For fragments shorter 
than 300 bp a 2.5% gel was used whereas products longer than 3 Kb were analysed on a 0.7% 
gel. 
 
 
4.3.4 DNA purification  
4.3.4.1 Purification of PCR products 
 
The PCR products (see DNA methods 4.3.1) that were longer that 100 bp were 
extracted from the agarose gel using the NucleoSpin® Extract Kit (Macherey-Nagel, Düren, 
Germany) whereas those that were approximately 100 bp long were purified with 
NucleoTrap® Kit (Macherey-Nagel, Düren, Germany), following the manufacturer's protocol. 
Gel slices with DNA samples were melted in dissolving buffer at 50°C. In general, in the 
presence of chaotropic salts contained within the buffers provided, DNA binds to the silica 
membrane of the NucleoSpin® column or to the specially activated silica matrix of suspension 
particles of the NucleoTrap® suspension. All contaminating salts and soluble macromolecular 
components were washed with an ethanol-containing buffer and DNA was eluted under low 
ionic strength conditions with 40 µl H2O and stored at -20°C.  
 
 
4.3.4.2 Purification of plasmid DNA  
 
Plasmid DNA purification was carried out using the NucleoSpin® Plasmid Kit 
(Macherey-Nagel, Düren, Germany) following the manufacturer's protocol. In general, 
plasmid DNA was released from the host cells with SDS / alkaline lysis buffer. Subsequently, 
a neutralizing buffer was added to the resulting lysate in order to obtain appropriate 
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conditions for adhesion of the plasmid DNA to the silica membrane of the NucleoSpin® 
column. SDS precipitate and cell debris was pelleted by centrifugation and the supernatant 
containing plasmid DNA was loaded onto the column. Salt, metabolites and soluble 
macromolecular cellular components were washed with an ethanolic buffer and pure plasmid 
DNA was eluted under low ionic strength conditions with 40 µl H2O and stored at -20°C. 
Quality of purified samples was analysed by agarose gel electrophoresis (see 4.3.3).  
 
 
4.3.4.3 Restriction enzyme digestion 
 
Restriction enzymes EcoRI, XhoI and NotI were purchased from New England 
Biolabs (NEB, Frankfurt, Germany) and one unit of enzyme per microgram of DNA was 
used. For a 100-200 µl digestion reaction, the mix typically included 2 to 3 µl of enzyme, 
DNA sample, 1 X appropriate NEB buffer and 1 X BSA (if required), according to the 
instructions given by NEB. The reaction was incubated for 3 to 5 hours at 37°C to insure 
complete digestion and the sample was analysed by agarose gel electrophoresis. Vectors were 
dephosphorylated with 2 µl shrimp alkaline phosphatase (USB, Cleveland, USA) to prevent 
religation.  
 
 
4.3.4.4 Ligation and transformation 
 
For the cloning of DNA fragments several commercially available vectors were used 
including pGEM (Promega, Mannheim, Germany), pGEX-4T-3 (Amersham, Freiburg, 
Germany), pMal-cxh (NEB, Frankfurt, Germany) and pCEP4 (Invitrogen, Carlsbad, CA). 
PCR products were amplified with primers containing restriction site sequences at their 5' 
ends, respectively. Two distinct cutting sites were used to ensure directional insertion of 
inserts. The cleavage with two different restriction enzymes was performed sequential or 
simultaneously by double digestions. For the ligation of PCR products into pGEM, 3 µl of 
DNA, 1 µl vector, 5 µl 2 X Rapid T4 DNA ligation buffer and 1 µl T4 DNA ligase (NEB, 
Frankfurt, Germany) were incubated at room temperature for 6 hrs. Pre-digested DNA 
fragments with appropriate restriction enzymes were cloned into pGEX-4T-3, pMal-cxh and 
pCEP4 vectors by incubating 10 µl reaction containing 1-3 µl DNA, 3-5 µl plasmid, 1 µl T4 
DNA ligation buffer and 1 µl T4 DNA ligase at 14°C overnight. The recombinant plasmid 
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was then transformed into E.coli XL1-blue electrocompetent cells by electroporation using 
Gene Pulser Electropotation system (Bio-Rad, Muenchen, Germany).. 
 
 
4.3.5 Sequencing 
 
The sequencing reactions were done using the ABI PRISM® BigDyeTM Terminator Kit 
(Applied Biosystems, Weiterstadt, Germany) and run on a single-capillary ABI PRISM® 310 
genetic analyser (Applied Biosystems, Weiterstadt, Germany). In a 10 µl final volume, 0.5 - 3 
µl PCR products were treated with 5 units of exonuclease I (USB, Cleveland, USA) and 1 unit 
of shrimp alkaline phosphatase (USB, Cleveland, USA), prior to sequencing. The reaction 
was incubated at 37°C for 15 min, terminating the reaction by enzyme inactivation at 80°C for 
an additional 15 min. For the 10 µl sequencing reaction, 5 µl of PCR product was mixed with 
1 µl PCR of the sequencing primer (10 pmol) and 2 µl BigDye mix. The 25 cycle sequencing 
protocol consisted of denaturation at 95°C for 30 seconds, followed by annealing at the 
primer Tm temperature for 30 sec and elongation at 60°C for 30 sec to 3 min. Plasmid DNA 
was sequenced directly, using a 2 µl aliquot. Amplified PCR products were precipitated using 
1/10 volume 3 M sodium acetate (pH 4.8) and 2.5 volume 95% ethanol. Analysis and 
sequence editing were done using Chromas software (Technelysium Pty Ltd, Helensvale, 
Australia).  
 
 
4.3.6 Virtual Northern blot analysis 
 
To obtain full-length first-strand cDNAs synthesis, 2 to 4 µg of total RNA from 
bladder, heart, lung, skeletal muscle, retina and RPE were used together with SMART III 
oligonuclotide (see cDNA library, 4.4.2.1), which is contained in the SMARTTM cDNA 
Library Construction Kit (Clontech, Heidelberg, Germany). Double stranded (ds) cDNA 
synthesis was performed in a 25 µl reaction mix containing 1 X PCR buffer (10 X PCR 
buffer: 1.2 M Tris-HCl, pH 8.0; 100 mM KCl; 60 mM (NH4)2SO4; 1% Triton X-100; 0.01% 
BSA), 100 mM each dNTP mix, 200 nM 5’ SMART primer and 200 nM CDS III/3’-PCR 
primer (Table 20, Appendix), 1 mM MgCl2 and 10 U KOD HiFi Taq polymerase (Merck 
Biosciences GmbH, Schwalbach, Germany). The skeletal muscle ds cDNA was subjected to 
19 cycles of amplification and all other samples were amplified in a 22 cycle PCR reaction. 
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Five hundred nanogram of amplified cDNA products were electrophoresed on 0.7% TBE 
agarose gels and blotted with 10 X SSC (1.5 M NaCl, 150 mM NaCitrate - pH 7.0) onto 
Nylon Hybond N+ membranes (Amersham Biosciences, Freiburg, Germany). Afterwards, 
cDNA was UV-crosslinked and the membranes were hybridized with radiolabeled DNA 
probes (see RNA methods, 4.6). After washing, filters were exposed to a storage phosphor 
screen (Amersham Biosciences, Freiburg, Germany) and scanned after seven days with a 
TyphoonTM 9200 Imager (Amersham Biosciences, Freiburg, Germany) or exposed to X - ray 
RETINA films (Fotochemische Werke, Berlin, Germany) at -80°C for 3 days.  
 
 
 
4.4 cDNA libraries 
4.4.1 Generation of a suppression subtracted cDNA library from the human retina 
 
An adult retina SSH library was constructed in pCR®2.1 TOPO TA cloning vector 
(Invitrogen, Karlsruhe, Germany) using the PCR-SelectedTM cDNA Subtraction Kit 
(Clontech, Heidelberg, Germany). This work was performed by Dr. Andrea Gehrig at the 
Institute of Human Genetics in Würzburg (for further details see PhD Thesis of Gehrig A, 
University of Würzburg, Germany; 2003) and the SSH library was kindly provided for further 
analysis.  
 
 
4.4.1.1 Sequencing of the clones from the library 
 
Sequencing was carried out with ABI 310 automated sequencer (as described above) 
or with a Beckman CEQ 2000 sequencer using the Dye Terminator Cycle Sequencing 
Chemistry provided by the Quick Start Kit (Beckman Coulter, Fullerton, USA). Colonies 
deriving from the transformed cells that were grown on LB/ampicilin plates at 37°C overnight 
were randomly picked, transfered to 100 µl LB medium with ampicilin and grown again 
overnight. In order to check if they are containing inserts, test PCR using M13F and M13R 
primers (Table 19, Appendix) was performed and products of positive clones were sequenced 
with either PCR-f or PCR-r or both primers (Table 19, Appendix). 
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4.4.2 Full-length cDNA library 
4.4.2.1 Construction 
 
Full-length mouse eye and human retina cDNA libraries were constructed in 
λTriplEx2 vector using the commercially available SMARTTM cDNA Library Construction 
Kit (Clontech, Heidelberg, Germany). Cytoplasmic RNA was purified from 240 mg pooled 
fresh mice eyes obtained from five animals and 140 mg fresh human retina using the 
Rneasy® Mini Kit (see RNA methods 4.2.2) with concentrations as determined by 
spectrophotometry (see RNA methods 4.3). Subsequently, poly(A)+ RNA was extracted from 
56.8 µg mouse and 44.7 µg human total cytoplasmic RNA, eluted with 100 µl RNase free 
water from OligotexTM suspension (see RNA methods 4.2.3).  
 
 
4.4.2.1.1 First strand cDNA synthesis 
 
First strand cDNA was synthesised from poly(A)+ RNA, which was separated from 
total RNA by oligo(dT) selection (see Poly(A)+ RNA isolation 2.2.3), using SMART cDNA 
Construction Kit (Clontech, Heidelberg, Germany). First strand cDNA synthesis was 
performed with denatured 0.5 µg poly(A)+ RNA at 72°C for 2 min together with 1 µl SMART 
III oligonuclotide and 1 µl CDS III/3' PCR primer (Table 19, Appendix) in a 5 µl final 
volume, following the manufacturers protocol. Subsequently, reverse transcription was 
carried out by adding 2 µl 5 X First strand buffer, 1 µl 20 mM DTT, 1 µl dNTPs mix (10 mM 
each) and 1µl SuperscriptIITM (200 U/µl) on 42°C for 1 hr.  
During first strand synthesis, reverse transcriptase terminal transferase activity adds a 
few additional nucleotides, primarily deoxycytidine, to the 3' end of generated cDNA. The 
SMART III (Switching Mechanism At 5' end of RNA Transcript) oligonucleotide used in this 
amplification system, has an oligo G sequence at it's end and base-pairs with the 
deoxycytidine stretch creating an extended template (Fig. 9). Enzyme then switches templates 
and continues replicating to the end of the oligonucleoide. 
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Fig. 9. Overall strategy for full-length cDNA library construction. The right side of the 
flow chart shows the fate of incomplete transcripts caused by RNA degradation or premature 
termination of reverse transcription (figure taken from SMART cDNA Library Construction 
Kit User Manual; PT3000-1; Clontech, Heidelberg, Germany). 
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4.4.2.1.2 Double strand cDNA synthesis and digestion 
 
In the following step of second strand synthesis by long-distance PCR, only those 
single stranded cDNAs with complete 5' end of the transcripts were selected through the 5' 
primer binding site and in this way, clones containing the full-length of the transcript should 
exclusively be synthesized. Double-stranded cDNA was synthesised using the Advantage 2 
PCR Kit (Clontech, Heidelberg, Germany). By mixing 2 µl first strand cDNA with 2 µl 50 X 
dNTP mix (50 mM each), 2 µl 5' PCR primer (Table 19, Appendix), 2 µl CDS III/3' PCR 
primer, 10 µl 10 X Advantage 2 PCR buffer and 2 µl 50 X Advantage 2 Polymerase Mix in a 
100 µl final volume. Only those single stranded cDNAs having proper primer binding site at 
the 5’ end amplified in the 22 cycle LD PCR. As a control a parallel cDNA synthesis of the 
provided human placenta poly(A)+ RNA was done. Yield and size distribution of double 
stranded (ds) cDNAs was determined by analysing 5 µl of the sample on a 1.1% agarose gel. 
The ds cDNA should appear as 0.1 to 4 Kb smear with some bright bands corresponding to 
the abundant tissue specific mRNAs. The quality of synthesized double stranded cDNA was 
tested by amplification of the GUSB gene using the GUS B3/ GUS B5 primers (Table 19, 
Appendix). 
In order to inactivate the DNA polymerase, 270 µl of PCR product (~10-15 µg ds 
cDNA) were mixed with 100 µg/ml of Proteinase K (20 mg/ml,stock concentration) and 
incubated on 45°C for 20 min. The DNA was then extracted with phenol/chlorophorm and 
ethanol precipitated (see DNA methods, 4.3.1). The sample was then digested with 200 units 
Sfi I restriction enzyme by incubating the mixture of 79 µl ds cDNA, 10 µl 10 X Sfi I buffer 
and 2 µg BSA for 2 hrs on 50°C. 
 
 
4.4.2.1.3 Size selection of ds cDNA 
 
Prior to ligation into the vector, ds cDNA was size selected by separation on a 0.6% 
TAE agarose gel without EtBr. A DNA size marker (1 Kb+ DNA ladder; Gibco, Eggenstein, 
Germany) was run in parallel with the DNA samples at 90V for one and a half hour. 
Subsequently, the gel lane with the DNA size marker was cut out, stained with EtBr 
(Applichem, Darmstadt, Germany) for 15 min and used to select the 850 bp – 3.0 Kb fraction 
of ds cDNA to be purified. The ds cDNA fractions were excised from the gel and purified by 
using Nucleospin® Extract Kit (see DNA methods, 4.3.4.1). Samples were eluted from the 
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columns with 100 µl dH2O and concentrated by centrifugation on a SpeedVac without heating 
for 2 hrs.  
 
 
4.4.2.1.4 Ligation to λTriplEx2 vector and packaging 
 
In the next step, ds cDNA was cloned into the Sfi I A & B-digested arms of the 
λTriplEx2 vector by incubating 2 µl dsDNA, 1 µl vector (0.5 µg/µl), 0.5 µl 10 X DNA ligation 
buffer (500 mM Tris-HCl, pH 7.8; 100 mM MgCl2; 100 mM DTT; 0.5 mg/ml BSA), 0.5 µl 
ATP (10 mM) and 200 U T4 DNA ligase at 16°C over night, in a 5 µl final volume reaction. 
The vectors were incorporated into the bacteriophage using λ phage packaging extracts 
(Gibco, Eggenstein, Germany) and following the manufacturer's protocol. Extracts were 
quickly thawed and 4 µl of the ligation reaction containing approximately 0.1-1.0 µg ligated 
DNA, were added and mixed by pipetting without introducing air bubbles. The tube was 
incubated at room temperature for 2 hrs. Afterwards, 500 µl SM buffer (5.8 g/l mM NaCl; 2 
g/l MgSO4 X 7H2O; 1 M Tris-HCl, pH 7.5; 2% gelatine) and 20 µl chlorophorm were added, 
gently mixed, and briefly centrifuged to sediment the debris. The supernatant containing the 
phages was stored at 4°C.  
 
 
4.4.2.2 Determination of library titre  
 
The titre of the library was determined by λ phage transduction of the host Escherichia 
coli XL1 blue cells. Host cells were grown at 37°C overnight in 15 ml LB/MgSO4/maltose 
medium (20 g/l peptone, 10 g/l yeast extract, 20 g/l NaCl, 20 mM MgSO4 and 0.2% maltose). 
The culture was centrifuged at 5.000 rpm for 5 min and the pellet was resuspended in 7.5 ml 
of sterile 10 mM MgSO4. In order to determine the titre of unamplified library, 600 µl of the 
host cells were mixed with 10 µl serial dilutions (1:1 to 1:104) of library aliquots and 
incubated for 20 min at 37°C allowing phage infection. Afterwards, 10 ml of top agar (20 g/l 
peptone, 10 g/l yeast extract, 20 g/l NaCl and 7.2 g/l agar) at 50°C was added to each aliquot, 
mixed by gentle inversion and poured onto prewarmed Petri dishes (Ø 135 mm) containing 
LB medium (20 g/l peptone, 10 g/l yeast extract, 20 g/l NaCl and 15 g/l agar). Plates were 
incubated overnight at 37°C and the next day the number of plaque forming units (pfu) was 
counted and used for the calculation of the titre (pfu/ml): 
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pfu/ml  =  number of plaques X dilution factor X 103 µl/ml 
                                               µl of diluted phage plated 
 
In order to determine the percentage of clones containing inserts, a test PCR with 1 µl λ 
dilution buffer containing phages (see 4.2.5) using λTriplEx2 5' and λTriplEx2 3' primers 
(Table 19, Appendix) was done. 
 
 
4.4.2.3 Library amplification 
 
In the next step, the library was amplified by plating the primary library onto six Bio-
Assay dishes (NUNC, Wiesbaden, Germany). For this purpose 2.1 ml of the host cells were 
mixed with 83 µl of the unamplified library and incubated (see cDNA libraries 4.4.2.2). After 
infection, 37 ml top agar was added and plates were incubated on 37°C for 15 to 18 hrs until 
plaques became confluent. One plate was then washed with precooled 30 ml 1 X  λ dilution 
buffer (10 X  λ buffer: 1 M NaCl; 0.1 M MgSO4 X 7H2O; 0.35 M Tris-HCl, pH 7.5) by 
shaking the plate for 2 hrs at 4°C. The lysate was then collected, transferred to another plate 
and the same procedure was repeated until all plates were washed. Washing was repeated in 
the same way with additional 10 ml 1 X λ dilution buffer and end volume of the amplified 
library lysate was approximately 35 ml since agar plates socked some of the buffer. 
Subsequently, 700 µl chlorophorm was added, cell debris was precipitated by brief 
centrifugation and the amplified library was stored at 4°C. The titre was determined by 
plating out serial dilutions (1: 103 to 1:108) of library aliquots (see cDNA libraries 4.4.2.2). 
For the long term storage, DMSO was added to a final concentration of 7% and 1 ml aliquot 
and tubes was stored at -80°C.  
 
 
4.4.2.4 Plating of phage library and preparation of replicas 
 
One million clones of the amplified library were plated on six LB Bio-Assay dishes, 
2.1 ml host XL1 blue cells were infected with 100 µl library aliquot per plate, as described in 
(see cDNA libraries 4.4.2.2). Plates were incubated at 37°C for 8 to 16 hrs in order to obtain 
well separated plaques and prevent cross contamination due to phage diffusion. Duplicates of 
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nylon membranes were used for making phage replicas from each plate. The Hybond N+ 
membrane (Amersham Biosciences, Freiburg, Germany) was placed on the surface and 
unsymmetric needle holes were made in order to make possible the localization of a particular 
colony after the hybridization of the colony filter. Subsequently, the filter was incubated with 
denaturing solution (0.5 M NaOH, 1.5 M NaCl) for 2 min and shortly with neutralizing 
solution (25 mM Na3PO4, pH 6.5) shortly and air dried. Plates and replicas were stored at 
4°C.  
In addition, three more retina cDNA libraries including DKFZ3 and DKFZ4 
(constructed in Heidelberg, Germany) and C1F1 (constructed by Claudia Berger), which were 
cloned in the λTriplEx2 vector, were plated out following the explained procedure and used 
for the isolation of the clones containing the sequence of the genes investigated in this project 
(DKFZ and C1F1 are local laboratory IDs). 
 
 
4.4.2.5 Isolation of positive clones from the phage library 
 
To isolate phage clones containing an insert of interest, library lifts were screened by 
colony filter hybridization with radioactively labelled probe (see RNA methods 4.5.3 and 
4.5.4). Positive plaques were visualized by autoradiography, excised from the plate and 
incubated in 350 µl 1 X  λ dilution buffer for 3 to 4 hrs at 37°C. In order to obtain optimal 
concentration of plaques per plate, the phage containing buffer was diluted for second round 
of plating. Lift for the second screen was made using the Colony/Plaque ScreenTM membrane 
(DuPont, Bad Homburg, Germany), which was hybridized with the same radioactive probe 
used in the first screening. Plaques corresponding to a positive signal were transferred from 
the plate to 350 µl 1 X  λ dilution buffer. 
 
 
4.4.2.6 Conversion of λTriplEx2 to pTriplEx2 
 
The conversion of a λTriplEx2 phage to a pTriplEx2 plasmid is performed by Cre 
recombinase-mediated site-specific recombination. E.coli BM25.8 cells were used as host 
since Cre recombinase is constitutively expressed in these bacteria. They were grown 
overnight at 31°C in 10 ml LB/MgSO4 medium containing MgCl2 at a 10 mM final 
concentration and 200 µl were mixed with 150 µl of the eluted positive plaque. After 30 min 
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incubation at 31°C, 400 µl of liquid LB medium were added and the reaction was incubated 
for an additional 1 hour at the same temperature with shaking. Subsequently, 10 µl of infected 
cell suspension were spread on an LB/ampicilin plate and single colonies from each clone 
were used to inoculate overnight cultures which were subsequently used for plasmid DNA 
isolation with Nucleospin® Extract Kit (see DNA methods, 4.3.4.2).     
 
 
 
4.5 Mammalian cell lines 
4.5.1 ARPE-19 cell line 
 
ARPE-19 is a retinal pigment epithelial cell line, which grows in a monolayer. This 
cell line derived originally from the globe of a 19-year-old male eye donor obtained from the 
Lions Eye and Tissue Bank, Sacramento, CA, USA (Dunn et al., 1996). Cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) / Ham’s F12 (1:1 mixture) (Sigma-Algrich, 
München, Germany) supplemented with L-glutamine, 15 mM HEPES, 42 mM NaHCO3, 
100.000 units/l penicillin and 100 mg/l streptomycin (Sigma, Eggenstein, Germany) and 10% 
fetal calf serum, FCS (PAN Systems, Aidenbach, Germany). The ARPE-19 cell line was 
maintained in a 5% CO2 environment at 37°C. 
 
 
4.5.2 Y79 cell line 
 
The Y79 cell line, which grows in a suspension, was derived from human 
retinoblastoma cells (Green et al., 1979). The cell line was obtained from the Westdeutsches 
Tumorzentrum Essen, Germany. Cells were grown in DMEM medium supplemented with 
10% FCS, 100.000 units/l penicillin and 100 mg/l streptomycin. The Y79 cell line was 
maintained in a 5% CO2 incubator at 37°C. 
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4.5.3 EBNA-293 cell line  
4.5.3.1 Maintenance 
  
The EBNA-293 cell line is composed of human embryonic kidney cells expressing 
Epstein-Barr virus (EBV) replicons, which include the genetic element oriP and a functional 
gene for Epstein-Barr nuclear antigen (EBNA-1) (Young et al., 1988). The cells, growing in 
monolayer, were cultured in DMEM medium containing L-glutamine, 4500 mg/l glucose and 
110 mg/l sodium pyruvate, supplemented with 10% FCS, 100.000 units/l penicillin, 100 mg/l 
penicillin, 100 mg/l streptomycin and 250 mg/l geneticin (G418 sulphate, Calbiochem, San 
Diego, USA), on 5% CO2. The EBNA-293 cell line was maintained in a 5% CO2 incubator at 
37°C. 
 
 
4.5.3.2 Transfection 
 
Transfection of the EBNA-293 cells was achieved by the calcium phosphate 
precipitation method (Chen et al., 1987). Cells were transformed with pCEP-1D4 plasmid 
constructs generated by inserting the respective insert into the multiple cloning site of the 
vector (primers listed in Table 21, Appendix). EBNA cells were seeded in a 10 cm Petri dish 
24 hrs prior to transfection. Cells were transfected with 20 µl plasmid DNA that was mixed 
with water and 123 µl 1M CaCl2 in 495 µl final volume. After 3 min of incubation, equal 
volume of 2 X BBS (50 mM N,N-bis[2-Hidroxyethyl]-2 aminoethane sulfonic acid, 280 mM 
NaCl, 1.4 mM Na2HPO4 X 2 H2O, pH 6.9) was added by dropping, with permanent gentle 
vortexing. The mixture was incubated for 17 min at room temperature to allow formation of 
calcium phosphate - DNA complexes and afterwards added onto the cells drop by drop. 
EBNA cells were incubated with transfection mixture for 16 hrs under their normal growth 
conditions. Subsequently, cells were washed with 1 X PBS (137 mM NaCl; 0.3 mM KCl; 8.1 
mM Na2HPO4; 6.7 mM KH2PO4, pH 7.4) containing 1 mM Na2EDTA and fresh medium was 
added. After two days of growth, EBNA cells were harvested and used for the preparation of 
protein extracts.  
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4.5.3.3 Purification of recombinant proteins 
 
EBNA-293 cells were solubilized in 1 X PBS with 2% Triton X-100, 20% glycerol 
and protease inhibitor, 1% SDS was added by dropping and vortexed for 30 min at 4°C. 
Afterwards, DNA, RNA and membrane fragments were precipitated by centrifugation at 
14.000 rpm for 20 min at 4°C. Supernatant containing soluble proteins was transferred to a 
clean tube and used for Western blot analysis.  
 
 
 
4.6 Nonsense mediated mRNA decay 
4.6.1 Principle of the decay 
 
Nonsense-mediated mRNA decay (NMD) is a molecular RNA surveillance system 
that detects and degrades mRNA transcripts containing premature termination codons (PTCs) 
whose translation could otherwise lead to potentially harmful truncated protein products 
(Wilkinson et al., 2002). In the case of mRNA that contains a premature termination codon 
more than 55 nt upstream of the last exon–exon junction, termination of translation occurs and 
a surveillance complex triggers decapping of the mRNA and its degradation (Fig. 10). 
 
 
4.6.2 Inhibition of protein synthesis 
 
Nonsense-mediated mRNA decay requires translation for nonsense codon recognition. 
It is inhibited by the antibiotics anisomycin, cycloheximide, emetine, pactamycin or 
puromycin, each of which binds to and inactivates translationally active ribosomes (Maquat 
2004). In order to block the decay, protein synthesis was inhibited by puromycin (isolated 
from Streptomyces albo-niger causing premature chain termination by acting as an analogue 
of the 3’ terminal end of aminoacil-tRNA) and by anisomycin (isolated from Streptomyces 
griseolus, inhibiting peptidyl transferase activity in ribosomes). 
Puromycin and anisomycin (Gibco, Eggenstein, Germany) were used at concentration 
of 100 µg/ml (Lamba et al., 2003). The ARPE 19 and Y79 cell lines (Mammalian cell lines, 
4.5.1 and 4.5.2) were grown in antibiotic-containing medium for 2 hrs. Subsequently, cells 
were washed with 1 X PBS and then grown in medium without antibiotic for an additional 4 
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hrs. Total RNA was extracted using the RNeasy® Mini Kit (RNA methods, 4.2.1) and the 
amount of ABCC5 isoform transcripts (ABCC5_SV1, ABCC5_SV2 and ABCC5_SV3) were 
quantified with qRT-PCR (DNA methods, 4.3.2.2). 
 
 
 
 
Figure 10. Role of the exon–exon junction in nonsense-mediated mRNA decay. 
Translating ribosome removes all the exon junction complexes (cEJCs) by the time of 
termination and translation proceeds to the next round. In the case of mRNA that contains 
PTC that is more than 55 nt upstream of the last exon–exon junction, translation termination 
occurs before all the EJCs are removed and surveillance complex triggers decapping of the 
mRNA and its degradation. (figure taken from Dreyfuss et al., 2002).  
 
 
 
 
4.7 RNA interference  
4.7.1 Principle of RNA interference 
 
A conserved biological response to double-stranded RNA, known as RNA interference 
(RNAi) or post-transcriptional gene silencing, mediates resistance to both endogenous 
parasitic and exogenous pathogenic nucleic acids, and regulates the expression of protein-
coding genes (Hannon 2002).  
RNAi has been cultivated as a means to experimentally manipulate gene expression in 
mammalian cells. Introduction of double-stranded RNA into the cells results in targeted post-
transcriptional gene silencing. The ability to specifically down-regulate the expression of the 
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targeted genes holds enormous scientific, commercial and therapeutic potential. RNAi can be 
induced in the cell using chemically synthesised individual double-stranded siRNAs duplexes. 
 
 
4.7.2 siRNA design and sequences 
 
The siRNA duplexes (HPP grade, 20nM) were synthesised by Xeragon (Qiagen, 
Hilden, Germany). The antisense siRNA was targeted against an AA(N)19 sequence (N, any 
nucleotide), the GC content of the duplexes was kept within 40-60% range and poly G and 
poly C sequences were avoided. Synthetic 21mer siRNA oligonucleotide was created with a 
dTdT 3’overhangs.  
 
siRNA.1 is targeting the ABCC5 isoforms ABCC5_SV1, ABCC5_SV2 and ABCC5_SV3 
Target DNA sequence 5’-AATTCAGCGTAGCTACCTCCA-3’ 
siRNA duplex sequence Sense:  5’ – UUCAGCGUAGCUACCUCCAd(TT) – 3’ 
    Antisense: 5’- UGGAGGUAGCUACGCUGAAd(TT) – 3’ 
 
siRNA.2 is targeting the ABCC5 isoforms ABCC5_SV1 and ABCC5_SV2 
Target DNA sequence 5’- AATCTCTCGCCAAGAGTTCAG -3’ 
siRNA duplex sequence Sense:  5’ – UCUCUCGCCAAGAGUUCAG d(TT) – 3’ 
    Antisense: 5’- CUGAACUCUUGGCGAGAGA d(TT) – 3’ 
 
siRNA.3 is targeting the ABCC5_SV1 isoform of ABCC5 
Target DNA sequence 5’- AACCAGTGACAGAAGCTGTTC -3’ 
siRNA duplex sequence Sense:  5’ – CCAGUGACAGAAGCUGUUCd(TT) – 3’ 
    Antisense: 5’- GAACAGCUUCUGUCACUGGd(TT) – 3’ 
 
Non-coding siRNA, without known homology to mammalian sequences (used for the 
control experiment) 
Targeted gene  No known homology to mammalian sequences 
Target DNA sequence 5’- AATTCTCCGAACGTGTCACGT -3’ 
siRNA duplex sequence Sense:  5’ – UUCUCCGAACGUGUCACGUd(TT) – 3’ 
    Antisense: 5’- ACGUGACACGUUCGGAGAAd(TT) – 3’ 
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The lyophilized oligonucleotides were dissolved in the provided Suspension buffer 
(100 mM potassium acetate, 30 mM HEPES-KOH, 2 mM magnesium acetate, pH 7.4) and 
annealed to double stranded siRNA duplexes by heating at 90°C for 1 min and incubating at 
37°C for additional 60 min. The dissolved siRNA was and stored at -20°C.   
 
 
4.7.3 siRNA transfection  
 
Human ARPE 19 cells were seeded in 6-well plates (1 X 106 cells/well) 24 hrs prior to 
transfection. Transfection of the cells with synthetic siRNA duplexes was carried out using 
TransMessengerTM Transfection Reagent (Qiagen, Hilden, Germany). Duplexes were used at 
different concentrations of 2.0, 4.0 or 8.0 µg/well. In the first step of TransMessenger-RNA 
complex formation, the siRNA was condensed by interacting with the provided Enhancer R 
reagent (1:2 ratio) in a denaturing buffer system and preincubated for 5 minutes at room 
temperature. In the second step, TransMessenger reagent (8 µl/well) was added to the 
condensed RNA and incubated for 10 min at room temperature for lipid complex formation. 
Subsequently, cell growth medium without serum and antibiotics (to avoid possible RNase 
contaminations), was added and the entire mixture was immediately dropped onto the cells 
which were then incubated for 3.5 hrs with the transfection mix under normal growth 
conditions. Afterwards, the transfection mix was removed, cells were washed with 1 X PBS 
and medium with serum and antibiotics was added. Total RNA was isolated from the cells at 
different posttransfectional time points with Rneasy® Mini Kit (RNA methods, 4.2.1) and the 
amount of ABCC5_SV1, ABCC5_SV2 and ABCC5_SV3 transcripts were quantified by 
qRT-PCR (DNA methods, 4.3.2.2). 
 
 
 
4.8 Polyclonal antibody production 
4.8.1 Expression of recombinant fusion proteins 
 
 Recombinant Glutatione-S-Transferase (GST; Amersham, Freiburg, Germany) and 
Maltose-Binding-Protein (MBP; New England Biolabs, Frankfurt, Germany) fusion proteins 
were constructed by inserting the gene fragment of interest into the multiple cloning site of 
the pGEX-4T-3 and pMal-cxh vectors. Expression of recombinant proteins in BL21 E.coli 
strain was induced by the lactose analog isopropyl b-D thiogalactoside (IPTG) since it is 
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under control of the tac promoter. BL21 cells were transformed with 20 µg plasmid DNA and 
grown in LB medium with 0.3 mM IPTG for 3 hrs. After incubation, cells were precipitated 
by centrifugation for 15 min on 4.000 g at 4°C and pellet was lysed with sonification. GST 
fusion proteins were purified from the cell lysate for immunization in mice (strain Balb/c), 
whereas lysates containing MBP fusion proteins were used afterwards for the analysis of the 
immune response of the mice by immunoblotting. 
 
 
4.8.2 Purification of GST fusion proteins 
 
GST fusion proteins were purified by affinity chromatography using glutation 
sepharose 4B beads (Amersham, Freiburg, Germany). Cell lysate was applied to the column 
containing beads, unbound proteins were cleaned up using 1 X PBS and fusion proteins were 
then eluted with elution buffer (10 mM reduced glutathion, 50 mM Tris-HCl pH 8.0 and 3 
mM Na2EDTA) by incubation on room temperature for 10 min. 
 
 
4.8.3 Immunization 
 
 GST fusions proteins coupled to SV2 peptide sequence (5’-NFQDGCILRSE-3’, 198-
208 aa of the L25SV2 protein, MW ~1.1 kDa; clone number: pGEX4T3_SV2_6) or SV3 
peptide sequence (5’-PSFGDCSISAEVCGNRLHCTAILLSCFT-3’, 198-225 aa of the 
L25SV3 protein, MW ~ 2.95 kDa; clone number: pGEX4T3_SV3_24) were used for the 
immunization. Immunization of the rabbit was performed by ImmunoGlobe (Himmelstadt, 
Germany). Immunization of the eight weeks old Balb/c female mice (Harlan Winkelmann, 
Germany) was carried out using the ImmunEasy Mouse Adjuvant (Qiagen, Hilgen, 
Germany), following the manufacturer's protocol. The mixture of 5-10 µg of fusion protein 
and 15 µg ImmunEasy Mouse Adjuvant was incubated for 5 min at room temperature. Mice 
were subcutaneously injected with protein suspension, and boosted two times at an interval of 
two weeks (Table 21, Appendix).  
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4.8.4 Analysis of the immune response 
 
 To determine if mice show positive immune response against the peptide of interest, 
MBP fusion proteins containing the same polypeptide were analysed by immunoblotting 
using the immune serum from the injected mice. In parallel, the recombinant SV2 full-length 
protein (peptide sequence 5’- MKDIDIGKEYIIPSPGYRSVRERTSTSGTHRDREDSKFRRT 
RPLECQDALETAARAEGLSLDASMHSQLRILDEEHPKGKYHHGLSALKPIRTTSKHQ
HPVDNAGLFSCMTFSWLSSLARVAHKKGELSMEDVWSLSKHESSDVNCRRLERLWQ
EELNEVGPDAASLRRVVWIFCRTRLILSIVCLMITQLAGFSGPNFQDGCILRS -3’, aa of 
the L25SV2 protein, MW ~ 25 kDa) and SV3 full-length protein (peptide sequence 5’- 
METKDIDIGKEYIIPSPGYRSVRERTSTSGTHRDREDSKFRRTRPLECQDALETAARAE
GLSLDASMETHSQLRILDEEHPKGKYHHGLSALKPIRTTSKHQHPVDNAGLFSCMET
TFSWLSSLARVAHKKGELSMETEDVWSLSKHESSDVNCRRLERLWQEELNEVGPDA
ASLRRVVWIFCRTRLILSIVCLMETITQLAGFSGPPSFGDCSISAEVCGNRLHCTAILLS
CFT -3’, aa of the L25SV3 protein, MW ~ 25 kDa) were fused to the 1D4 tag (amino acid 
sequence: 5’-TETSQVAPA-3’), clone numbers: pCEP4_SV2_4 and  pCEP4_SV3_3, 
respectively, and subjected to immunobloting in order to test if polyclonal antibodies 
generated against part of the protein (underlined amino acid sequence) reveals immunaffinity. 
Immune serum was separated from the blood cells with BD microtainers (Becton Dickinson, 
Heidelberg, Germany) by 2 min centrifugation on 10.000 rpm, using the renal vain blood 
samples. 
 
 
4.8.5 Western blot analyses 
4.8.5.1 SDS - polycrilamide gel electrophoresis (SDS-PAGE) 
 
Proteins were electrophoretically separated by SDS-PAGE using the Mini-protean 
system (BioRad, München, Germany). The SDS-polyacrylamide gel was composed of two 
layers: stacking buffer (0.4% SDS, 50 mM Tris-HCl, pH 6.8) was used for upper gel and 
separating buffer (0.4% SDS, 150 mM Tris-HCl, pH 8.8) was used for lower gel preparation. 
The stacking gel ensures that proteins are entering the separating gel simultaneously. To 
activate polymerization, 10 µl TEMED and 30 µl 10% ammonium persulfate solution (APS) 
were added to the 10 ml gel mixture. Prior to loading, proteins were mixed with 4 X sample 
buffer, made from stock sample buffer (240 mM Tris-HCl, 240 mM SDS, 40% glycerol, 20% 
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β-mercaptoethanol, pH 6.8), and denatured on 90°C for 3 min. In general, protein molecules 
bind SDS during heating and negatively charged SDS-polypeptide complexes migrate along 
the gradient gel according to their size. A prestained protein molecular weight marker 
(BioRad, München, Germany) was run in parallel with 10-30 µl of the sample loaded per 
lane. The acrylamide gels were run for 1.5 hrs at a constant voltage of 120V in a 1 X SDS 
buffer (10 X SDS buffer: 30 mM Tris, 14% glycine, 1% SDS; pH 8.6). After electrophoresis, 
protein gels were subjected to immunoblotting. 
 
 
4.8.5.2 Immunoblotting 
 
Proteins were transfered to a Millipore Immobilon-P membrane (PVDF membrane, 
Eschborn) using the Trans-Blot system (BioRad, München, Germany). The membrane was 
activated with 100% methanol for 30 sec and transfered at a constant current of 40 mA for 2 
hrs in transfer buffer (25 mM Tris, 192 mM glycine, 15% methanol). Afterwards, the 
membrane was blocked in 1 X PBS containing 2% non-fat dry milk for a minimum of 2 
hours. Mice serum was diluted in 0.2% dry milk / 1 X PBS, blot was incubated for 1 hour at 
room temperature with shaking and washed 3 minutes in 1 X PBS / 0.05% Tween. Blot was 
then incubated with secondary goat anti-mouse antibody (Calbiochem, San Diego, USA), 
diluted in 0.2% dry milk / 1 X PBS, for a minimum of 30 min at room temperature with 
shaking and washed again 3 times in 1 X PBS / 0.05% Tween. Secondary anti-mouse 
antibodies conjugated to horseradish peroxidase were detected with chemiluminescence 
detection system (SuperSignal West Pico Chemiluminescent Substrate; Perbio, Bonn, 
Germany) and membrane was exposed to X - ray RETINA films (Fotochemische Werke, 
Berlin, Germany). 
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5 RESULTS 
 
5.1 Evaluation of a cDNA library enriched for retinal transcripts by the suppression 
subtraction hybridization (SSH) technique 
 
Efficient suppression subtraction hybridization decreases the concentration of 
(housekeeping) genes expressed ubiquitously, and conversely increases the concentration of 
genes expressed differentially in a given tissue (Diatchenko et al., 1996). Human retina RNA 
was amplified by reverse transcription (RT) using oligoT primers, subtracted with cDNAs 
from two nonocular tissues, namely kidney and liver, and cloned into the pCRII vector (see 
Materials and Methods, 4.4.1.1.).  
In total, 1113 clones randomly isolated from the retina SSH cDNA library were 
partially sequenced by Maren Weikert and Lynkeus BioTech Company (Lynkeus, Science 
Park Würzburg). The distribution of the insert length was between 150 to 850 bp. The 
sequences of cDNAs were analysed and compared with sequences deposited in the GenBank 
database. On the basis of BLASTN algorithm analysis, clones were classified in four 
categories including those with I) significant homology to known human genes (766/1113), 
II) significant homology to partial transcripts and hypothetical gene predictions (162/1113), 
III) no homology to known mRNAs (149/1113), and IV) vector sequences and clones derived 
from mitochondrial genes (36/1113) (Table 1). The extent of redundancy in clones originating 
from known genes, ESTs and novel sequences was also determined. After correcting for 
redundancy, category I represented 234 known human genes and category II a total of 92 
unknown transcripts (Table 1). 
 
Table 1. Bioinformatic analysis of 1113 clones from the retina SSH cDNA library 
 
 
Category 
 
Homology to 
 
Number of 
clones  
 
Number of 
genes  
 
I 
 
Known human gene 
 
766  
 
234 
 
II 
 
Partial transcripts and 
hypothetical gene predictions 
 
162 
 
 
92 
 
 
III 
 
Unknown human gene 
 
149 
 
unknown 
 
 
IV 
 
Vector sequences and clones derived from 
mitochondrial genes 
 
 
36 
 
 
6 
 
 
Total number  
of genes 
  1113 
 
>332 
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Alignment of clone sequences demonstrated that 96% of the inserts derived from 
known genes, unknown sequences or novel retina ESTs. As further shown in Fig. 11, 28% of 
cDNAs do not show identity to known GenBank sequences and therefore represent novel 
human retinal transcripts. Of these, 15% were classified as partial transcripts or hypothetical 
genes, whereas 13% of sequences derived from anonymous sequences, i.e. sequences reported 
by ESTs and genomic sequences with no annotation or assigned function. A total of 68% of 
analyzed clones showed identity to known GenBank entries. Minor fractions of inserts 
derived from mitochondrial genes (1%) or were vector sequences (3%). cDNAs representing 
known and mitochondrial genes as well as vector sequences were discarded from further 
analysis. All in silico analysis of the clones were performed on February 2002.  
 
 
 
1113 clones from retina SSH cDNA library divided into subcategories
68%
15%
13% 1% 3%
Known human gene 766/1113
Partial transcripts and hypothetical gene
predictions 162/1113
Unknown human gene 149/1113
Mitochondrial genome 7/1113
Vector sequences 29/1113
 
Fig. 11. BLASTN analysis of 1113 clones from retina SSH cDNA library.  
Based on BLASTN homology search, 1113 clones were divided into subcategories including 
those that derived from known human gene (68%), partial transcripts and hypothetical genes 
(15%), unknown human gene (13), vector sequences (3%) and clones which derived from 
mitochondrial genes (1%). 
 
 
 
5.1.2 Expression analysis 
 
Clones from category II, representing a total of 92 unknown transcripts, were selected 
for expression analysis by RT-PCR which was performed using RNA from 9 human tissues 
including brain, heart, lung, retina, RPE, placenta, thymus, uterus and fibroblast (Fig. 12). For 
each gene, primers were designed based on the clone sequences (primers are listed in 
Appendix, Table 20).  
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L1F/R
L2F/R
L3F/R
L4F/R
L5F/R
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-252
-262
-173
-515
-643
-233-422
-472
-262
-278
-254
-310
-830
-182
-850
-192
-242
-440
-1504
-323
-1615
626-
217-
282-
500-370-
 
 
Fig.12.Expression analysis of 92 cDNAs isolated from retina SSH cDNA library, representing 
partial transcripts and hypothetical genes, by RT-PCR in a panel of  9 human tissues: 1) brain, 
2) heart, 3) lung, 4) retina, 5) RPE, 6) placenta, 7) thymus, 8) uterus, as well as 9) fibroblast 
cDNA, 10) genomic DNA, 11) negative control. L represents internal laboratory ID. 
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- 291
- 145
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- 976
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- 221
- 189
- 676
- 113
- 779
 
 
 
Continue Fig. 12. Expression analysis of 92 cDNAs isolated from retina SSH cDNA library, 
representing partial transcripts and hypothetical genes, by RT-PCR. 
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L41F/R
L42F/R
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-403
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-290
-338
-176
-1181
-476
-1181
-456
-3941
-391
-403
-327
-489
-270
 
 
 
Continue Fig. 12. Expression analysis of 92 cDNAs isolated from retina SSH cDNA library, 
representing partial transcripts and hypothetical genes, by RT-PCR. 
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L63F/R
L64F/R
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-175
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-272
-271
-194
-144
 
 
 
Continue Fig. 12. Expression analysis of 92 cDNAs isolated from retina SSH cDNA library, 
representing partial transcripts and hypothetical genes, by RT-PCR. 
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Continue Fig. 12. Expression analysis of 92 cDNAs isolated from retina SSH cDNA library, 
representing partial transcripts and hypothetical genes, by RT-PCR. 
 
 
 
 
Based on the expression pattern, analysed transcripts were divided in four categories, 
including 1) retina-specific, 2) neuronal-specific, 3) abundant in retina and 4) ubiquitously 
expressed (Table 2). Representative examples of expression profiles, determined by RT-PCR 
analysis, are L33, L45, L18 and L9 genes, respectively (Fig. 12).  For three genes (L50, L51 
and L69) conditions for PCR amplification could not be optimized. Of 92 genes analysed, 16 
were expressed exclusively in retina, 13 were expressed at considerably higher amounts in 
retina compared to the other tissues, and 12 were generally expressed in neuronal tissues 
(Table 2). Thus, the expression analysis resulted in the identification of 29 genes exclusively 
or abundantly transcribed in the human retina. These transcripts are of great potential interest 
for future investigations (Table 3). Of these, retina specific genes L25, L33, L35, L37, L38 
and L40 were selected for further analysis in the course of this thesis. 
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Table 2. Evaluation of the expression analysis of the 92 genes from category II 
 
 
 
Gene expression 
Partial transcripts and  
hypothetical gene predictions 
 
Retina-specific expression 
 
16 
 
Abundant expression in retina 
 
13 
 
Neuronal-specific expression 
 
12 
 
Ubiquitous expression 
 
48 
 
No data 
 
3 
 
Total number of genes 
 
92 
 
 
 
 
Table 3. Chromosomal location and expression pattern of 29 genes that are expressed 
specifically or abundantly in the human retina 
 
 
Lab ID 
 
 
Chromosomal localization 
 
RT-PCR expression 
L02 3p23 Abundant in retina 
L04 1p22.3 Abundant in retina 
L05 10q21.3 Abundant in retina 
L10 14q32.2 Abundant in retina 
L14 2q33.1 Abundant in retina 
L16 2 Retina-specific 
L18 2p15 Abundant in retina 
L20 5 Abundant in retina 
L21 12p12.1 Abundant in retina 
L25 3q27.1 Retina 
L27 2 Abundant in retina 
L28 15q26.1 Abundant in retina 
L30 4 Abundant in retina 
L33 15q23 Retina-specific 
L34 5q13.2 Retina-specific 
L35 7p21.2 Retina-specific 
L36 12p11.21 Abundant in retina 
L37 3q22.1 Retina-specific 
L38 12q21.2 Retina-specific 
L39 4q21.22 Retina-specific 
L40 7p21.2 Retina-specific 
L47 1p21.2 Retina-specific 
L48 11q12.3 Retina-specific 
L48 11q12.3 Retina-specific 
L50 11q23.3 Retina-specific 
L54 9q33.1 Abundant in retina 
L56 11q13.5 Retina-specific 
L59 3p21.31 Retina-specific 
L86 3p14.1 Retina-specific 
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5.2 Construction of a human retina full-length cDNA library 
5.2.1 Optimization of the conditions for the full-length cDNA library construction 
 
To identify the full-length mRNA sequences of the retina-specific genes a full-length 
human cDNA library was constructed. Full-length cDNA identification and characterisation 
still remains the most reliable way to determine the exon – intron organization of a gene. Pre-
mRNA, transcribed in the nucleus, still contains exons and intervening sequences. After 
splicing, the intronic sequences are eliminated, and mature mRNA transcripts containing 
exonic sequences are transported to the cytoplasm. For cDNA library construction, the 
cytoplasmic RNA fraction was used. By removing a bulk of nuclear pre-mRNA, this 
modification significantly decreases the amount of intron-containing clone inserts. 
Construction of a mouse retina cDNA library was first performed to optimize the 
conditions for subsequently generating a human retina cDNA library. Efficiency of 
cytoplasmic RNA isolation was tested using XISTF and XISTR primers (Table 19, Appendix) 
(Fig. 13). The XIST gene is unique among X-linked genes in being exclusively expressed 
from the inactive X chromosome in mammals, with the majority of the transcripts having 
nuclear localization (Das et al., 2001 and Brown et al., 1992). Therefore, efficiency of the 
cytoplasmic RNA separation from the nuclear RNA fraction, isolated from the female mouse 
retina, was tested by performing PCR using the XIST primers. 
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Fig. 13. Fractionation of the cytoplasmic RNA from the mouse retina. 
RT-PCR analysis of the XIST gene in cytoplasmic and total RNA fraction using primers 
directed against the nuclear mouse XIST transcript (see Appendix, Table 19). Cytoplasmic 
RNA preparation does not contain any contaminating nuclear XIST transcript, as shown on 
the picture. Integrity of the generated cDNA was tested using primers which are annealing to 
the mouse G3PDH gene (G3PDHEx8F and G3PDHEx9R, Appendix; Table 19). 
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The mRNA was extracted from the cytoplasmic RNA (Fig 14A) and used for the first 
and second strand cDNA synthesis (see Materials and Methods, 4.4.2.1.1 and 4.4.2.1.2). As 
shown in Fig. 14B, the ds cDNA appeared as a 0.1 - 4 Kb smear, as expected, with several 
bright bands distinguishable against the background smear, corresponding to the abundant 
mRNAs for this tissue. In order to avoid generation of the non-specific PCR products by 
overcycling, the optimal number of cycles for the second strand cDNA synthesis was assessed 
as 22 thermal cycles (Fig. 14B and 14C). 
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Fig. 14. Cytoplasmic RNA and synthesized ds cDNA. A. Formaldehyde/agarose gel 
analysis of the cytoplasmic RNA isolated from fresh mouse retina. Ten micrograms of RNA 
was fractionated on a 1% agarose/formaldehyde gel and visualised by staining with EtBr. 
Arrows indicate the positions of migration of the 28S and 18S rRNA, respectively. B. 6 µl 
(0.5 µg) of the mouse retina poly (A)+ was used as a starting material in a first-strand cDNA 
synthesis. Afterwards, 2 µl of the first strand cDNA served as a template for the optimization 
of the number of cycles for the long distance PCR based second-strand synthesis, using the 
18, 20, 22, 24 and 26 thermal cycles. C. Analysis of a 5 µl sample of the ds cDNA amplified 
with 22 cycles, which is thought to be optimal, alongside of the 1-Kb DNA size marker, on a 
1% agarose/EtBr gel.   
 
 
The 1 – 12 Kb ds cDNA fraction was separated from the low-molecular-weight cDNA 
fragments in order to avoid generation of the library having the abundance of small inserts 
and ligated into the λTriplEx2 vector. The packaged DNA produced more than 1 X 105 
plaques. From ~ 50.000 obtained independent clones, more than 84% were recombinant. 
After their amplification, titre of the final cDNA library was more than 2 X 109 plaques. To 
determine the average size of the cloned cDNA, 36 clones were isolated from the amplified 
cDNA library. Subsequently, plasmid DNA was prepared from randomly picked clones and 
the length of the inserts was examined using agarose gel electrophoresis. The results are 
summarized in the Table 4. There were 11.1% of clones having inserts longer than 2Kb, 
27.8% of cloned inserts which are 1-2 Kb in size, whereas the same percentage of clones had 
inserts below 1 Kb, indicating that size fractionation of the ds cDNA was not overly efficient.  
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Table 4. Size distribution of isolated clones from the mouse cDNAs library 
Fragment size (bp) Number of clones Percentage of clones analyzed (%) 
 
no insert 
 
8 
 
22.2 
0 ~ 500 9 25.0 
500 ~ 1000 5 13.9 
1000 ~ 2000 10 27.8 
> 2000 4 11.1 
Total 36 100.0 
 
 
Obtaining the complete 5’ end of a transcript is the most difficult step in full-length 
cDNA cloning. To evaluate the efficacy of the cDNA cloning for the construction of the 
mouse retina cDNA library, 9 clones were selected for the sequencing of both ends using 
λTriplEx5’ and λTriplEx3’ primers (Table 19, Appendix). The 5’ part was considered 
complete when the published initiation site for transcription was included within the 
sequenced clone insert. The results show that the percentage of the clones having homology 
to the coding sequence of the gene (CDs) for those with mRNA of <1Kb, 1 - 2 Kb, and >2 Kb 
were 100.0%, 80% and 66.7%, respectively (Table 5). When the initiation site of the 
translation was searched, results demonstrated that the likelihood for clone to contain the 5’ 
end was mainly dependent by the size of mRNA since for mRNAs <1 Kb and between 1 and 
2 Kb, the percentages of the inserts having initiation site of translation were 100 and 40.0, 
respectively. For genes with mRNAs longer than 2 Kb none of the clones contained the 
translation initiation ATG (Table 5).  
 
 
Table 5. Coverage of the 5’ end of known genes in selected mouse cDNA clones 
mRNA size Number of clones  CDs included (%) 5’ end included (%)* 
<1 Kb 3 3 (100.0) 3 (100.0) 
1-2 Kb 5 4 (80.0) 2 (40.0) 
>2 Kb 3 2 (66.7) 0 
Total 11 9 (81.8) 5 (45.5) 
*Defined as the clone containing published initiation site of translation. 
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5.2.2 Evaluation of the human retina full-length cDNA library  
 
 Human retina full-length cDNA library (local library ID: Jelena) was constructed 
using the same conditions optimized for the construction of the mouse cDNA library. The 
fraction of 850 bp – 3 Kb of synthetized ds cDNA (Fig. 15C) was selected for the ligation into 
the λTriplEx2 vector. The packaged DNA produced more than 1.3 X 106 plaques. From ~ 
650.000 obtained independent clones, 68% were recombinant. After their amplification, titre 
of the final cDNA library was more than 5.6 X 109. The size of the cloned cDNA was 
analysed by sequencing of the 50 clones from the library. There were 22% clones containing 
inserts which are between 500 bp and 1 Kb in size, and 16% having inserts longer than 1 Kb 
(Table 6).  
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Fig. 15. Cytoplasmic RNA and synthesized ds cDNA. 
A. Formaldehyde/agarose gel analysis of the 10 µg cytoplasmic RNA isolated from fresh 
human retina. RNA was visualised by staining with EtBr. Arrows indicate the positions of 
migration of the 28S and 18S rRNA. B. Analysis of the 5 µl sample of the ds cDNA amplified 
with 23 thermal cycles, which were determined as optimal, alongside of 1-Kb DNA size 
marker, on a 1% agarose/EtBr gel. For this purpose 6 µl (~0.4 µg) of the human retina 
poly(A)+ was used as a starting material in a first-strand cDNA synthesis and 2 µl of the first 
strand cDNA served as a template for the second-strand synthesis. C. Analysis of the 5 µl 
sample of the size selected 850 bp – 3 Kb ds cDNA fraction on a 1% agarose/EtBr gel. 
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Table 6. Size distribution of isolated clones from the human retina full length cDNAs  
   library 
Fragment size (bp) Number of clones Percentage of clones 
characterized (%) 
 
no insert 
 
19 
 
38 
0 ~ 500 12 24 
500 ~ 1000 11 22 
1000 ~ 2000 6 12 
> 2000 2 4 
Total 50 100 
 
 
 
To examine the representation of full-length cDNA clones in the human retina cDNA 
library, 17 clones were selected for further analysis. They were sequenced from both ends 
with λTriplEx5’ and λTriplEx3’ primers (Table 19, Appendix). The percentage of the clones 
having homology to a known open reading frame (ORF) of a gene for those with mRNAs <1 
Kb, between 1 and 2 Kb, and >2 Kb were 100.0%, 100.0% and 33.3%, respectively (Table 7). 
The results show that the likelihood for a clone to obtain the 5’ end was again determined by 
the size of the corresponding mRNA. For mRNAs of <1Kb and 1 - 2 Kb, the percentages of 
the inserts containing a translation initiating first ATG were 85.7 and 100.0, respectively, 
whereas for genes with mRNA longer then 2 Kb none of the clones reached initiation site of 
translation (Table 7).  
 
 
Table 7. Coverage of the 5’ end of known genes by human cDNA clones 
mRNA size Number of clones  CDs included (%) 5’ end reached (%)* 
<1 Kb 7 7 (100) 6 (85.7) 
1-2 Kb 4 4 (100) 4 (100) 
>2 Kb 6 2 (33.3) 0 
Total 17 13 (76.5) 10 (58.8) 
*Defined as the clone containing published initiation site of translation. 
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5.3 Cloning and characterization of retina specific genes 
5.3.1 Cloning and functional characterization of three novel ABCC5 splicing variants 
5.3.1.1 Identification of the full-length cDNA sequences 
 
Sequence analysis of the clones from the human retinal cDNA library constructed by 
suppression subtraction hybridization identified two clones (6D2F and A06-Ret7) that derive 
from an identical locus on chromosome 3q27. The genome sequence comparison also 
revealed that these sequences map within intron 5 of the ABCC5 gene (Fig. 16A). Additional 
BLASTN homology searches with a consensus sequence assembled from the two clones led 
to the identification of AL524917, an mRNA which contains the first five known 5’ exons of 
ABCC5 plus two exons located in the fifth intron of the reference sequence for ABCC5. 
Clone BF954562 which contains two exons of ABCC5 plus one exon also mapped to the 
same intron (Fig. 16A). Since the AL524917 sequence terminates 119 bp upstream from 
clone 6D2F it suggests that the retina sequences could derive from a novel ABCC5 variant. 
To investigate this, retina cDNA was amplified using primers L25F2 and L25R which anneal 
to the first exon of ABCC5 and to the novel retina sequence within intron 5, respectively (Fig. 
16A). A 1700 bp long PCR product could be amplified (Fig. 17A).  
To obtain the full-length sequence of the gene, a radiolabeled 364 bp PCR product was 
amplified with primers L25F and L25R and used to screen the human retina full-length cDNA 
library (local library ID: Jelena), which was cloned in the λTrplEx2 vector. After two rounds 
of screening, three positive clones (L25_1/2, L25_5/1 and L25_6/2) were isolated from 
approximately 1 X 106 recombinant phages. Insert clones ranging from 700 to 850 bp were 
partially or completely sequenced. All clones overlapped the novel retina transcript (Fig. 
16A). In addition, clone L25_6/2 revealed a potential polyadenilation signal (AATAAA) 
located 21 bp upstream from the start of the poly (A) tail and a 30 bp long poly (A) tail.  
To further analyze the novel splice variants, retina cDNA was amplified with primer 
L25F1, which anneals to the fifth exon of ABCC5 and L25rR3 which was designed from the 
novel exon sequences located in intron 5. The PCR reaction not only amplified the expected 
203 and 275 bp products corresponding to BF954562 and AL524917, respectively, but also a 
novel 353 bp product (Fig. 16B). The latter amplicon resulted from the use of an alternative 
splice acceptor site generating an exon termed 5a. The shorter exon isoform is referred to as 
exon 5b whereas the last novel exon was named exon 5c.  
To determine whether the alternatively spliced exons may also constitute additional 
internal exons of the ABCC5 transcript, PCR amplification with primers F1 and R1, which 
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binds to the sixth exon of the ABCC5, was carried out. Only a 267 bp product was amplified, 
indicating that there are no additional exons as part of the full-length ABCC5 transcript and 
that the novel exons encode an alternative 3’ end of the gene (Fig. 16B). In agreement with 
this is the cDNA sequence BC050744, made public at a later time point. This cDNA contains 
the complete 5c exon and a poly (A) tail (Fig.16A). 
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Fig. 16. Genomic organization of the ABCC5_SV1, ABCC5_SV2 and ABCC5_SV3 
isoforms.  
A. Identification of the novel exons 5a, 5b and 5c (represented by the shaded boxes), located 
between exons 5 and 6 of the ABCC5 transporter, was based on the analysis of the 6D2F and 
A06-Ret7 clone sequences from the human retina cDNA library constructed by suppression 
subtraction technique, those isolated from the human retinal full-length cDNA library (local 
library ID: Jelena) (L25_1/2, L25_5/1 and L25_6/3) and known human cDNAs (Acc. No. 
BF954562, AL524917 and BC050744). Exons and introns are not represented in proportional 
sizes. The names and positions of the primers used in this study are shown above the 
schematic representation of the ABCC5 gene. B. Sequences of the ABCC5_SV1 (SV1), 
ABCC5_SV2 (SV2) and ABCC5_SV3 (SV3) isoforms which were assembled by alignment 
of the clone sequences and three PCR products (amplified with L25F1 and L25rR3 primers) 
to the corresponding human draft sequence. Calculated full-length sequences of the isoforms 
and relative locations of stop codons (TGA) are indicated. 
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5.3.1.2 Genomic structure  
 
Three novel alternative exons of ABCC5 transporter named 5a, 5b and 5c and 
comprise 152 bp, 75 bp and 1.142 bp, respectively. They have splice donor and acceptor 
sequences that correspond to the consensus splice junction sequences (Table 8) and conform 
to the GT-AG rule (Burset et al, 2000). The score for the donor splice site is 0,803 for both 5a 
and 5b exons, and scores for the acceptor splice sites for 5a, 5b and 5c exons are 4.07, 10.666 
and 5.16 respectively, which is within the expected range for true donor (0-11) and acceptor 
site (0-20) (spreadsheet compiled by Dr. Christian Sauer, 2001; Institute for Human Genetics, 
Wuerzburg, Germany).  
In conclusion, analyses resulted in the identification of three splicing variants of 
ABCC5 gene, named ABCC5_SV1 (GeneBank accession number AY754874), ABCC5_SV2 
(GeneBank accession number AY754875) and ABCC5_SV3 (GeneBank accession number 
AY754876). All three splicing variants share the first five exons with ABCC5, but contain 
different 3' ends derived from alternative splicing of exons located in intron 5 of ABCC5. As 
a result their mRNAs are 2039 bp, 1962 bp, and 1887 bp long, respectively.  
 
 
 
 
5.3.1.3 In-silico analysis of cDNA sequences ABCC5_SV1, ABCC5_SV2, ABCC5_SV3 
 
Analysis of the open reading frames of the novel isoforms led to the discovery that the 
stop codon of SV3 is located in the last exon, whereas those of SV1 and SV2 are located 
upstream of the last exon-intron junction. The SV2 termination codon is located only 39 bp 
upstream of the last exon/exon junction, but the SV1 stop codon is found more than 100 bp 
upstream of the last exon/exon junction (Fig. 16B). 
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Table 8. 
Exon-intron boundaries of the human ABCC5 gene 
 
a For the splice junctions, intronic and exonic sequences are shown in small and capital letters, 
respectively. The 5’ splice-donor and 3’ splice-acceptor sequences are given in bold. 
b Scores were calculated to references (Berg et al, 1988 and Penotti et al. 1991). 
Approximately 99% of sites have a score of 0-20 (3’acceptor site) and 0-11 (5’donor site). 
 
 
 
 
 
 
 
 
Exon 
 
3' Splice acceptor sitea 
 
5' Splice donor sitea 
 
Intron 
 
No. Size (bp) Sequence Scoreb Sequence Scoreb No. Size (bp) 
1 60   ..CAGgtaggt.. 1.894 1 3.382 
2 184 ..gaatttttaatttcagG.. 6.629 ..CCGgtcagt.. 4.773 2 28.880 
3 158 ..ctatctgctggaacagT.. 10.655 ..CAAgtaaga.. 3.140 3 498 
4 156 ..ggttttctctccttagA.. 4.766 ..AAGgtaggc.. 3.041 4 654 
5 148 ..gtgtgcccttgttaagA.. 10.527 ..CCAgtaagt.. 3.517 5 4.762 
5a 152 ..ctctctccacctgcagC.. 4.070 ..CAGgtaagg.. 0.803 5 409 
5b 75 ..agaagctgttctttagA.. 10.666 ..CAGgtaagg.. 0.803  409 
5c 1.142 ..cctgctgtcctttcagC.. 5.160     
6 234 ..gtgtctctccctgtagG.. 4.096 ..GAGgtgagt.. 0.944 6 149 
7 174 ..tctttgtatcttatagC.. 6.558 ..ATGgtgagt.. 1.783 7 576 
8 148 ..tcgcttttcctttcagA.. 2.577 ..AAAgtgagt.. 2.384 8 3.075 
9 149 ..tgctttttattcatagA.. 5.030 ..CAGgtcagg.. 4.142 9 878 
10 108 ..cttctcctattttcagG.. 2.779 ..AAGgtaagt.. 0.221 10 5.597 
11 357 ..tcacaactcctatcagA.. 9.244 ..GAGgtaagt.. 0.865 11 3.796 
12 72 ..tgtgtgccttgtccagG.. 6.334 ..CAGgtaaga.. 1.057 12 2.193 
13 125 ..gtgtctctctccctagA.. 4.571 ..AAGgcaagg.. 6.406 13 119 
14 73 ..tctttgtgtcctccagA.. 3.885 ..GAGgtacag.. 6.034 14 1.596 
15 204 ..ttctgggctcttgtagA.. 7.324 ..CAGgtatgg.. 3.131 15 1.730 
16 144 ..ctgcctttgccttcagT.. 4.647 ..GAGgtaaga.. 1.921 16 1.675 
17 103 ..ttttaaatattattagA.. 11.973 ..AAGgtaatg.. 3.913 17 6.462 
18 185 ..tttttttcttacctagG.. 3.505 ..GGGgtaagg.. 2.994 18 1.082 
19 147 ..ctttggcttcaaacagA.. 8.116 ..AAGgtatgc.. 3.474 19 286 
20 130 ..gtgctctgctcctcagG.. 4.412 ..AAGgtattt.. 5.437 20 1.315 
21 154 ..ttatttgtttccacagT.. 4.791 ..CAGgtaaat.. 2.459 21 90 
22 129 ..ctcattctctctccagG.. 2.016 ..CAGgtttgt.. 5.249 22 2.242 
23 187 ..gttgtctttctcacagA.. 3.740 ..CAGgtcagt.. 3.339 23 1.384 
24 90 ..tgttttccattatcagT.. 6.957 ..AAGgtcaga.. 4.616 24 2.933 
25 190 ..acccttgtctccccagA.. 3.950 ..CAGgtaagg.. 0.803 25 4.666 
26 160 ..tcttctgactcatcagG.. 6.244 ..CAGgtgagg.. 0.883 26 9.075 
27 79 ..ctgtgtttctccctagA.. 4.674 ..TGTgtaagt.. 4.885 27 1.303 
28 114 ..gtttctttctccctagA.. 3.357 ..AAGgtaagg.. 1.025 28 1.610 
29 165 ..tctgcttctctggcagA.. 4.977 ..CAGgtaccg.. 5.517 29 4.153 
30 1.468 ..tctccttcttttgcagG.. 1.220    
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bp         aa 
 Exon 1                                             
1        CCGGGCAGGTGGCTCATGCTCGGGAGCGTGGTTGAGCGGCTGGCGCGGTTGTCCTGGAGC 
 
 Exon 2  
61  AGGGGCGCAGGAATTCTGATGTGAAACTAACAGTCTGTGAGCCCTGGAACCTCCACTCAG 
121 AGAAGATGAAGGATATCGACATAGGAAAAGAGTATATCATCCCCAGTCCTGGGTATAGAA 
             M  K  D  I  D  I  G  K  E  Y  I  I  P  S  P  G  Y  R   18 
181 GTGTGAGGGAGAGAACCAGCACTTCTGGGACGCACAGAGACCGTGAAGATTCCAAGTTCA 
   S  V  R  E  R  T  S  T  S  G  T  H  R  D  R  E  D  S  K  F  38 
 
 Exon 3 
241 GGAGAACTCGACCGTTGGAATGCCAAGATGCCTTGGAAACAGCAGCCCGAGCCGAGGGCC 
  R  R  T  R  P  L  E  C  Q  D  A  L  E  T  A  A  R  A  E  G     58  
301 TCTCTCTTGATGCCTCCATGCATTCTCAGCTCAGAATCCTGGATGAGGAGCATCCCAAGG 
  L  S  L  D  A  S  M  H  S  Q  L  R  I  L  D  E  E  H  P  K     78 
 
                                                   Exon 4 
361 GAAAGTACCATCATGGCTTGAGTGCTCTGAAGCCCATCCGGACTACTTCCAAACACCAGC 
  G  K  Y  H  H  G  L  S  A  L  K  P  I  R  T  T  S  K  H  Q     98 
421 ACCCAGTGGACAATGCTGGGCTTTTTTCCTGTATGACTTTTTCGTGGCTTTCTTCTCTGG 
  H  P  V  D  N  A  G  L  F  S  C  M  T  F  S  W  L  S  S  L  118 
481  CCCGTGTGGCCCACAAGAAGGGGGAGCTCTCAATGGAAGACGTGTGGTCTCTGTCCAAGC 
  A  R  V  A  H  K  K  G  E  L  S  M  E  D  V  W  S  L  S  K  138 
 
                              Exon 5 
541  ACGAGTCTTCTGACGTGAACTGCAGAAGACTAGAGAGACTGTGGCAAGAAGAGCTGAATG 
  H  E  S  S  D  V  N  C  R  R  L  E  R  L  W  Q  E  E  L  N  158 
601  AAGTTGGGCCAGACGCTGCTTCCCTGCGAAGGGTTGTGTGGATCTTCTGCCGCACCAGGC 
   E  V  G  P  D  A  A  S  L  R  R  V  V  W  I  F  C  R  T  R  178 
 
                                                          Exon 5a 
661  TCATCCTGTCCATCGTGTGCCTGATGATCACGCAGCTGGCTGGCTTCAGTGGACCACTTG 
  L  I  L  S  I  V  C  L  M  I  T  Q  L  A  G  F  S  G  P  L  198 
721  CTTGGTGCTGTCAGGATCTGGATTTGGGGGGAGTCTCTCTGTAGTGGAACCAGTGACAGA 
   A  W  C  C  Q  D  L  D  L  G  G  V  S  L -                 212 
 
  Exon 5b 
781  AGCTGTTCTTTAGAATTTTCAGGATGGCTGTATTCTGCGGTCAGAATGAGAGAGTCAAGC 
                        N  F  Q  D  G  C  I  L  R  S  E  -          208 
  
                              Exon 5c 
841  TGGGCAGAATCTCTCGCCAAGAGTTCAGCCTTCCTTTGGAGACTGCTCCATCAGTGCCGA 
                                      P  S  F  G  D  C  S  I  S  A  E 205  
901  GGTGTGTGGGAACAGGCTTCACTGCACCGCCATCTTACTGAGTTGCTTCACGTGAGGAAA 
   V  C  G  N  R  L  H  C  T  A  I  L  L  S  C  F  T  -        225  
961  AGGGGGCTTTGGCCCTGTGACTCAGTTCCACATTTTGGATTGCATACTGGAAAAGAAGCC 
1021 AATCTTCTTGCTAGTAAACCAGCAACCCGGCTGTATACAGTGGTGACCCAAGCAATGGAT 
1081 ATAAACCTAAAAATCTGAGGGAGGGGAGAGGTGGAATACAGTAGTTCTTGGAATCTGAAG 
1141  TCTCCTATTTGATCAGGTTATTTCCTGGGACTTGGCAAAAATCTGATTGGTGGGGATCTC 
1201 CTAGGACCTAGTGGACATCTGGTATTAATTTAATCTCAGGAAAAACAAGAAATTAACCCA 
1261  GAGAGAGTCTGGGTTTTGGAATTCAGCGTAGCTACCTCCAGACCGTGGTGTCTGGCCTCC 
1321 ATTTTTGTCTGTCATTCAGCTCTGACTTACAGCTGCAGTCACCTTTGCTATAAGGCACCT 
1381 GGGTAGAAGGGTGGATGGGCTTCACATCAATTTTTTTCTTCCTTTAGGGTGGGGGATTGG 
1441 TTTGGCTTTCTTTTGTTGTGGTTTTTTGTTTTATTTTTGTCAAGATTGATTTTTAGATGC 
1501 AAGGACTTGAAAAGACCCAGAAGGATGCCACCAGTTTTTCCTTGAGGCCTAGGATTTTTT 
1561 ATTCTGTCCCGAGCAGAGGTAATTCCTCACAACTTAGTGCACCAGTAGCACCAGCCATTT 
1621 TGAGCAGAGTACCTCTTTGGGGAGCTTTTCGTTTTGTTTTGTTTTTAATTCTCTTTCCTT 
1681 AGCAGCAAGGTCTTTTTTCCTAGAGAATCTACTCCGTTGCAGAATCATTGCAACCTCAGG 
1741 AGCCCTCACTGATTGAGTGCTGTCAGCCTGATATACTACTTTGGACTCTGGAAACAGATA 
1801 TGGGTTCTATTCTCTATTTCTACTGTGTGTCGTTAAACAACCGTCGGAGACCAGATGACC 
1861 TGTTAGATGGCTAGTCCTGTATAACTCGACTCTGTATGTTTCAATGTATGTTACTGCAAT 
1921 GCTTCACCTGCTGTACAGTGTTTGTGAGATGCTCTTTGAAGATGGTACTTTTATATTTTT 
1981 TCATTTTCAATAAAAGTACATTCCTTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
 
Fig. 17. Full-length cDNA sequence and putative ORFs of ABCC5 splicing variants SV1, 
SV2 and SV3. Nucleotide sequence is numbered starting with the first base of the ABCC5 
cDNA. The corresponding amino acid sequence and amino acid positions are indicated 
bellow the nucleotide sequence. All three splicing variants contain common 197 amino acid 
stretch (grey highlighted), whereas 15 aa (yellow background), 11 aa (pink highlighted) and 
28 aa (green highlighted) are encoded specifically by SV1, SV2 and SV3 transcripts. Start 
codon, stop codons (located in exon 5a, 5b and 5c in SV1, SV2 and SV3, respectively) and 
putative polyadenilation signal (AATAAA) are boxed. 
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5.3.1.4 Expression analysis  
 
RT-PCR amplification was done with primers L25F2 and L25R, which are amplifying 
SV1, SV2 and SV3 splicing variants, in a panel of 18 human tissues and showed that all three 
isoforms are highly expressed in retina with lower expression level in brain, fetal brain, spinal 
cord, bone marrow, RPE, spleen, skeletal muscle, testis and prostate (Fig. 18A). The reported 
ubiquitous expression of the ABCC5 transporter determined by Northern blot analysis 
(McAleer et al., 1999) was confirmed in a PCR with primers F1 and R1 (Fig. 18A). However, 
high levels of expression of ABCC5 transcript were identified in retina and RPE.  
The relative expression of each isoform was determined by qRT-PCR in 10 tissue 
panel. Analysis confirmed abundant expression in retina for all three splicing variants (Fig. 
18B). The level of expression of the SV1 transcript in retina is 2.5-fold higher than in 
cerebellum and approximately 4-fold higher compared to other tissues. The SV2 isoform is 
expressed in retina and RPE at almost the same level and approximately 50% less in bladder 
compared to its expression in retina, whereas expression in other tissues is much lower. 
Compared to retina, 3-fold weaker expression of the SV3 splicing variant was determined in 
cerebellum and RPE, whereas transcription was almost not detectable in the remaining tissues 
of the panel. Quantitative real-time PCR analysis of ABCC5 confirmed abundant expression 
of the transcript in retina, as shown already with RT-PCR, with approximately 2-fold lower 
expression in cerebellum, occipital cortex (occ. cortex) and RPE and very weak expression 
obtained in other tissues.   
To determine the size of the various splice variants of ABCC5 and to confirm the 
hypothesis that exon 5c is used as their internal exon, a radiolabeled PCR fragment was 
amplified from exon 5c and hybridised to a virtual Northern blot containing cDNAs from six 
human tissues (Fig. 18C). A strong band of approximately 2 Kb, which corresponds to the 
calculated length of the novel SV1, SV2 and SV3 isoforms of ABCC5, was detected 
exclusively in retina. 
RT-PCR with primer pair L25F1 and L25rR3, which is amplifying all three splicing 
variants, demonstrated that they are expressed at different levels in retina (SV3>SV2>SV1, 
Fig. 16B). 
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Fig. 18. Expression analysis of the ABCC5 isoforms.  
A.  Expression analysis of ABCC5 wild type and SV1, SV2 and SV3 alternatively spliced 
transcript in 18 human tissues done by RT-PCR. Primer pair L25F2 and L25R, amplifying all 
three splicing variants, showed that they are abundantly expressed in retina and weaker in 
brain, fetal brain, spinal cord, bone marrow, RPE, skeletal muscle and testis. Expression 
analysis performed with primers L25F1 and L25R1 determined that ABCC5 gene is 
ubiquitously expressed in human tissues with high abundance in retina and RPE. The same 
panel was amplified with G3PDH specific primers as a control of cDNA quality. B. Relative 
expression of ABCC5 isoforms done by qRT-PCR in panel of 10 human tissues. Expression 
analyses were performed with primers specific for each isoform. For each isoform expression 
data were normalized to four housekeeping genes (see Materials and Methods, 4.3.2.2) and to 
the highest expression of in the panel, which was set as 1. Analysis showed that all tested 
isoforms are abundantly expressed in retina. C. Transcript size of SV1, SV2 and SV3 was 
determined by virtual Northern blot analysis and signal at approximately 2.0 Kb was detected 
in retina. 
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5.3.1.5 Functional characterization of the splice variants 
5.3.1.5.1 Nonsense mediated mRNA decay in isoform SV1 containing a premature 
termination signal  
 
It has been shown that a stop codon found 50-55 bp upstream of the last exon-exon 
junction is recognized as premature termination codon (PTC) by the translational machinery. 
As a consequence, the transcript will undergo nonsense mediated mRNA decay (NMD) 
(Henze and Kulozik 1999). To investigate whether this mechanism plays a role in the 
degradation of the SV1 isoform, which fulfils this criterion, a protein synthesis inhibition 
method was used. It is known that the NMD machinery operates in a translation dependent 
manner which can be inactivated by blocking protein synthesis with a number of antibiotics 
(Maquat, 2004). Specifically, human cell lines ARPE-19 and Y79 were treated with either 
puromycin or anisomycin for two hours. Total RNA samples were extracted from untreated 
cells and those treated with antibiotic and RT-PCR was conducted to assess the level of 
expression for the various splicing variants. As expected for a transcript which normally 
undergoes NMD, treatment of the cell lines with protein synthesis inhibitors demonstrates 
clear enrichment of the SV1 transcript over those not undergoing NMD (such as SV2 and 
SV3) (Fig 19). 
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Fig. 19. Protein synthesis inhibition selectively increases PTC containing SV1 RNA. 
Antibiotic treatment was performed on ARPE-19 and Y79 cell lines. Total RNA was isolated 
from untreated cells (-) or those treated with 100 µg/ml puromycin (P) or 100 µg/ml 
anisomycin (A) for 2h. RT-PCR amplification was done with L25F1 and L25rR3 primers 
which are amplifying all three splicing variants. 
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To confirm the results obtained, again the cells were treated with antibiotics, the 
antibiotic was then removed by washing with 1 X PBS and half of the cells were incubated in 
drug-free medium for an additional 4h (Lamba et al., 2003). In order to generate consistent 
and reliable results, all experiments were done in triplicates and the amount of all three 
splicing variants was determined by qRT-PCR. The amount of SV1 drastically increased as a 
result of protein synthesis inhibition but returned to previous levels after protein synthesis was 
restored, whereas no changes in the amount of SV2 and SV3 transcripts were detected (Fig. 
20). In particular, puromycin treatment increased the relative amount of SV1 mRNA almost 
3-fold in the ARPE-19 cell line and more than 2-fold in the Y79 cell line, whereas the amount 
of wild type ABCC5 mRNA decreased by a factor of two in both cell lines at comparable 
time points (Fig. 20). The initial transcript concentrations were restored after washing.  
In the cell lines treated with anisomycin, an average 4- and 2-fold increase of SV1 
mRNA was determined in ARPE-19 and Y79, respectively, whereas ABCC5 mRNA levels 
decreased to half of the original amount. Even four hours after antibiotic removal, higher 
expression levels of SV1 and less quantity of ABCC5 mRNA were still detectable in the 
ARPE-19 cells. The recovery of protein synthesis after anisomycin treatment in the Y79 cell 
line seemed to be faster as the level of expression for both isoforms were slowly returning to 
normal (Fig. 20). Again, drastic changes of amounts of SV2 and SV3 mRNA were detected in 
the course of inactivation of the NMD machinery. This observation suggests that ABCC5 
expression might be regulated by the transcription level of ABCC5_SV1. 
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Fig. 20. Effects on inactivation of NMD on wild type and alternatively spliced ABCC5 
transcripts.  
Treatment of the human cell lines ARPE-19 and Y79 with inhibitors of protein synthesis 
puromycin or anisomycin resulted in stabilisation of PTC containing SV1 transcript, followed 
by decrease in amount of ABCC5 mRNA, two hours after the treatment with antibiotic. 
Expression of the transcripts were monitored by qRT-PCR analysis using samples of the total 
RNA which was isolated from the untreated cells, cells treated with antibiotic (puromycin or 
anisomycin) and from the cells 4h after the treatment (Post-Puromycin and Post-Anisomycin). 
Expression of all transcripts were normalised to their expression level in untreated cells which 
was set as 100%, and to four housekeeping genes (see Materials and Methods, 4.3.2.2). Error 
bars represent standard errors. 
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5.3.1.5.2 Silencing of SV1, SV2 and SV3 isoforms with siRNA duplexes  
 
To investigate whether the expression of the ABCC5 isoforms is co-regulated by the 
transcription level of ABCC5_SV1 mRNA, three alternative isoforms were systematically 
silenced by RNA interference. First, the sequence of the siRNA.1 probe was designed to 
anneal to the 3’ untranslated region common to all three isoforms as described in Materials 
and Methods (see siRNA design and sequences, 4.7.2). Silencing of target transcripts was 
examined in cultured ARPE-19 cells transfected with siRNA.1 duplexes and their effects 
were compared with mock-transfected cells (Fig. 21).  
To optimize conditions for effective RNA silencing, the time course for siRNA-
mediated reduction of SV1, SV2 and SV3 expression was determined. Cells were harvested at 
8, 24, 48 and 72 hours after siRNA transfection in order to prepare RNA extracts. Gene 
silencing potential was monitored by qRT-PCR and analysis revealed that all three transcripts 
were effectively silenced 48h after transfection with siRNA.1, leading to approximately 80% 
decrease of expression in comparison to control cells (Fig. 21). The amount of SV3 remained 
low even 72h posttransfection time, whereas inhibition of SV1 and SV3 increased again at 
this time point. Obtained data indicate that siRNA.1 have a high degree of specificity which 
resulted in specific decrease of SV1, SV2 and SV3 expression without detected effects on the 
expression level of control housekeeping genes (data not shown).  
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Fig. 21. Optimization of the conditions for effective RNA interference.  Time course of 
reduction of expression of SV1, SV2 and SV3 transcripts was examined in ARPE-19 cells, 
which were transfected with siRNA.1 duplexes (2.0 µg/well) directed against all three 
alternatively spliced transcripts. Mock control was generated by addition of the buffer instead 
of the volume of siRNA used for the transfection of the culture. Extracts of RNA were 
prepared from each set of these cells at 8, 24, 48 and 72 hours posttransfection and analysed 
by real-time PCR using primers specific for each transcript. The amounts of SV1, SV2 and 
SV3 transcripts were calculated according to a model published by Vandesompele et al. 
(2002), by normalization to housekeeping genes B2M, TBP, SDHA and HPRTI (see 
Materials and Methods 4.3.2.2) and to mock-transfected cells (expression was set as 100). 
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After successful optimization of the conditions for specific knockdowns of SV1, SV2 
and SV3 using siRNA.1 duplexes, experiments were repeated in triplicates in order to 
generate consistent results. The 80% decrease of SV1, SV2 and SV3 expression 48h after 
siRNA transfection was reproducible and it was followed by linear increase of ABCC5 which 
was observed during this same time period (Fig. 23A). In order to specify which of the three 
splicing variants may influence expression of the full-length transporter ABCC5, silencing 
experiments were performed with siRNA.2 duplexes directed selectively against SV1 and 
SV2 isoforms and with siRNA.3 designed to inhibit exclusively SV1. The most effective 
silencing of SV1 obtained with siRNA.2 duplexes was monitored 24h after transfection, 
whereas the most effective inhibition of SV2 mRNA was monitored 48h after transfection. 
This knockdown of both, SV1 and SV2 led to increase of ABCC5 expression to a level of 
approximately 50% compared to control cells (Fig. 23B). Incubation of the ARPE-19 cells 
with siRNA.3 resulted in 50% decrease of SV1 expression one day after transfection, 
followed by a significant increase of ABCC5 (Fig. 23C). As expected, siRNA.2 did not alter 
the amount of SV3 mRNA. In contrast, the reason for the significant decrease of SV2 and 
SV3 transcripts in cells transfected with siRNA.3 is not clear. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 76
 
 
 
SV 1
SV 2
SV 3
ABCC5
Re
la
tiv
e 
ex
pr
es
sio
n
200
150
100
50
0
MOCK 8h 24h 48h
siRNA.1
0
50
100
150
200
250
MOCK 8h 24h 48h
R
el
at
iv
e
ex
pr
es
sio
n
siRNA.3
0
25
50
75
100
125
150
175
MOCK 8h 24h 48h
R
el
at
iv
e
ex
pr
es
sio
n
siRNA.2
Fig. 22. Silencing of SV1, SV2 
and SV3 transcripts. A. The 
A R P E - 1 9  c e l l  l i n e  w a s  
t ra nsf e ct e d wi th  s i RN A.1  
duplexes (2.0 /well) directed 
against all three alternatively 
spliced transcripts. B. The ARPE-
19 cell line was transfected with 
siRNA.2 duplexes (4.0 ) 
designed to silence SV1 and SV2, 
selectively. C. The ARPE-19 cell 
l ine  wa s  t ra nsfe ct ed  wi th  
siRNA.3 (8.0 ) directed 
selectively against SV1. Extracts 
of RNA were prepared from the 
cells at 8, 24 and 48 hours after 
transfection and analysed by real-
time PCR using primers specific 
f o r  S V1 ,  SV 2  a n d  SV 3  
transcripts. The amount of each 
transcript was normalization to 
housekeeping genes B2M, TBP, 
SDHA and HPRTI and to mock-
transfected cells (calculations 
were done according to a model 
published by Vandesompele et al. 
(2002)). Moc k control  wa s 
generated by transfection of the 
culture with non-silencing siRNA 
duplexes (Qiagen) and expression 
of the transcript obtained in these 
cells was set as 100. Data are 
average of three independent 
experiments  and error bars 
represent standard errors.
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5.3.1.5.3 Characterization of truncated proteins 
 
Above, we have shown that SV1 mRNA is degraded by a NMD surveillance 
mechanism. Transcripts of SV2 and SV3 have stop codons that are 3’ of the last splice site 
and according to the rules of NMD (Henze and Kulozik, 1999), these transcripts should not be 
targets of NMD. Their mRNAs should be stable and serve as a template for the translation of 
C-terminally truncated ABCC5 proteins. The length of the putative proteins should be 208 aa 
and 225 aa, respectively, each sharing the first 197 aa with ABCC5 (Fig. 17). In-silico 
analysis of the remaining 11 aa encoded by SV1 and 28 aa encoded by SV3 (Fig. 17) did not 
reveal any sequence homologies to known protein domains, nor did it yield clues as to their 
putative functions.  
It has been reported that similar to other ABC transporters, human ABCC5 contains 
Walker A, B and C motifs, two nucleotide binding domains (NBD1 and NBD2) and twelve 
transmembrane spanning helices in two hydrophobic domains (TMD1 and TMD2) (Kool et 
al., 1999). TMD1 is encoded by exons 5-8; each of the NBDs in encoded by five exons, 11-15 
for NBD1 and 25-29 for NBD2, encode each of the NBDs; the TMD2 is encoded by exons 
17-23 (Fig. 23). Both TMDs, each have six transmembrane helixes. Based on the membrane 
protein topology prediction method TMHMM, which is available at 
http://www.cbs.dtu.dk/services/TMHMM-2.0/, it was determined that the first transmembrane 
helix of TMD1 corresponds to aa 179-201. This amino acid stretch is almost completely 
contained in both putative truncated proteins encoded by ABCC5_SV2 and ABCC5_SV3 
isoforms. Hydropathy analysis of putative membrane spanning domains by TMHMM did not 
predict transmembrane domains, suggesting that the two isoforms may be soluble proteins. 
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Fig. 23. Genomic organization of the human ABCC5 gene. Exons coding transmembrane 
domains (TMDs) and nucleotide binding domains (NBDs) of ABCC5 have been underlined. 
The ABCC5 has 30 exons and inclusion of exons 5a, 5b and/or 5c (exons are boxed) 
introduce alternative stop codons and activate the NMD machinery (inclusion of exon 5a), or 
generation of putative C-terminally truncated ABCC5 proteins (transcripts containing 5b 
and/or 5c exons). Exons and introns are drown in proportional sizes and start and stop codons 
of ABCC5 are represented with arrows in 2nd and last 30th exon, respectively.  
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5.3.1.5.4  Polyclonal antibody production 
 
Immunofluorescence analysis of ABCC5 using antibodies raised against its N-
terminus (82-168 amino acids) revealed predominant plasma membrane localization with 
some intracellular staining (Wijnholds et al., 2000). The latter staining may indicate the 
truncated proteins encoded by SV2 and SV3 transcripts. In order to demonstrate the existence 
of those two C-terminally truncated ABCC5 proteins, generation of polyclonal antibodies 
against their unique C-termini was initiated. 
To obtain a polyclonal antiserum, mice were immunized with synthetic GST-fusion 
protein constructs containing the antigenic regions specific for each putative protein. The 
epitopes selected for generation of polyclonal antibodies were amino acids 198 to 208 for the 
SV2 protein (5’-NFQDGCILRSE-3’) and amino acids 198 to 225 (5’-
PSFGDCSISAEVCGNRLHCTAILLSCFT-3’) for the SV3 protein (Fig. 17). In order to 
obtain synthetic constructs, cDNA fragments corresponding to selected amino acid stretches 
were amplified by RT-PCR using primer pairs L25SV2-EcoRI-F and L25SV2-XhoI-R 
specific for SV2 and L25SV3-EcoRI-F and L25SV3-XhoI-R1 specific for SV3 (Appendix, 
Table 21). Obtained products were cloned in frame into the multiple cloning site of the 
pGEX-4T-3 vector (see Materials and Methods, DNA methods, 3.4.3 and 3.4.4) and 
expressed in BL21 cells (see Materials and Methods, 4.1 polyclonal antibody production). 
Different amounts of affinity purified GST-fusion proteins were used for immunization of six 
Balb/c mice (see Materials and Methods, .2). Mice were boosted twice with corresponding 
GST-fusion proteins.  
The specificity of polyclonal mouse serum was tested by Western blot analysis using 
the MBP-fusion proteins containing the corresponding SV2 and SV3 peptides (for generation 
of the constructs see Materials and Methods, 4.4 polyclonal antibody production). Results 
showed that antisera failed to detect any of the MBP-fusion proteins (data not shown). In 
addition, the 1D4 tag was inserted in frame in the C terminus of the full-length SV2 and SV3 
proteins (see Materials and Methods, 4.4), and the resulting recombinant gene was transfected 
into the 293-EBNA cell line. Western blot analysis with cellular extracts containing both 
overexpressed fusion proteins revealed no positive response. As a control, labelling was 
observed with monoclonal anti Rho-1D4 antibodies recognized corresponding fusion protein 
of approximately 25 kDa (data not shown). In addition, immunoractivity was not detected in 
the preimmune serum (data not shown).   
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5.3.1.6 Conservation of exons 5a, 5b and 5c of isoforms SV1, SV2 and SV3 
 
Amino acid sequence of the human ABCC5 (MRP5) and mouse Abcc5 (mrp5) is 
highly conserved (94.1%) (Suzuki et al., 2000). In order to analyse whether the sequences of 
novel exons 5a, 5b and 5c are evolutionary conserved among mammalian species, nucleotide 
homology searches with human cDNA sequences of those three exons were done and 
revealed high level of identity to bovine, porcine and mouse ESTs for exon 5b (Fig. 24). 
Homology searches failed to show significant evolutionary conservation for exons 5a and 5c. 
 
      * 
Human 1 AATTTTCAGGATGGCTGTATTCTGCGGTCAGAATGAGAGAGTCAAGCTGGGCAGAATCTCTCGCCAAGAGTTCAG 
Bovine 1 AATTTTCAGGATGGCTGTATTCTGCGGTCAGAATGAGAGAGTCAAGCTGGGCAGAATCTCTCGCCAAGAGTTCAG 
Porcine 1 AATTTTCAGGATGGCTGTATTCTGCGGTCAGAATGAGAGAGTCAAGCTGGGCAGAATCTCTCGCCAAGAGTTCAG 
Mouse 1 AATTTTCAGGATGGCTGTATTCTGCGGTCAGAATGAGAGAGTCA-GCTGGGCAGAATCTCTCGCCAAGAGCTCAG 
 
 
Fig. 24. Multiple sequence alignment of the nucleotide sequences of the 5b exon.  
Human exon sequence is aligned with bovine, porcine and mouse EST sequences using 
ClustalW program. The conserved sequence is shaded with BoxShade. Species and EST 
accession numbers are: bovine, Bos taurus (GeneBank Acc.No. BI848281); porcine, Sus 
scrofa (GeneBank Acc.No. BI345271) and mouse, Mus musculus (GeneBank Acc.No. 
AW124768).  
 
 
To investigate possible splicing events in mouse, RT-PCR was performed using 
primers L25F1, located in exon 5 of the murine Abcc5 and L25R4_Mus, primer sequence 
designed based on mouse AW124768 cDNA which sequence is almost identical to the human 
5b exon. Amplification resulted in two PCR products ubiquitously expressed in various 
mouse tissues (Fig. 25B). After sequencing their nucleotide sequences were aligned to the 
mouse genomic DNA, confirming an orthologous exon 5b in the murine AW124768 cDNA. 
Analysis of the nucleotide sequences showed that exon 5a is not conserved in mouse, whereas 
difference in length of two PCR products derives from usage of alternative splice acceptor site 
in an exon corresponding to human 5b. PCR amplification using L25F1 primer that binds to 
the fifth exon of the Abcc5 and L25R1 primer that binds to the sixth exon of the Abcc5 
resulted in only a single PCR product, suggesting that there are also no additional exons 
between exon five and six in the full-length transcript of the murine Abcc5 (Fig. 25A).  
Analysis of the nucleotide sequences of the PCR products amplified with L25F1 and 
L25R4_Mus suggest presence of two different splicing variants of the Abcc5 gene, both 
homologues to ABCC5_SV2 transcript, having a stop codon in an exon that is orthologuous 
to human 5b (Fig. 25C).  
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Fig. 25. Identification of novel splicing isoforms of murine Abcc5 and their structural 
comparison to human homologue sequences. A. RT-PCR with primers L25F1 and L25R1 that 
anneal to the fifth and sixth exon of Abcc5, respectively, showed that there are no additional 
exons between those two exons in the transcript of the mouse transporter. B. RT-PCR 
performed with forward L25F1 primer, which anneals to the fifth exon of Abcc5 and reverse 
L25R4_Mus primer, which anneals to the exon 5.3 of Abcc5. Two different PCR products, 
which were 297 bp and 258 bp long, were amplified from mouse brain, heart, lung, eye, 
skeletal muscle, liver and kidney cDNAs showing ubiquitous expression of the transcripts 
among those tissues. C. Schematic comparison of human ABCC5 and murine Abcc5 showing 
differential splicing affecting the fifth intron of this gene in both species.  
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5.3.2 Cloning and characterization of the L33 gene 
5.3.2.1 Identification of the full-length cDNA sequence  
 
Initial sequences of the L33 (laboratory internal ID number) gene were 14 clones 
isolated from the retina SSH cDNA library. These sequences belong to partial transcripts with 
retina specific expression.. A number of additional clones were publically available from the 
same locus on chromosome 15q23. The consensus sequence representing 4F10F, G09_Ret15, 
E11_Ret15, F12_Ret14, D10_Ret6 and 3A4F clones (Fig. 26B) were subjected to a homology 
search against GenBank database using the BLASTN program and additional human ESTs 
were obtained. Analysis of the longest fragments (accession number BQ189587 and 
BF529111) confirmed the compiled consensus cDNA sequence (Fig. 26B). Moreover, four of 
the matching EST clones (GenBank accession numbers AI478365, BE220398, BF110735 and 
BF446762) were obtained from the I.M.A.G.E. consortium, but their sequencing did not 
reveal any new information.   
To obtain the full-length sequence of the L33 gene, the human retina full-length cDNA 
library (local library ID: Jelena), cloned in λTriplEx2 vector, was screened with a 826 bp long 
PCR fragment, obtained with PCR primers L33F and L33R1 primers and labelled with [α-
32P]dATP. Among 106 phage plaques, three positive clones (L33_1/3, L33_2/4 and L33_3/4) 
were isolated, each with a 1550 bp long insert. Complete sequencing of the L33_1/3 and 
L33_2/4 clone with the λTriplEx 5’ and the λTriplEx 3’ primer showed that they were highly 
similar to previously obtained sequence (Fig. 26B). The 3’-terminus of both clones ended 
with potential polyadenilation signal (AATAAA) and a stretch of a 28 bp poly (A) tail.  
Assembly of analysed sequences resulted in identification of the full-length cDNA of 
the L33 gene, which is 1663 bp long.  
Two human mRNAs, which were made public at a later time point, contain additional 
sequences from the 5’ end (Fig. 26B), indicating that there could be alternative 5’ end and 
possibly alternative splicing of the transcript. This was not studied further. 
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Fig. 26. Genomic structure of L33 gene.  
A. Schematic representation of the L33 gene structure. The boxes represent the exons with 
their relative size and original organization. Numbers below boxes indicate exon numbers. 
The names and positions of the primers used for the analysis of L33 gene are shown above the 
schematic illustration. B. A consensus cDNA sequence was assembled using sequence of 14 
clones from the human retinal cDNA library which was constructed by suppression 
subtraction hybridization (Ret-SSH cDNA library) together with the homologues human 
ESTs, four sequenced I.M.A.G.E. clones and two cDNA clones retrieved from cDNA library 
screening (clones have internal ID number). Only representative clones were selected for the 
schematic presentation. 
 
 
 
 
 
5.3.2.2 Genomic structure of L33 
 
In order to determine the genomic structure of L33 gene, the full-length cDNA 
sequence was aligned to the human genome draft sequence. The L33 gene spans 13 Kb of 
genomic sequence. It consists of five exons (Fig. 26A) which are 204 bp, 187 bp, 215 bp, 334 
bp and 695 bp long, respectively (Tab 9.). Exons conform to the exon/intron boundary 
consensus GT/AG and very good scores for the consensus splice junction sequences (Tab 9). 
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Table  9. 
Exon-intron boundaries of the human L33 gene 
Exon 
 
3' Splice acceptor sitea 
 
 
5' Splice donor sitea 
 
Intron 
 
No. Size (bp) Sequence Scoreb Sequence Scoreb No. Size (bp)
 
1 204   ..GAAgtaagt.. 2,948 1 4,782 
2 187 ..tttctttgtctgcaagA.. 7,633 ..AAAgtgagt.. 2,384 2 287 
3 215 ..ccctctatgattgcagG.. 5,352 ..GAGgtactg.. 6,463 3 1,389 
4 334 ..catcgttgtcctgtagG.. 6,184 ..TCGgtgagt.. 2,829 4 5,212 
5 695 ..gtaaattcattttcagT.. 9,349    
 
a For the splice junctions, intronic and exonic sequences are shown in small and capital letters, 
respectively. The 5’ splice-donor and 3’ splice-acceptor sequences are given in bold. 
b Scores were calculated to references (Berg et al, 1988 and Penotti et al. 1991). 
Approximately 99% of sites have a score of 0-20 (3’acceptor site) and 0-11 (5’donor site). 
 
 
 
5.3.2.3 Expression analysis of L33 
 
To examine the tissue expression of L33, RT-PCR amplification was performed with 
primers L33F annealing to exon three and L33R annealing to exon five in a panel of 20 
human tissues. Analysis showed that the gene is highly expressed in retina with lower levels 
of expression in brain, fetal brain, spinal cord, kidney, trachea, skeletal muscle and testis and 
very low expression in liver, colon and uterus (Fig. 27A). 
Virtual Northern blot analysis of the ds cDNAs from different human tissues was 
performed using radiolabeled PCR fragment, amplified with L33F and L33R1 primers. A 
signal at approximately 1.6 Kb was most abundant in retina and very weak in RPE (Fig. 27A), 
confirming already determined predominant expression of the gene in retina and obtained 
length of the transcript. Weak bands, one at approximately 1.0 Kb and another around 3.0 Kb 
could also be detected in retina (Fig. 27B). They could derive from alternatively spliced full-
length transcript to which radiolabeled probe was hybridized.   
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Fig. 27. Expression analysis of L33 gene. 
A. Expression analysis of L33 gene in 20 tissue panel, with exon spanning primers L33F and L33R 
that were designed based on consensus sequence of the clones from the Ret-SSH cDNA library, 
showed that gene is abundantly expressed in retina and weakly in brain, fetal brain, spinal cord, 
kidney, trachea, skeletal muscle and testis. The same panel was amplified with G3PDH specific 
primers as a control of cDNA quality. B.  The transcript size of the L33 gene was determined by 
virtual Northern blot analysis with radioactive labelled PCR product amplified with L33F and L33R 
primers. Signal at approximately 1.6 Kb was determined only in retina.   
 
 
 
 
5.3.2.4 In-silico analysis of the cDNA sequence 
 
 
To reveal the protein encoded by the L33 transcript, ORFs within the consensus cDNA 
were investigated. Unexpectedly, termination codons were located all over the sense strand of 
the cDNA, and no reasonably long ORFs that could encode proteins were observed in any of 
the three reading frames (Fig. 28).  
 
 
 
2
3
ORF1 ORF2 ORF3
1
1 2 3 4 5
 
Fig. 28. ORF analysis of L33 cDNA.  
The relative positions of all initiation and termination codons are indicated by vertical lines 
and filled triangles, respectively, for each of the sense open reading frames of the L33 cDNA. 
Three longest predicted ORFs are represented with arrows.  
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F      bp                                                                                                                                                                                                            aa      
                                                                                                                                                                                                                 
 Exon 1 
    1    CCTGCATCTTAATCCACTCCAGAGCTGAGGCTTCCTGATCCCTCTAACCAGGTGCATGTTCACTGGGCTTCCAGCTTCCA 
+3                 M  F  T  G  L  P  A  S    8 
 
    81 AGCCTTCTACCTGTGGAATGCTTGGTCCAATGTCTGGGGCACCCACTCTTACTCCAAACTCCTCCAGATCTGCAGAGTGG 
+3 K  P  S  T  C  G  M  L  G  P  M  S  G  A  P  T  L  T  P  N  S  S  R  S  A  E  W   35 
 
                       Exon 2 
    161 CCCAGCATATTCTCTTCTTGAAAGGAGGTCTTTGCCTAACAGAAATGGAATAAAAAGGCCTACCTCATTGGGCTCGTGTG 
+3  P  S  I  F  S  S  -                                                              41 
 
 
241   TGAGGAGAACTGAAGAGTCTGAGAGCGCGGCACGAGCCAGAGGCTACGGAAAACACTGCCCTCCTACACTCCACCTTG 
 
                                                                                        Exon 3 
    321 GAGAGACCCAGAAAAGAACAAGCTTCATTTGTAAAAAAGGAAAACAACTCAGGCAATGGGGGTGGCTTAAAGGCACTCTA    
    401 AAACAACTCAGGCAATGGGGGTGGCTTAAAGGCACTCTACAGTGTGCAGATGCCTTCCACTTCTTCCATCTGCCCTGTCT 
 
    481 CTCCAAGAACCCCTATGGCCCCGGTCTCAGAACAGAGCTGAGTGCAGAAATGAAAATCTATGGCTCTGTGTTCCAAAACG 
     M  K  I  Y  G  S  V  F  Q  N    10 
 
    561 ATGAAGAATTTCAAGATGGTGGCAGTGGTAAAATCTTTCTCCAGGAAAAATCTGTCCTTGGCCCAATGTGTAAACACTTG 
+3        D  E  E  F  Q  D  G  G  S  G  K  I  F  L  Q  E  K  S  V  L  G  P  M  C  K  H  L   37 
 
 
 Exon 4  
    641 CTGAGGAACTTGGAATAACTTGCAGTGTCTTGCAGTATTGTGAAACCAGCAACTTGTTCACAATTCTTCTGAATTTCTTG 
+3  L  R  N  L  E  -                                                                 42        
 
 
    721 GGAAATTTGAAGTGGAGTACCTGTACCAACATGAAATGACACGAATTTAAGTGACGCTCAACAACGAAAAGCAAAAAGAA 
 
    801 CCAAAGAGGAAGCAACTGAAACAACATCTGGATGTATTTAAAAATATACAATGCCTCCAAAATCAGGTGTCATTAATGAA 
+3  M  P  P  K  S  G  V  I  N  E   10  
  
    881 AATTCTGAAGAAATGCCACCGGACATAGCCAACGCACCTACGCTGTTGTTATTCATTTCCTGCTTTTCACAGAAAACAAT 
+3  N  S  E  E  M  P  P  D  I  A  N  A  P  T  L  L  L  F  I  S  C  F  S  Q  K  T  I  37 
 
                              Exon 5 
    961 TTTGTTGCATGGAAGATCGTGAACTTCAAAGGGCAGAGGGGAAACTGTCCCTTGGCCTCTACCCCTCCAAGGCCCCACTT 
+3         L  L  H  G  R  S  -                                                              43 
  
   1041  TTTTGTCAACACTCCTTGGACGCAGCAGAAGTATGAACATAATATGGTCCTGAATGAGGCTGAGTCTTTGGGCGCAGAAG 
   1121  ACCCGGGTTAATAAAAATAGGAAGGTAAGAAAAGAAAAGAAAAATCAAGACACATCATAGGACTAAATTCCTATTATTTA 
   1201  TCCACTCAGGATTGACCACCCCTTTGGGCCAGATAGTTGTACCCCCATGTACCAGGTGGGCACATGAAGACACAAGAAGT 
   1281  GCTGTGATGGTTCATTTTGCACGTCACCTTGCGTGGAGTATGCCAACTCATTGTTTGGTCAAACACTAGTCTGGACATGG 
   1361  TGGTAAAGGTATTTTTTAGATGAGATTAACACTTAAATCAGTAAAGCAGGTTACCCACCATACTACGGGTGGGCCCTGTC 
   1441 CAATCAGTTGAAGGCATTAAGAACAAAGATTGAGGTTTCCTAAAGAAGATGGAATTCTCCTTGAGACTACAACATAGAAA 
   1521 CCCTATCTGAGTTTCCAGCCTGTTGCCCTGTGGAATTCAAACTCAGGACTCCGGTCTATGACATTAACCCTCACTTAACT 
   1601 TTTCAGCCTGCCAGCCTGCCCTATGGATTTCGGACTTGCCAGCCACACAATTCCTTAAAATAAATCTCTCCGTCAAAAAA 
   1681 AAAAAAAAAAAAAAAAAAAAAA 
 
 
 
Fig.  29. Nucleotide sequence of L33 gene. 
The complete cDNA sequence is numbered starting with the first base of the 4F10F clone. 
Amino acid sequences encoded by putative ORFs are indicated bellow the nucleotide 
sequence and length of the potential proteins are given on the right side. Potential initiation 
(ATG) and termination (TGA/TAA) codons of the putative ORFs are boxed and putative 
polyadenilation sequence (AATAAA) of the L33 transcript is underlined. 
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Table 10. The longest ORFs for the L33 transcript 
 
 
ORF no.a 
 
Frame 
 
Start 
 
Stop 
 
Length (bp) 
 
Initiator sequenceb 
 
 
ORF1 3 56 178 123 a g g t g C A T G t 
ORF2 3 491 616 126 G C a G a a A T G a 
ORF3 3 811 940 129 t a t A C a A T G c 
Consensus Kozak’s rule:nnnn  
 
 
 C C  A C C A T G G  
G C C   C C A T G G 
GC C  G C C A T G G  
 
 
a The ORF no. column shows the assigned numbers of three ORFs ordered in length. 
b The initiator sequence column shows the -6 to +4 sequence of the putative initiator site. The 
start (ATG) codon is shown in bold. The nucleotides that match with the Kozak’s consensus 
are shown by upper case. 
 
 
 
The longest putative ORF (ORF3; +811 to +940, Table 10, Fig. 29) encodes 43 amino 
acid residues. There are a total of three ORFs that could encode more than 41 amino acid 
residues (123 nt, Table 10). Among them, ORF2 would be the most likely one, particularly in 
regard to the strong consensus of the translation initiation sequence for many mammalian 
mRNAs proposed by Kozak (1987; Fig. 29; Table 10), with ATG representing the initiation 
methionine. 
To examine whether the longest predicted ORF indeed may encode a protein, it was 
analysed further under the assumption that a functional ORF should be conserved among 
species. The overall nucleotide sequence of the L33 transcript had no significant homology to 
any nucleotide sequence available at the public databases, including genomic or ESTs.  In 
addition, none of the ORFs had putative conserved domains or significant sequence similarity 
to any other known protein. This finding may indicate that ORF1, ORF2 and ORF3 do not 
encode amino acid stretches. 
Performed analysis of the nucleotide sequence and putative amino acid stretches 
encoded by the three longest ORFs suggest that the L33 transcript may not encode a protein, 
but instead may function as a regulator mRNA.  
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5.3.3 Cloning and characterization of the L35 gene 
5.3.3.1 Identification of the full-length cDNA sequence  
 
Identification of the cDNA sequence of the L35 gene was based on four clones (6E1F, 
3B6F, C10_Ret10, F04_Ret15 and H01_Ret15) from the retinal SSH cDNA library. These 
clones belong to the category of partial transcripts with retina specific expression. Genome 
sequence comparison revealed that these clones are deriving from a locus on chromosome 
7p21, all mapping to the first intron of the MEOX2 gene (Fig. 30A). Orientation of splicing of 
6E1F was opposite to that of the MEOX2 gene. The remaining clones which partially overlap 
represent a continuous cDNA sequence. BLASTN homology search with the consensus 
sequence revealed two ESTs (accession numbers AI417984 and BG184437) which showed 
homology to 6E1F, thus extending its sequence by 385 bp at the 3’ end (Fig. 30A). Analysis 
of the BG184437 clone suggested that there could be another isoform of the transcript. In 
order to investigate possible splicing events further, sequence information from the 6E1F 
cDNA was used to design exon spanning forward and reverse primers L35F and L35R, 
respectively. RT-PCR amplification yielded a 145 bp long PCR product of the expected size, 
which was very weak in abundance, and an unexpected highly expressed PCR product of 288 
bp in size. Sequencing of the two PCR products revealed that the shorter one was identical to 
6E1F clone, whereas the longer one suggested the presence of an additional exon. 
In order to retrieve the full-length cDNA sequence encoding the L35 gene, a mix of 
adult human retina libraries DKFZ3, DKFZ4 and C1F1, was hybridised with a 288 bp long 
PCR fragment amplified with L35F and L35R primers and labelled with [α-32P]dATP. 
Screening of the libraries in duplicates identified four positive clones (L35_2.3, L35_3.1, 
L35_3.2 and L35_4.1) which were completely or partially sequenced with λTriplEx 5’ and 
λTriplEx 3’ primers.  Further analysis of the L35_2.3 clone which was partially sequenced 
from both ends extended the sequence of 6E1F by 195 bp at its 5’ end (Fig. 30A), whereas its 
3’ end overlapped with remaining novel retina sequences, suggesting that all five clones from 
the retinal SSH cDNA library derive from the same transcript. The L35_2.3 sequence 
terminated with putative polyadenilation signal, which was followed after 13 bp by 19 bp 
long poly (A) tail (also contained in retinal BX538274 mRNA which was sequenced at a later 
time point). 
In addition, the human retina full-length cDNA library (local library ID: Jelena) was 
screened with the same radiolabeled 288 bp PCR fragment. After two rounds of hybridization 
two positive clones, L35_2/2 and L35_3/2, with approximately 750 bp long inserts were 
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obtained from approximately 1 X 106 recombinant phages. Complete sequencing of both 
inserts with λTriplEx 5’ and λTriplEx 3’ primers showed that they are highly similar to 
previously obtained cDNA sequences (Fig. 30A). Interestingly, isolated clones terminate 
upstream from identified potential polyadenilation signal, both having 28 bp long poly (A) 
tail.  
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Fig. 30. Genomic structure of L35 gene.  
A. Schematic illustration of L35 gene structure, located in the first intron of MEOX2 gene, 
with opposite orientation. The boxes represent the exons with their relative size and original 
organization. Numbers below boxes indicate exon numbers. The names and positions of the 
primers used for the analysis of L35 gene are shown above diagram. Clones from retinal SSH, 
full-length, DKFZ (3 and 4) and C1F1 cDNA libraries and PCR products have internal ID 
number and only representative one were selected for the schematic presentation. Broken line 
represents partially sequenced clones. B. Sequences of the L35_SV1 (SV1) and L35_SV2 
(SV2) isoforms were assembled by alignment of all clone sequences and two PCR products, 
which were amplified with gene specific primers L35F and L35R, to the corresponding 
human genome sequence.  
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Assembly of analysed sequences resulted in the identification of two cDNA isoforms, 
named L35_SV1 and L35_SV2. The cDNA sequence of the L35_SV1 is 3759 bp long, 
whereas L35_SV2 is shorter, due to lack of an exon which is 141 bp in size (Fig. 30B). While 
a polyadenylation signal is present in both isoforms 32 bp upstream of the most 3’-end of the 
isolated cDNAs (Fig. 33), the presence of a poly (A) tail in L35_2.3 and L35_3.1 clones 
suggests usage of an alternative polyadenylation signal generating a 749 bp long transcript. 
 
 
5.3.3.2 Genomic structure of L35 
 
To determine the genomic structure of L35, the full-length cDNA sequence was 
aligned to the human genome draft sequence. Accordingly, the L35 gene consists of four 
exons that span approximately 13 Kb. It is located in the first intron of the MEOX2 gene, 
which is encoded from the opposite strand. The exons of L35 are 350, 141, 185 and 2.779 bp 
in size, respectively, and are separated by 7.723, 1.302 and 1.266 bp intervening sequences 
(Table 11). All exon/intron junctions have appropriate splice donor/acceptor sites and reveal 
high scores for the consensus splice junction sequences (Table 11). 
 
 
Table 11. 
Exon-intron boundaries of the human L35 gene 
 
Exon 
 
3' Splice acceptor sitea 
 
 
5' Splice donor sitea 
 
Intron 
 
No. Size (bp) Sequence Scoreb Sequence Scoreb No. Size (bp)
 
1 350   ..ATAgtaaat.. 6,246 1 7,723 
2 141 ..attatttattcaaaagG.. 9,839 ..GGGgtttgt.. 7,439 2 1,302 
3 185 ..ttcggttgactcttagG.. 7,369 ..CTGgtaaga.. 2,539 3 1,266 
4 2,779 ..tgttttttccttgtagC.. 4,268    
 
a For the splice junctions, intronic and exonic sequences are shown in small and capital letters, 
respectively. The 5’ splice-donor and 3’ splice-acceptor sequences are given in bold. 
b Scores were calculated to references (Berg et al, 1988 and Penotti et al. 1991). 
Approximately 99% of sites have a score of 0-20 (3’acceptor site) and 0-11 (5’donor site). 
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5.3.3.3 Expression analysis of L35 
 
The expression pattern of L35 in 20 different human tissues was determined by RT-
PCR analysis with forward primer L35F, located in the first exon, and L35R, located in the 
third exon of the gene (Fig. 30A). Highest expression of the two isoforms was found in retina, 
whereas in skeletal muscle and testis a longer isoform was present at very low levels (Fig. 
31A). A weak PCR product of approximately 400 bp in size was also detected in skeletal 
muscle and testis and might be amplified from alternatively splicing or unspliced mRNA 
species (Fig. 31). This was not analysed further. 
Virtual Northern blot hybridization experiments using ds cDNAs from six different 
human tissues was performed using as a probe the 288 bp long PCR fragment labelled with 
[α-32P]dATP. The experiment showed that L35 is expressed as a transcript of about 3.5 Kb 
exclusively in retina (Fig. 31B), confirming tissue specific expression results obtained by RT-
PCR analysis. 
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Fig. 31. Expression analysis of the L35 gene 
A.  Expression analysis of L35 gene in 20 tissue panel, done by RT-PCR, showed that gene is 
expressed abundantly in retina and very weakly in skeletal muscle. The same panel was 
amplified with G3PDH specific primers as a control of cDNA quality. B.  The length of the 
L35 transcript was determined by virtual Northern blot analysis using radioactively labelled 
PCR product amplified with L35F and L35R primers. Obtained signal correspond to 
transcript which is approximately 3.0 Kb long and confirmed retinal expression.     
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5.3.3.4 In-silico analysis of the cDNA sequence 
 
A striking feature of the full-length L35 cDNA sequence is the high density of stop 
codons in all three reading frames (Fig. 32), which suggests that if L35 is a coding RNA, the 
protein product is likely to be very small. Analysis of the coding potential of the L35 cDNA 
revealed four open reading frames (Table 12). The most probable one would be the ORF2, 
with regard to a reasonable consensus to the translation initiation sequence proposed by 
Kozak (Fig. 32; Table 12), whereas the longest ORF4 would encode 54 aa. The alternative 
splicing of exon 2 would not change the predicted open reading frames.  
 
 
ORF1
ORF3
1
2
3
3740
3’5’
1 1000 2000 3000
1 2 3 4
(bp)
(A)19
ORF2
ORF4
 
 
Fig. 32. Open reading frame analysis of L35 cDNA.  
The relative positions of ATG codons and termination codons (TGA, TAA and TAG) are 
indicated by upper and lower vertical lines, respectively, for each of the three open reading 
frames. Four longest ORFs are represented with arrows. The four open boxes represent exons 
1-4 of the L35 gene.  
 
 
 
 
bp                                                                                                                                                                                                                 F      aa 
 Exon 1 
1 AGGACACAGTTAAACAACAGATCCACTTTATTCCATCCCCTTGGAATAACATATTTAAATTTCTTATTGGTTTAATTCGT 
81 TTTTCTCACATCCCGAGTTTTCAAGGTAAAGCCAAGTAATGTGGAAACTACCTATTTCTACTGTGTACTAACATGCATTT 
 
161 AACTACAGTTGACCTTTGAACAACAGGGGGTGGAAACTGTGTAGGTCTACTTATGCATGGATTTTCTTCCGCCTCTCCTA 
  M  D  F  L  P  P  L  L  +1      8   
 
241 CCTGAGACAGAAGACCTTTGCCTTCTCTTGCTCCTTCTGCTCAGCCTGCTCAACCTGACGGTGATGAAAACTGAAGCCCT 
 P  E  T  E  D  L  C  L  L  L  L  L  L  L  S  L  L  N  L  T  V  M  K  T  E  A  L  +1    35 
 
 Exon 2 
321 TGATGATGATCCACTTCCGCTTAATGAATAGCACTGTAGAAGTCTCGCATATATGATCATTTAAAATTTCGCTGAAGTCA 
         D  D  D  P  L  P  L  N  E  -                                                    +1    44 
 
401 TGTCTGAATTCTGCACACTGCCTTGTGGATGTGGGAGAGGTGACTAAACTGAGTCAACGCAGTCAACCACCCAGGACTTG 
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 Exon 3 
481 CAATTCCAGGGGGTTGCATCCACCTAACCCTCCGGGGTTCTGGCTTCGGATAGTGTTTGATCAATGGAAGCAACAAAAGA 
 
 
561 AGATTGGAGGACATGAAGACAGGTTACTGGATGATATTCGACATGAGCTGCAATCCTCCATCTGAGGTCCCAACTTTTCC 
 M  K  T  G  Y  W  M  I  F  D  M  S  C  N  P  P  S  E  V  P  T  F  P  +3   23   
     
                                            Exon 4 
641 AGAAGGCTTCTGTCCTGTTGCGCTCATTGGATTCTGCATTATGGGATTCTCTTGAAGTGTGTGAAGAATAATGAGCTAAA 
         E  G  F  C  P  V  A  L  I  G  F  C  I  M  G  F  S  -                             +3  40 
 
721 TAAAGAGGAAAAACAAAAGAAAACAAAAACTGCAGGGACTTTTATAACTATCATTGATTGCCAGCTTAAGCCTGCTGGAC 
801 TCTTCACAAAACTATATATGCTTCAAGCTTAATATTTAATTTTGTAATTGGAACATTTATAATCATATTATGCATTTAAT 
881 AAGGATGCTCTAATTCAGATTTACTATTATCAGGAAATTAAATTTGGAGTTACAGTAATGCATGCATATATATGTGTGGG 
961 TGTGAGTGTGCATATACCTATATATGTATATACATATATAAAGTAAACGCCTTCTTTTAACGTGTGTTTTAAGTATAGCT 
1041 TCCATGTCCTAGTTAATTCAGCACCCTCCCTTTTATCCTTTCCTTGCCATTGTCCTCTCTACTAGACTACAATAAAAACA 
1121 AAAAACTATGAAAGTAAGCAGCTTATAATCATAATTTTAATCAATGTAGCCTATGCAAGCTTTAAGAAACATACGTCTAA 
1201 CATCTTAGAAAGAAAGCTTATGAACACAAACAGCAGAATACTTAAATACATTTGAAACATTCACATTGAATTGATTCTAC 
1281 AAAATTTTGAAGAGCAACAGCTTTTGAATTTAGAGCTATAATCAGTACCCTAAAGTTTTTACCACTGAGTTACTACCTAG 
1361 TAAAAATATGTTATATTTGCAATAAAAGTACACATTGTAAGGACATAAGAATTGTCATCAAGGTACACAAACATTTTAGA 
1441 ATTATTAAACATTTAAATAAATGGAAATTTTAAAAATAAAATAACAATATTATCATACAAGTTAATGATCCAGTTTATTA 
1521 ATTTCTAATTCTATTGATAAAACAAGGGATTATTTTTGAAAGGGTTTTTCTATCTTTCATACAAACCCTTTCCAAAAATG 
1601 TATAGATACAGTACGGATTCTACCTGATCATTCTTGTGCATATGGTGATGTAAGAAACCAAAAAAATGTAAATTATTTTC 
1681 ATAACACTGTGAAAACCAATATTTAAAAATACAGTGCACAATTAGTAGTGAGTAACATATATAAATTTAGAAATATTATA 
1761 TTTCTGTACACAAAGTAACATTATAAATGAAAGCTTCAGGAATAATGAGCTACTTATTATTCCGGAAATTATATATCAAA 
1841 AATTTCAAATATAGAGGAAAATTAAAAACCCACTCATGACCCATGAAAATTAATAACCCATTCGATCATACACTTACCAT 
1921 GTAACTTTCTGTTAATTTGGTAATAAATAATGTCAAGAGATTTTAAATGAAAATACTTATTCTGAAACATAAAAACAACA 
 
 
2001 TCTGAGATGAGCACAAATGGATCAATAGATACATTATTGATTATTTTGTATCATAAAATACTATCTAGTACAACATTCTT 
 M  S  T  N  G  S  I  D  T  L  L  I  I  L  Y  H  K  I  L  S  S  T  T  F  F  +3    25    
 
2081 TAAAAAATTCAATATTTTTATAATGTAAGTAAAACGGGAAGAACTGTTAGAGAAATGGGCATCAGATTTAGATTAATTCT 
         K  K  F  N  I  F  I  M  -                                                       +3    33 
 
2161 GCCTCTAACGCAAATTGTAGGCTGAGCCCTATATGTTCTTGACCATTCTAAGTTTTACTACATTAAAACACATAAAATAT 
2241 TCTGCGAGGTTTTCTCCAATGGGATTTTGAATCTCACTGATGACTGTGATTTAGGAGTAATGTAGAGAGTTTTGCAACTA 
2321 ACTTTACTTTACACCGTTACTCCTTTTCTACTTGGGGGTTCAGTTCAACACGCTAGTAAAAGAAATAGTCATGAGAGCAT 
2401 CCTAAGGAAAGTAGGCAAAATGTTAGTGCCTCATTATATTTACAATCTTTACAAAACATGTATGTCAGTAAACCATATTA 
2481 ACATCTAAAGCACATGATATGTAGAAACAAATTGTGACTACAAAATGTGTCTTGTTTCTTAAATATGCTAAATAGGAAAT 
2561 AAATCACATCTACTTCAATTTTTAATCTGTGGACTTTGGCCTTAGTTTGTGTTTTATTTTATTTTTTTGCTTTTGATTTT 
2641 AACCACTGAAATCATTTACCAATACTATAAGCCAGGAAATACAATGTAACTGGCCAGTTGAGAATTAAGCCTTCTCTTTT 
 
 
2721 TATTATTACAATCAAGGGGGGAAATGCTTATATATCTTCCTGCACAAAATGTTTCATTTATCAAAAAAAAAAGTGAGAAA 
 M  L  I  Y  L  P  A  Q  N  V  S  F  I  K  K  K  S  E  K  +2  19  
 
2801 AATAAAGAAAATTTGGGTGAGATAAATAATCCACAACTATTAATTCAACAGATATTATTTAAGAAATTCCTACCTGTAAT 
 N  K  E  N  L  G  E  I  N  N  P  Q  L  L  I  Q  Q  I  L  F  K  K  F  L  P  V  I +2      46       
 
2881 TTATTTTCTAATATTTCTGCATCCTTAGTATTTATCGCTCAAAGATATTTGCAGCCCTCATAGCAGTGCTTGGAAAAGAG 
 Y  F  L  I  F  L  H  P  -                                                       +2      54 
 
2961 ATTTGCTCTGAAAATTTAGAAATAAATTCCTGAGGTGAATACAGTTCAAAACTAAAATATATTGCTGTATTATATTGGTT 
3041 TTTCTCATTTGAAATTAAAATCTAAAAAACCTTCATATTAGGTTGTGTGTGTCAAGCTGCCATTATAAAAACACTAAATG 
3121 AATAAAATTTCGCAAGCAAGGCAGCATTATCAGGCTAAGTACATGTAGTGGGCTTATATATGGTGATGTTTTACATAATT 
3201 CAGCTATTAATTCATCTATAGATTTACATTTCTTAAGTGCAAAAAAAAATGTAATTATTTCATTACATATGGAATTCACC 
3281 TCCCAAATTTCTCAGAATCTAAGAGAAAGGATTGACATTTTCTGATATTTCATTTTTGCTTAAAATTAAGTTCTTAGGAT 
3361 GTTTAGATTTTATTATAAATATTACAACTTAAATTCCAGAGTTATAATGAACGGTCTATGTTTTGAAACACAGAGGGAGA 
3441 ATGGGGTAATGACTGAAGTACTGTTTTTTCAGTTTATTAGTAAAGATCAGCTTATAAGATGTCATTGTAAAGGTTTCTAT 
3521 TGATAATTACCATAAACAAAGATTAAAACTTTAAATACTAAGTTCTGGATTTCTAAGCCCGGTGAAAGTTTGTGCAATAC 
3601 CATACCTTGCATTTATGATTTTTCTTTTAAAATGAACTATAAATGAAGAAATTTACACAGAATTGGAAACTATTCCTACT 
3681 TTTATTTGCATTCTTCCTTCCATTCATTGCTAATGTTCAACAATAAAGCATTTTAATTCTAAAAAAAAAAAAAAAAAAA 
 
 
 
 
Fig.  33. The complete nucleotide sequence and amino acid translations of the L35 gene. 
The complete cDNA sequence is numbered starting with the first base of the 6E1F clone from 
the retinal SSH cDNA library. Amino acid sequences encoded by the four putative open 
reading frames are indicated bellow the nucleotide sequence. Potential initiation (ATG) and 
termination (TAG/TGA) codons of the putative ORFs are boxed. Putative polyadenilation 
sequence (AATAAA) of the L35 transcript is underlined. 
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Table 12. The longest ORFs for the L35 transcript 
 
 
ORF no.a 
 
Frame 
 
Start 
 
Stop 
 
Length (bp) 
 
Initiator sequenceb 
 
 
ORF1 1 218 349 132 t t a t g C A T G G 
ORF2 3 574 693 120 G a g G a C A T G a 
ORF3 3 2.006 2.107 99 t C t G a g A T G a 
ORF4 2 2.744 2.906 162 G g g G a a A T G c 
Consensus Kozak’s rule:nnnn  
 
 
 C C  A C C A T G G  
G C C   C C A T G G 
GC C  G C C A T G G  
 
 
a The ORF no. column shows the assigned numbers of three ORFs ordered in length. 
b The initiator sequence column shows the -6 to +4 sequence of the putative initiator site. The 
start (ATG) codon is shown in bold. The nucleotides that match with the Kozak’s consensus 
are shown by upper case. 
 
 
 
 
The complete cDNA sequence of the L35 transcript has no significant homology to 
any genomic or ESTs sequence available in the public databases, suggesting that the putative 
ORFs are not conserved among species.  In addition, none of ORFs show homology to 
putative conserved domains or reveal significant sequence similarity to any other known 
proteins. These findings may suggest that the predicted ORFs do not encode proteins, but may 
function as a regulatory mRNA.  
 
 
 
5.3.4 Cloning and characterization of the L37 gene 
5.3.4.1 Identification of the full-length cDNA sequence  
 
Identification of L37 was initiated with the 3H5F clone isolated from the human 
retinal SSH cDNA library. This clone represents a partial transcript for which expression was 
determined as retina specific and which is mapping to chromosome 3q22. It is located in the 
36 Kb first intron of ATP2C1, but spliced with opposite orientation to the ATP2C1 gene (Fig. 
34). The clone sequence was subjected to BLASTN homology searches but homologues 
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cDNA sequences could not be obtained. In the next step, the human retina full-length cDNA 
library (local library ID: Jelena)  was screened with a 275 bp fragment obtained by PCR 
amplification with L37F and L37R primers and labelled with [α-32P]dATP. Among 106 phage 
plaques, three positive clones (lab ID numbers: L37_3/1, L37_5/3 and L37_6/2) were 
isolated, with inserts of approximately 400 bp. Complete sequencing of the clones with 
λTriplEx 5’ and λTriplEx 3’ primers showed that they were highly similar to the previously 
obtained sequences of 3H5F (Fig. 34), which terminated with a potential polyadenilation 
signal. The 3’-termini of both 3/1 and L37_5/3 ended with a 29 bp long poly (A) tail. 
Sequence information from the 3H5F cDNA fragment was used to design specific primers 
L37F and L37R. RT-PCR analysis resulted in a single band of expected size verifying the 
identified sequence (Fig. 34). Thus, assembly of obtained nucleotide sequences resulted in 
identification of the full-length L37 cDNA of 419 bp.  
 
 
 
 
3H5F
L37F L37R
Exon ATP2C1 ATP2C1
5' 3' 5'3'
L37F/R
L37_5/3
L37_3/1
1 2
12
 
 
 
 
Fig. 34. Genomic structure of L37 gene.  
Schematic representation of two exon gene, located in the first intron of ATP2C1, but spliced 
with opposite orientation. A consensus cDNA sequence of L37 was assembled using 
sequence of 3H5F clone from the human retinal SSH cDNA library together with two cDNA 
clones isolated from the full-length retinal cDNA library (L37_5/3 and L37_3/1). PCR 
product, which was amplified with L37F and L37R primers, verified already identified 
sequence. Exons of both genes are represented in proportional sizes and original organization. 
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5.3.4.2 Genomic structure of L37 
 
To determine the genomic structure of L37, the identified full-length cDNA sequence 
was aligned to the human genome draft sequence. L37 consists of two exons (Fig. 34) of 
which the first is 171 bp and the second is 219 bp (Table 13). The two exons are separated by 
approximately 30 Kb of intervening sequence (Table 13). They have conserved splice donor 
and acceptor sequences that conform to the GT-AG rule by reasonable scores for the 
consensus splice junction sequences (Table 13). 
 
 
Table 13. 
Exon-intron boundaries of the human L37 gene 
 
Exon 
 
3' Splice acceptor sitea 
 
 
5' Splice donor sitea 
 
Intron 
 
No. Size (bp) Sequence Scoreb Sequence Scoreb No. Size (bp)
 
1 171   ..CAGgttagt.. 2.921 1 30.223 
2 219 ..tatacttttgtcgtagC.. 7.648    
 
a For the splice junctions, intronic and exonic sequences are shown in small and capital letters, 
respectively. The 5’ splice-donor and 3’ splice-acceptor sequences are given in bold. 
b Scores were calculated to references (Berg et al, 1988 and Penotti et al. 1991). 
Approximately 99% of sites have a score of 0-20 (3’acceptor site) and 0-11 (5’donor site). 
 
 
 
5.3.4.3 Expression analysis  
 
RT-PCR analysis with gene specific primers L37F and L37R located in the first and 
second exon, respectively, examines the expression of the L37 mRNA in various human adult 
tissues. As shown in Fig. 35, L37 is expressed exclusively in the retina. To determine the 
transcript size of the L37 mRNA, the analysis of virtual Northern blot containing the ds 
cDNAs from bladder, heart, lung, skeletal muscle, retina and RPE were performed. The 
radiolabelled PCR probe was generated with the same primer pair used for the RT-PCR 
analysis. As shown in Fig. 36, a specific transcript of approximately 400 bp was detected 
exclusively in retina. 
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Fig. 35. Expression analysis of L37 gene 
A. Expression analysis of L37 gene was performed by RT-PCR in the panel of 20 human 
tissues using exon spanning L37F and L37R primers. Analysis showed that gene is 
exclusively expressed in the retina. B.  Hybridization of the radioactively labelled PCR 
product, amplified with the same primer pair, to the virtual Northern blot. A signal of 
approximately 400 bp was detected exclusively in retina.     
 
 
 
 
 
5.3.4.4 Analysis of the L37 cDNA sequence 
   
  Analysis of the coding potential of the novel retinal L37 gene predicts two putative 
proteins consisting of 33 and 35 amino acid residues, respectively (Fig. 36). Both ORFs are 
predicted in the first reading frame. While the first ORF is spanning exon 1 and 2, the second 
ORF is located in the second exon of L37. The amino acid sequences of the two predicted 
ORFs was subjected to a homology search against public protein databases using the BLAST 
P algorithm, but no homologuous sequences could be detected. Conserved putative domains 
were not found for both proteins.  
 
 
 
 
 
 
 
 
 
Fig.  36. Sequence of L37 gene (see next page) 
The 419 bp long full-length cDNA sequence of the L37 gene has two putative ORFs. ORF1 
and ORF2 are both predicted in the first frame and 33 aa and 35 aa long, respectively. Start 
and stop codons of the putative ORFs are boxed. Corresponding amino acid sequence and 
their positions are indicated bellow the nucleotide sequence. 
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            bp                                                                                                                                                              F                     aa 
 
                                                                                                                                                                                            ORF1      ORF2 
       Exon 1  
      1 TCTCCATTTTAACTACTCCTCTTAGTCAGTCAGCTCATAGCTGATCTACCCAGAAAAGAC 
     61 AACTGGCTACTCTTTCAACGCACCATGACAACAAGTCAGACTTTAAGAGCTATTCACAAA 
                          M  T  T  S  Q  T  L  R  A  I  H  K    +1     12 
 
     Exon 2 
    121 CTAGGAGAAAAACAAGAAGTAAAAGAGACCAGACAAGCAAAGGATGCACAGCAACTTAAA 
  L  G  E  K  Q  E  V  K  E  T  R  Q  A  K  D  A  Q  Q  L  K    +1     32 
 
    181 GCCTGAAGACAGAAGATACACAGTTGACTCTTTAACAACATGAGTTTCAACTGTAAAGGT 
  A  -                                   M  S  F  N  C  K  G    +1     33      7    
 
    241 CTACTTATACTCAGATTTGCTTCTGTCACCCGAGACAGCAAGACCAACCCCTCCTTTTCT 
  L  L  I  L  R  F  A  S  V  T  R  D  S  K  T  N  P  S  F  S    +1            27 
 
    301 TCAGCCTACTCAAAGCGAAGACAATGAGGATGAAGACCTTTATAGTGATCCACTTCTGCT 
  S  A  Y  S  K  R  R  Q  -                                     +1            35 
 
    361 TAATGAATTATAAATATATTTTCTCCTCCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
 
 
 
 
 
 
5.3.5 Cloning and characterization of the L38 gene 
5.3.5.1 Identification of the full-length cDNA sequence  
 
Sequence analysis of the clones isolated from the human retinal SSH cDNA library 
identified clone 4E9R which localizes to chromosome 12q21 (Fig. 37A). Sequence 
comparison of the clone using the BLAST algorithm did not reveal homologuous cDNA 
sequences.  
To retrieve full-length cDNA sequences of L38, a radiolabeled 221 bp PCR fragment 
was amplified with exon primers L38F and L38R, which were designed based on sequence 
information from the 4E9R cDNA fragment and used to screen the human retina full-length 
cDNA library (local library ID: Jelena) . After two rounds of screening, three positive clones 
(L38_1/2, L38_2/2 and L38_3/2) were identified among approximately 1 X 106 recombinant 
phages. Cloned inserts ranged from 750 to 950 bp and were partially or completely sequence. 
They revealed high sequence identities to the previously analysed retinal fragment (Fig. 37A). 
Their consensus sequence extended the 4E9R cDNA for 459 bp and 354 bp at the 5’ and 3’ 
end, respectively. The 3’-termini of the longest L38_1/2 clone contained a potential 
polyadenylation signal AATAAA and terminated with a 29 bp long poly (A) tail. Analysed 
nucleotide sequences of isolated clones suggested that there could be another isoforms of the 
transcript.  
To examine the splicing event, primer L38R1 was designed from the sequence of the 
first known exon and L38F was designed from the sequence of the last identified exon. RT-
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PCR amplification with retinal cDNA as template yielded the expected 711 and 576 bp 
products, and in addition, there were also two products of 440 and 270 bp in size (Fig. 37B). 
Sequencing of the four amplicons determined that the two longer ones, 711 and 576 bp in 
size, were amplified from variants identical to the L38_1/2 and L38_2/2 clones, respectively, 
Moreover, sequence analysis of the remaining two PCR products that are 440 bp and 270 bp 
in size determined that they represent the transcripts which have an internal deletion of 271 bp 
and 431 bp, respectively, due to the use of an alternative splice acceptor sites.  
Assembly of the analysed sequences obtained from the retinal cDNA libraries and by 
RT-PCR resulted in the identification of a 1164 bp full-length cDNA sequence for the L38 
gene.  
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Fig. 37. Genomic structure of the L38 gene.  
A. L38 gene contains five exons, it is located on the chromosome 12q21 spanning    
approximately 21 Kb of genomic sequence. The boxes represent the exons with their relative 
size and original organization. Numbers below boxes indicate exon numbers. The names and 
positions of the primers used for the analysis of L38 gene are shown above the schematic 
illustration. Based on cDNA sequence of the 4E9R clone from the retina SSH cDNA library 
primers L38F and L38R were designed and used for the amplification of the retinal cDNA. 
Obtained radioactive amplicon was used for the screening of the retinal full-length cDNA 
library which resulted in isolation of the L38_1/2, L38_2/2 and L38_3/2 clones. B. A 
consensus cDNA sequence was assembled using sequence of obtained clones and four 
different PCR products which were amplified with L38F and L38R1 primer pair. Calculated 
length of the transcripts is shown on diagram.  
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5.3.5.2 Genomic structure of the L38 gene 
 
To determine the genomic structure of L38, the full-length cDNA sequence was 
aligned to the human genome draft sequence. This resulted in the identification of five exons 
with sizes of 93, 136, 135, 367 and 433 bp, respectively (Fig. 37A, Table 14). Their 
respective splice donor and acceptor sequences correspond to the consensus splice junction 
sequences (Table 14) and conform to the GT-AG rule (Burset et al, 2000). The exons are 
separated by four intervening sequences that are 1.352, 9.786, 3.844 and 3.244 bp in size 
(Table 14).  
The above mentioned analysis resulted in the identification of four isoforms for the 
L38 gene, named L38_SV1 (SV1), L38_SV2 (SV2), L38_SV3 (SV3) and L38_SV4 (SV4). 
Their respective mRNAs are 1164 bp, 1029 bp, 893 and 733 bp in size, respectively (Fig 
36B).  
 
 
Table 14. 
Exon-intron boundaries of the human L38 gene 
 
Exon 
 
3' Splice acceptor sitea 
 
 
5' Splice donor sitea 
 
Intron 
 
No. Size (bp) Sequence Scoreb Sequence Scoreb No. Size (bp)
 
1 93   ..CAGgtaaga.. 1,057 1 1,352 
2 136 ..acttcatgaatttcagT.. 9,701 ..CAGgtataa.. 5,843 2 9,786 
3 135 ..tcttttccttctgcagG.. 0,957 ..GCTgtaagt.. 4,542 3 3,844 
4 367 ..tttttatcatttccagA.. 4,638 ..CAGgtaaga.. 1,057 4 3,244 
5 433 ..actcactgttccacagG.. 5,518    
 
a For the splice junctions, intronic and exonic sequences are shown in small and capital letters, 
respectively. The 5’ splice-donor and 3’ splice-acceptor sequences are given in bold. 
b Scores were calculated to references (Berg et al, 1988 and Penotti et al. 1991). 
Approximately 99% of sites have a score of 0-20 (3’acceptor site) and 0-11 (5’donor site). 
 
 
 
5.3.5.3 Expression analysis  
To examine the tissue expression of L38, RT-PCR analysis was performed with gene 
specific primers L38F located in exon 4 and L38 located in exon 5 using cDNAs from 20 
different human tissues as template. The results demonstrate that L38 is expressed 
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preferentially in the retina with minor expression in bone marrow, heart, placenta and adrenal 
gland (Fig. 38A).   
Virtual Northern blot analysis of the ds cDNAs from different human tissues was 
performed using a radiolabeled PCR fragment, which was amplified with the L38F and L38R 
primers. A signal at approximately 1.1 Kb was detected exclusively in retina (Fig. 38B), thus 
confirming the previous results obtained by RT-PCR.  
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Fig. 38. Expression analysis of L38  
A. Expression analysis of L38 in 20 tissue panel was done by RT-PCR using gene specific 
primers L38F and L38R. Analysis showed that L38 is exclusively expressed in human retina. 
The same panel was amplified with G3PDH specific primers as a control of cDNA quality. B. 
The length of the L38 transcript was determined by virtual Northern blot analysis using 
radioactively labelled PCR product amplified with the same primer pair which was used for 
the RT-PCR analysis. Obtained signal correspond to transcript which is approximately 1.1 Kb 
long and confirmed retinal expression.     
 
 
 
5.3.5.4 In-silico analysis of the L38 cDNA sequence 
 
Analysis of the consensus sequence of the L38 transcript revealed that stop codons 
were present throughout the sense strand of the cDNA (Fig. 39). The peptide encoded by the 
longest ORF is predicted in the first reading frame and is only 34 aa (Fig. 39 and 40).  
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Fig. 39. Open reading frames of the L38 gene.  
Positions of potential translation start and stop codons in all three reading frames are indicated 
by vertical lines and filled triangles, respectively. The longest predicted ORF is represented 
with arrow. 
 
 
The nucleotide sequence flanking the ATG codon (ACCCCCATGA) of the putative 
ORF corresponds reasonably well to the Kozak consensus sequence (GCCPurCCATGG). 
However, this ORF is located within the LTR/MaLR repeat sequence of the last exon of the 
gene. The putative protein has no conserved domain nor does it reveal significant sequence 
similarities to other known proteins. It was also not possible to obtain significant homology of 
the complete L38 transcript to any genomic or cDNA sequences among different species.  
Performed analysis of the cDNA sequence and protein encoded by the longest ORF, 
suggest that L38 transcript does not encode a protein, but may act as a regulatory mRNA.  
 
 
 
     bp                                                                                                     F     aa 
 
  Exon 1 
  1 CTTATACATATATGGAAAAAAATGTGGACATGAAGAAGGAAAAAAAATGAGCAGTGATCT 
 
          Exon 2 
     61 GATCCATCAGGACATTCAAATTTTCTGAGTCAGTGACTTCGAGTGGCAGAAAATTTAAGA 
    121 GATGCAGTATCTTCGGAGAGTAATGACATATAATCCACACATTCATGGAAGAATGGAGAC 
 
   Exon 3  
    181 CTGAAGTCTTTGAAAGGGAGTAAGCAGAGAGGAAAATAGATGTGAACAGGAAGTCATTGT 
    241 TCCAGGGACTGTTTATAGAGGCAGATTTTCAAAGGCCTCCAAACTCCAATTAAGATCATT 
    301 TTGGCTTAAGAACACCCTCTCATTTATTACAGGATTTTCTTTAAGTACACAAAAGTTGCA 
 
 Exon 4 
    361 TGCTATGATCTACCTTATTTTGGAATTAAGAAACACTTGAAGATTATTCTCAGAAATGCC 
    421 ATAAGGGATATTTAAAAATCTTGGAGCACACAAGAAGTACAAGAGGAATGAAAATGTCAT 
    481 GTCTTAATTTTCCAAAAAAGAGAATATTTTAGTTTTTAGTATATAAAGGCAGATTAACAA 
    541 ACCTTCACACAAATCTAAATTTTATTACTAAATTAATTGATTACACTTTGTGTTTACTAG 
    601 GTCACAGGGAATTTCAGTGGGTTTACTCTGCAAAAGATTTCATGTGAAATACATTTTTCT 
    661 ATTCTGAAAGGTTTTTCAAGATTTTCAAGGCAACTAAGAAGTTTTCTAAAAAGACAGTGT 
 
    Exon 5 
    721 TTGTAATACAGGCTCTATAGAAAGCATCGTTGTGGAGGCCTCAGGAAACTTACAATCATG 
    781 GCAGAAGGCGAAGGGAAGCAGGCACATCTTACGTGGCTGGAGAAGGAGGAAGAGAGAGCA 
    841 GAGGAAGGTGCTACACATTTTTAAACAACCGGATCTCATGAGAACTCACTCACTATCACA 
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    901 AGAACAGCAGGGAAATCCACCCCCATGATTCTATCACCTCCCACTAGCCCTCTCCTCCTT 
                          M  I  L  S  P  P  T  S  P  L  L  L   +1    12 
 
  
    961 CAACACTGGGGATTACAACTCCACATAAGGTTTGGGCAGGGACACACATCCAAACCATAT 
  Q  H  W  G  L  Q  L  H  I  R  F  G  Q  G  H  T  S  K  P  Y   +1    32 
 
 
   1021 CATCACTAATTAATGTTTCTGAAAGCTAGAGTTACATTACAACCACCTGAGGAGCTTTTA 
  H  H  -                                                      +1    34 
 
 
1081 GAAAATTACAGATCCCTGAGCTTCCATCTAGATTGATTAAATAAAAATATCTGGGAAAAA 
1141  AAAAAAAAAAAAAAAAAAAAAAAA 
  
 
Fig.  40. Sequence of L38 gene. 
Complete cDNA sequence of the L38 gene is numbered starting with the first base of the 2/2  
clone from the retinal full-length cDNA library. Amino acid sequences encoded by one 
putative open reading frame are indicated bellow the nucleotide sequence and length of the 
potential protein is given on the right side. ATG and TAA codons of the putative ORFs are 
boxed and putative polyadenilation sequence of the L38 transcript is underlined. 
 
 
 
 
5.3.6 Cloning and characterization of the L40 gene 
5.3.6.1 Identification of the full-length cDNA sequence  
 
Initially two clones (5B4F and B04_Ret5) from the retinal SSH cDNA library were 
isolated belonging to a partial transcript with retina specific expression. Partially overlapping 
clones were derived from the same locus on chromosome 7p12 by bioinformatics searches in 
the nucleotide databases. The consensus sequence representing both clones (Fig. 41B) was 
subjected to a homology search against GenBank database using the BLASTN program. 
Results obtained showed that the first exon of the B04_Ret5 clone overlapped with the 
seventh exon of the Zona pellucida-binding protein (ZPBP) gene, suggesting that the retina 
sequences identified could represent a novel splicing variant of ZPBP.  
Screening of the human retina full-length cDNA library (local library ID: Jelena)  was 
performed with the most 3’ end of the previously isolated cDNA as a probe, which was 
amplified with exon spanning primers L40F and L40R. Three positive clones, L40_2/4, 
L40_3/3 and L40_6/3, were obtained from approximately 1 X 106 recombinant phages, with 
inserts ranging from 750 bp to 1150 bp. Partial or complete sequencing of the clone inserts 
revealed that they were highly similar to the previously identified retinal sequences. The 
largest clone L40_2/4 was characterized further and analysis of its nucleotide sequence 
demonstrated that it extends the sequence of the B04_Ret5 clone for 508 bp to the 5’-end, 
whereas the 3’-termini of both clones terminate with a potential polyadenylation signal 
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(AATAAA) and a 48 bp long poly (A) tail. Interestingly, the second exon of the L40_2/4 
clone overlapped with the fifth exon of the ZPBP gene, whereas its third exon overlapped 
with the seventh exon of ZPBP. Nucleotide sequence analysis of clone L40_6/3 showed that it 
was amplified from a shorter transcript with an internal deletion of 310 bp, suggesting that 
there could be another isoform of the transcript (Fig. 41B). To investigate the splicing 
behaviour in more detail, sequence information from the identified cDNA fragments was used 
to design isoform-specific primers. Retinal cDNA was amplified with primer pair L40R2, 
which was designed at the 5’ end of the L40_2/4 and L40_6/3 clones and L40F3, which 
anneals to the seventh exon of the ZPBP. PCR amplification revealed a product with 
unpredicted size, which contained an additional 219 bp, thus suggesting this product to 
represent novel splicing variant of the L40 transcript. Another primer pair L40R1, which 
anneals to the seventh exon of the ZPBP and L40F, which was designed from the 3’end of the 
cDNA sequences of the 5B4F and B04_Ret5 clones was used for the amplification of the 
retinal cDNA, which revealed a PCR product of the expected length of 175 bp in size (Fig. 
41B). 
The 1.037 bp consensus cDNA sequence of L40 gene was determined by assembling 
the sequences of representative clones and PCR products.  
 
 
 
 
 
 
 
 
 
Fig. 41. Genomic organization of the L40 and ZPBP genes (see next page).  
A. Schematic representation of the genomic organization of two overlapping genes, ZPBP 
(zona pellucida-binding protein) and L40. Two promoters, P1 and P2, used for the initiation 
of the transcription of mRNAs of both genes are indicated by arrows and shared exons are 
boxed. The approximate positions of the primers used for PCR amplification are indicated 
above diagram. B. Transcripts of ZPBP and L40 genes. White boxes represent the protein 
coding region, black boxes represent untranslated regions. The ZPBP gene is made up of eight 
exons, whereas L40 gene has seven exons. Three exons which are common to both transcripts 
are boxed. C. The complete cDNA sequence was assembled using sequences of the clones 
isolated from the human retinal SSH and full-length cDNA library together with PCR 
products amplified with L40F3/R2 and L40F1/R1 primers. Only representative clones were 
selected for the schematic presentation. 
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 5.3.6.2 Genomic structure of the L40 gene 
 
To determine the genomic structure of L40, the full-length cDNA sequence was 
aligned to the human genome draft sequence. This resulted in the identification of the gene 
that spans approximately 156 Kb of genomic sequence and is organized in seven exons (Fig. 
41A) which are 200 bp, 219 bp, 77 bp, 178 bp, 132 bp, 98 bp and 83 bp in size, respectively 
(Table 15). Alignment of its full-length cDNA sequence to the human genome also showed 
that three exons of L40 (exons 2-4) overlap with three exons (exons 5-7) of ZPBP gene (Fig. 
41A). All exon/intron boundaries of L40 reveal conserved splice donor and acceptor 
sequences that conform to the GT-AG rule with excellent scores for the consensus splice 
junction sequences (Table 15).   
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Table 15. 
Exon-intron boundaries of the human L40 gene 
 
Exon 
 
3' Splice acceptor sitea 
 
 
5' Splice donor sitea 
 
Intron 
 
No. Size (bp) Sequence Scoreb Sequence Scoreb No. Size (bp)
 
1 200   ..AAGgtaata.. 4,166 1 24,874 
2 219 ..tgttaattttttacagC.. 6,889 ..CAGgtaagt.. 0 2 12,775 
3 77 ..taatatattttctcagT.. 8,469 ..AAGgtatgt.. 2,549 3 34,72 
4 178 ..tgtatttatgttttagG.. 7,596 ..GTGgtatgt.. 4,675 4 64,294 
5 132 ..ttttttttttaaacagA.. 4,859 ..CAGgtaatt.. 2,888 5 17,7 
6 98 ..tcttgtcttattgcagT.. 5,161 ..ACAgtaagt.. 3,738 6 666 
7 83 ..cttttgtttcttatagC.. 4,579    
 
a For the splice junctions, intronic and exonic sequences are shown in small and capital letters, 
respectively. The 5’ splice-donor and 3’ splice-acceptor sequences are given in bold. 
b Scores were calculated to references (Berg et al, 1988 and Penotti et al. 1991). 
Approximately 99% of sites have a score of 0-20 (3’acceptor site) and 0-11 (5’donor site). 
 
 
 
5.3.6.3 Expression analysis  
 
The expression pattern of the L40 and the ZPBP genes in various human tissues was 
determined by RT-PCR analysis. In order to examine the expression profile specific for each 
of the two overlapping genes, L40F2 was designed as forward primer in the first shared exon, 
whereas reverse primers L40R2 and L40R3 were designed within isoform-specific sequences 
within the first exons of L40 and ZPBP, respectively. As shown in Fig. 42, high level of 
expression of L40 is restricted to the retina and minor expression was detected in RPE, 
whereas expression of ZPBP was specific for the testis. 
A radiolabelled PCR probe, amplified with the L40F and L40R primers, was 
hybridised to a virtual Northern blot containing ds cDNAs from several human tissues 
including bladder, heart, lung, skeletal muscle, retina and RPE. Hybridization failed to show 
clear signals for the expression of the L40 gene. Thus, the transcript length could not be 
determined (data not shown). 
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Fig. 42. Expression analysis of L40 and ZPBP genes. 
A. Expression pattern of two overlapping genes was determined by RT-PCR in the panel of 
18 human tissues, using primer pair specific for each gene. For those analysis forward primer 
was designed in the shared exon and used for both expression analysis, whereas reverse 
primer was designed in the first exons of L40 and ZPBP, which are specific for both genes 
(see Fig. 41A). Expression of L40 was determined using primers L40F2 and L40R2, whereas 
expression of ZPBP was determined using the same forward primer and reverse primer 
L40R3. Analysis showed that L40 mRNA is exclusively expressed in the human retina, 
whereas ZPBP expression was restricted to testis. The same panel was amplified with G3PDH 
specific primers as a control of cDNA quality. 
 
 
 
 
5.3.6.4 Analysis of the cDNA sequence 
 
Bioinformatic analysis of the L40 nucleotide sequence indicated that its largest open 
reading frame is 333 bp by exons 2-5 possibly encoding 111 amino acid residues (Fig. 43). 
The L40 gene overlaps ZPBP in coding sequences (Fig. 41A) and both genes share a common 
stretch of 100 amino acids (Fig. 43). ZPBP is one of several proteins that are thought to 
participate in secondary binding between acrosome-reacted sperm and the egg-specific 
extracellular matrix, the zona pellucida (McLeskey et al., 1998). It was determined that the 
deduced 351-amino acid ZPBP protein has no N-terminal signal peptide Katoh and Katoh 
(2003), but contains an N-terminal transmembrane domain and a long extracellular domain of 
almost 300 amino acids with which the L40 gene overlaps. 
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bp                                                                     aa 
  Exon 1 
1 GGAAATGCGCTGACAAAAGGAGAACTTGCAGTGATTTTCTTTGAAAATCAAAGAAGAAGC 
61 CACATGCCAAATAATGAAGGCAGCCACTACAGCTAGAAATGACAAAGAATTGGATTCCCC 
121 CTAAAGCTTTCAGAATGAATACAGCTTGATTTTTGCTTAGTAAGACTCATTTTGGATTTC 
 
             Exon 2 
181 TGATCTCCAGAGCCATAAGCTTATCGTGAGCCTCATTATTATTATCAGTTCACAGCTCGA 
241 TATCATGCAGCTCCCTGCAATAGCATTTATAATATTTCTTTTGAGAAGAAACTTCTTCAG 
301 ATTTTAAGCAAACTGCTTCTTGACCTTTCATGTGAAATTTCCTTACTTAAGTCTGAATGC 
 
          Exon 3 
361 CATCGCGTTAAAATGCAAAGAGCTGGTTTGCAAAATGAATTGTTCTTTGCATTTTCAGTT 
             M  Q  R  A  G  L  Q  N  E  L  F  F  A  F  S  V     16   
 
421 TCATCTCTAGACACTGAAAAAGGACCCAAGCGATGTACAGACCATAACTGTGAACCTTAC 
 S  S  L  D  T  E  K  G  P  K  R  C  T  D  H  N  C  E  P  Y     36 
 
 Exon 4 
481 AAAAGACTTTTTAAGGCTAAAAATCTCATAGAGAGATTTTTTAATCAACAAGTAGAAATT 
 K  R  L  F  K  A  K  N  L  I  E  R  F  F  N  Q  Q  V  E  I     56 
 
541 CTTGGCAGACGTGCAGAACAATTACCTCAAATATACTATATTGAAGGTACTCTCCAAATG 
 L  G  R  R  A  E  Q  L  P  Q  I  Y  Y  I  E  G  T  L  Q  M     76 
 
601 GTTTGGATTAATCGCTGCTTTCCAGGATATGGAATGAATGTCCAGCAACATCCAAAATGT 
 V  W  I  N  R  C  F  P  G  Y  G  M  N  V  Q  Q  H  P  K  C     96 
 
          Exon 5 
661 CCTGAGTGCTGTGAGTCTTGCTCTGTTACCCAGGCTGGAGTGCAGTGACGCGATCTCGGC 
 P  E  C  C  E  S  C  S  V  T  Q  A  G  V  Q  -                 111 
 
721 TCAAGCAACCTCCACCCCCTCGGTTTAAGGGATTCTCCTGCCTCAGCCTCCCGAGTAGAT 
 
 Exon 6 
781 TACAGGCATGTGCCACCATGCCCAGTAGTTGGGACTTCCACTATGATGTTGAAAGGAAAT 
841 GAAGAAAGGAGACAGCCTTATTTTGTTCCTAATCCTGGTGGGAAAGTTTCAAGTTTCTCA 
 
 Exon 7 
901 ACACAATTTGCATCCTCTTTTTTGTTCTTAGCTTGGTGAGATACTTAGAACTTTTATTAA 
961 TCTTTTCAATAAACAAGCTTTTGTTTCGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
1021 AAAAAAAAAAAAAAAA 
 
 
Fig. 43. The complete cDNA sequence of L40 gene.  
The 1037 bp long full-length cDNA sequence of the L40 gene is coding 111 aa. Amino acid 
sequence overlapping to ZPBP gene is underlined. Start and stop codons are boxed. 
Corresponding amino acid sequence is indicated bellow the nucleotide sequence. 
 
 
 
 
This study revealed that two major mRNA species of the ZPBP and the L40 genes 
share three exons but differ in their 5’-untranslated regions. They are transcribed in a tissue-
specific manner through the use of different promoters (Figure 40A). The first mRNA form is 
transcribed through the P1 promoter and is expressed in testis, whereas the second gene is 
transcribed through the P2 promoter and is expressed in the retina.  
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5.3.7 Identification of the single nucleotide polymorphisms (SNPs) in L33, L35 and L38 
genes 
 
 Cloned genes with retinal specific expression are potential candidates for the retina 
disease genes. This was used as criterion for the selection of putative RNA genes: L33, L35 
and L38 for identification of single nucleotide polymorphisms which are going to be used as 
markers for disease mapping and as target disorder, complex disease AMD was chosen. SNPs 
of these genes were identified by direct DNA sequencing or by denaturing high performance 
liquid chromatography (dHPLC). The genomic loci of these genes together with 5 Kb 
upstream (5’ UTR) of the first exon and 5 Kb downstream (3’ UTR) of the last exon were 
analysed. Primers were designed to amplify the known exons together with exon/intron 
junctions, intervening sequences (IVS) and UTRs (primers for each gene are listed in the 
Table 23, Appendix). For the primer design regions containing repeats were avoid. Location 
of the identified SNPs within the exon sequences was counted starting from the first 
nucleotide of the first exon which is not in correlation with nomenclature rules, since it is 
supposed that those genes are not coding proteins and thus do not have start codon. 
 
 
5.3.7.1 Identification of the single nucleotide polymorphisms (SNPs) in L33 gene 
 
As already described above, the L33 gene spans 13 Kb of genomic sequence on 
chromosome 15q23 and consists of five exons.  In total, 16 fragments covering 23 Kb of the 
genomic locus were amplified from eight control individuals. Amplicons were directly 
sequenced or analyzed on the DHPLC. Analysis resulted in the identification of 25 SNPs. Of 
these, seven had allele frequency above 20% for the minor allele (marked with bold in Table 
16), including one localized in the 5’UTR, one in the first intron of the gene, two in the forth 
intron and remaining four in the 3’UTR.  Some of them were analysed further and the allele 
frequencies were determined in 48 control individuals. Although, frequencies of their minor 
allele were above 20% in eight controls, further analysis of the polymorphisms I1-120G>C 
and I4-1540G>A determined their lower frequency in the larger control samples, whereas for 
other nucleotide changes frequencies are higher then previously identified (Table 16). 
Nucleotide changes which are marked with the same colour are in strong linkage 
disequilibrium (Table 16). 
 
 
 
Results 
 109
        Table 16. SNP card of the L33 gene 
 
 
Part of 
the gene 
 
The name of 
the fragment 
 
Nucleotide 
change1 
 
Allele 
frequency 
 
Frequency 
of minor allele 
5’ UTR 5’U-F1/R1 -532C>A 23/56 0.41 
IVS1 I1-F1/R1 IVS1+385G>A 1/16 0.06 
IVS1 I1-F4/R4 IVS1+1274 A>G 1/12 0.08 
IVS1 I1-F4/R4 IVS1+1492 G>T 1/12 0.08 
IVS1 I1-F4/R4 IVS1+1562 C>T 1/12 0.08 
IVS1 I1-F4/R4 IVS1+1647 A>G 1/12 0.08 
IVS1 I1-F3/R3 IVS1-1672G>A 1/16 0.06 
IVS1 I1-F6/R6 IVS1-1293C>T 1/12 0.08 
IVS1 I1-F6/R6 IVS1-1149 G>C 1/12 0.08 
IVS1 Ex2F/R IVS1-165T>A 1/14 0.07 
IVS1 Ex2F/R I1-120G>C 5/84 0.06 
IVS2 Ex2F/R IVS2+18delG 1/14 0.07 
IVS2 Ex3F/R IVS2-24A>G 1/16 0.06 
Exon 4 Ex4F/R 737C>A 1/16 0.06 
Exon 4 Ex4F/R 812A>G 1/16 0.06 
Exon 4 Ex4F/R 939C>T 1/16 0.06 
IVS4 I4- F2/R2 I4-1540G>A 11/88 0.13 
IVS4 I4- F2/R2 IVS4-1487C>G 4/16 0.25 
3’ UTR 3’U-F1/R1 +750G>T 1/16 0.06 
3’ UTR 3’U-F4/R4 +1130C>T 1/14 0.07 
3’ UTR 3’U-F4/R4 +1450T>C 1/14 0.07 
3’ UTR 3’U- F2/R2 +2283A>T 19/92 0.21 
3’ UTR 3’U- F2/R2 +2359G>A 1/14 0.07 
3’ UTR 3’U- F2/R2 +2631C>T 3/14 0.21 
3’ UTR 3’U-F3/R3 +3419delC 3/14 0.21 
           1Location of the SNP, counted from the first base of the reference genomic sequence.  
           2The same colours of the SNPs mean that they are in linkage disequilibrium. 
 
 
5.3.7.2 SNP analysis of the L35 gene  
 
L35 is a four exon gene, spanning 13 Kb of genomic sequence on chromosome 7p21. 
In total, 17 fragments were designed covering 23 Kb. Conditions for the PCR amplification 
could not be optimized for 5’U-F3/R3, 5’U-F4/R4 and Ex4F5/Ex4R1 fragments. The 
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remaining 14 fragments were amplified from eight control individuals. Generated amplicons 
were directly sequenced or run on the DHPLC. Analysis resulted in the identification of 13 
SNPs. Of those, ten had allele frequencies of the minor allele of above 20% (marked with 
bold in Table 17), including one localized in the 5’UTR (-127G>A), one in the first intron of 
the gene (IVS1+7723T>C), three in the second exon (+1484A>G, +1775A>T, +4264C>T), 
one in the second exon (+364A>G), and the remaining four in the 3’UTR (+150G>A, 
+989C>G, +1519G>A, +2436C>T).  Some of these were analysed further and included the 
sequence analysis of the fragments in 48 control individuals. Although, frequencies of their 
minor allele were above 20% in the eight controls, further analysis of the +1519G>A 
polymorphism resulted in a lower frequency in the larger control sample, whereas for other 
nucleotide changes frequencies are higher then previously identified (Table 17). Nucleotide 
changes which are marked with the same colour are in strong linkage disequilibrium (Table 
17). 
 
 
       Table 17. SNP card of the L35 gene 
Part of 
the gene 
The name of 
the fragment 
Nucleotide 
change1 
Allele 
frequency 
Frequency 
of minor allele 
5’ UTR Ex1F1/R1 -127G>A 11/32 0.34 
IVS1 I1-F1/R1 IVS1+1818T>C 1/16 0.06 
IVS1 I1-F2/R2 IVS1+3496C>T 2/16 0.13 
IVS1 I1-F2/R2 IVS1+3664G>A 1/16 0.06 
IVS1 I1-F3/R3 IVS1+7723T>C 13/20 0.65 
Exon 2 Ex2F/R +364A>G 40/80 0.50 
Exon 4 Ex4-F6/R5 +1484A>G 3/14 0.21 
Exon 4 Ex4-F6/R5 +1775A>T 5/14 0.36 
Exon 4 Ex4F4/L35R1 +4264C>T 4/12 0.33 
3’ UTR 3’U-F1/R1 +150G>A 4/16 0.25 
3’ UTR 3’U-F2/R2 +989C>G 4/14 0.29 
3’ UTR 3’U-F2/R2 +1519G>A 12/96 0.13 
3’ UTR 3’U-F3/R3 +2436C>T 4/14 0.29 
           1Location of the SNP, counted from the first base of the reference genomic sequence.  
           2Gray background means that SNPs are in linkage disequilibrium. 
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5.3.7.3 SNP analysis of the L38 gene 
 
The L38 gene comprises five exos which span 25 Kb of genomic DNA on 
chromosome 12q21. In total, 14 fragments were designed to covering 35 Kb of the genomic 
locus (long repeat regions within the locus were the main reason for choosing the small 
number of fragments). Conditions for PCR amplifications could not be optimized for the 
Ex3F/R, I3-F1/R1 and I3-F2/R1 fragments. The remaining 11 fragments were amplified from 
eight control individuals. Generated amplicons were directly sequenced or run on DHPLC. 
Analysis resulted in the identification of 11 nucleotide changes including one deletion. Of 
these, only two (+1062C>T and +del:2186-2191) had allele frequencies for the minor allel 
above 20% (marked with bold in Table 18) and both of these are localized in the 3’UTR of 
L38. They were both analysed further and were screened in 48 control individuals. Although, 
frequencies of their minor allele were above 20% in eight controls, further analysis 
determined that the frequencies indeed were below 20% in the larger control samples (Table 
18). It was also determined that these markers are not in linkage disequilibrium (Table 18). 
 
 
       Table 18. SNP card of the L38 gene 
 
 
Part of 
the gene 
 
The name of 
the fragment 
 
Nucleotide 
change1 
 
Allele 
frequency 
 
Frequency 
of minor allele 
 
5’ UTR 
 
5’U-F3/R3 
 
-3733G>T 
 
44/84 
 
0.52 
5’ UTR 5’U-F2/R2 -2216C>T 1/16 0.06 
5’ UTR 5’U-F1/R1 -1205G>A 2/16 0.13 
5’ UTR 5’U-F1/R1 -1144insT 2/16 0.13 
5’ UTR 5’U-F1/R1 -858C>T 1/16 0.06 
Exon 1 Ex1F/R +50A>G 1/16 0.06 
Exon 1 Ex1F/R +67T>C 1/16 0.06 
IVS1 I1-F1/R1 +3315A>C 1/16 0.06 
Exon 4 Ex4F/R +627(G>T) 6/12 0.5 
3’ UTR 3’U-F1/R1 +1062C>T 7/96 0.07 
3’ UTR 3’U-F2/R2 +2161C>T 1/16 0.06 
3’ UTR 3’U-F2/R2 +del:2186-2191 17/88 0.19 
           1Location of the SNP, counted from the first base of the reference genomic sequence.  
           2Gray background means that SNPs are in linkage disequilibrium. 
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6 DISCUSSION 
 
The goal of this project was identification of the novel genes which are expressed 
preferentially in the human retina. The retina is highly-complex system specialized for the 
reception and processing of visual information and identification of the genes with expression 
restricted to this tissue will further our understanding of its physiology. In addition, 
expression analysis of the known genes which are associated with retinal degenerations 
showed that most of them are exclusively or abundantly expressed in the retina. Therefore, we 
decided to constructed cDNA library by SSH technique in order to identify novel retinal 
transcripts. Our efforts concentrated on the generation of a catalogue of the retina-specific 
genes, which will be discussed at the beginning of this chapter. Several of the retina-specific 
genes were selected for further analysis and challenges encountered in cloning and functional 
characterization of the these genes opened many questions and brought us to the following 
topics including i) alternative splicing, ii) mechanism of NMD and its possible involvement in 
the regulation of gene expression and RNAi as a mechanism to study gene expression (e.g. 
ABCC5 and its three newly identified isoforms), iii) regulatory ncRNA genes (e.g. L33, L35 
and L38) and iv) genes overlapping on the same strand (e.g. L40), which are going to be 
discussed in the following paragraphs.  
 
 
6.1 Identification of novel retinal transcripts 
 
Towards the identification of the novel genes that are expressed exclusively in the 
human retina, cDNA library was constructed using suppression subtractive hybridization 
(SSH) technique (Diatchenko et al., 1996) which combines normalization and subtraction step 
in a single procedure in order to obtain enrichment of differentially expressed retinal genes of 
both high and low abundance. The normalization step equalized the abundance of cDNAs 
within retinal population, whereas subtraction step excluded the common sequences between 
retina and two other nonocular cDNA populations which were used.  
In total, 1113 clones were isolated randomly from the retina SSH cDNA library and 
subjected for the further analysis. After correcting for redundancy, clustering of the clones 
showed that 162 of them derived from 92 partial transcripts representing unknown human 
genes, whereas 234 known human genes were represented by 766 clones (Table 1). The 92 
transcripts were selected for the expression analysis which showed that sixteen genes were 
Discussion 
113 
expressed specifically in the retina, thirteen showed abundant expression in the retina, 
whereas for twelve genes expression was determined as neuronal (Table 2). Thus, evaluation 
of the cDNA library demonstrated enrichment of retinal transcripts and the presence of a large 
number of as yet unidentified tissue-specific genes. Of these, L25, L33, L35, L37, L38 and 
L40 transcripts with retina specific expression were selected for further analysis including 
cloning of the full-length cDNA and their functional characterization. 
 
 
6.2 Cloning and characterization of L25 gene  
 
The cloning and characterization of the L25 gene was begun by identification of two 
clones from retinal SSH cDNA library that derived from the chromosome 3q27, for which 
expression was determined as retina specific (Fig. 12). The fact that clones are mapping to the 
fifth intron of ABCC5 gene initiated analysis of the splicing events of this gene. Performed 
analysis resulted in the identification of the three novel splicing variants of ABCC5, named 
ABCC5_SV1, ABCC5_SV2 and ABCC5_SV3, which share the first five exons with ABCC5 
but have different 3' ends, and their length was determined as 2039 bp, 1962 bp, and 1887 bp, 
respectively.  
ABCC5 protein belongs to the ATP-binding cassette (ABC) transporter superfamily, 
which represent the largest family of transmembrane proteins. In general, ABC proteins bind 
ATP and use the energy to drive the transport of various molecules across all cell membranes 
(Higgins 1992; Childs and Ling 1994; Dean and Allikmets, 1995). Most of the ABC 
transporters translocate a wide variety of substrates including sugars, amino acids, metal ions, 
peptides, proteins and a large number of hydrophobic compounds and metabolites across 
extra- and intracellular membranes. They usually move compounds into endoplasmatic 
reticulum, mitochondria and peroxisome or from the cytoplasm to the outside of the cell 
(Dean et al., 2001). Mammalian ABC genes are divided into seven subfamilies (Dean et al., 
2001). One of them is ABCC subfamily, which contains 12 full transporters that perform 
different functions including ion transport, toxin secretion, and signal transduction (Borst et 
al., 2000). For example, ABCC1, ABCC2 and ABCC3 transport drug conjugates and other 
organic anions. Other transporters, like ABCC8 and ABCC9 proteins bind sulfonylurea and 
regulate potassium channels involved in modulating insulin levels (Dean et al., 2001). Nine 
members of ABCC subfamily are also known as multidrug resistance proteins (MRPs) (Borst 
et al., 2000). They play an important role in multidrug resistance, in which the cell is resistant 
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to several drugs in addition to the initial compound, which is a particular limitation to cancer 
chemotherapy (Dean et al., 2001). One of these proteins is ABCC5, also known as multidrug 
resistance protein 5 (MRP5), which was identified as cellular export pump for cyclic 
nucleotides with 3’, 5’-cyclic GMP (cGMP) as a high-affinity substrate and cAMP as low 
affinity substrate (Jedlitschky et al., 2000). The cyclic nucleotides cAMP and cGMP are 
major second messengers in the cell. cGMP is formed from GTP by the action of guanylate 
cyclase, whereas cAMP is formed from ATP by adenylate cyclase. Both cyclases can be 
activated by a variety of intracellular and extracellular stimuli. Guanylate cyclase is 
stimulated by nitric oxide, which leads to a build up of cGMP in the cell, whereas adenylate 
cyclase is activated by the binding of ligands to membrane receptors (Beavo and Brunton, 
2002). Afterwards, cGMP and cAMP are hydrolyzed by the phosphodiesterases to 5’-GMP 
and 5’-AMP, respectively, thus returning cyclic nucleotide concentrations to basal levels and 
making the cell susceptible to a new stimulus. In addition to metabolic degradation by 
phosphodiesterases, active cyclic nucleotide export as an elimination route has been observed 
in many tissues (Woods and Houslay, 1991; Billiar et al., 1992; Patel et al., 1995; Sager et al., 
1998). In addition to a possible role in the regulation of intracellular cyclic nucleotide level, 
efflux of cyclic nucleotides may also have a signaling function, as suggested by reports 
showing biological effects of extracellular cGMP (Poulopoulou and Nowak, 1998; Touyz et 
al, 1997).  
As already mentioned, ABCC5_SV1, ABCC5_SV2 and ABCC5_SV3 transcripts are 
generated by alternative splicing of the ABCC5 mRNA. Alternative splicing of ABCC5 gene 
has already been reported. Suzuki et al. (1997) demonstrated existence of the short type of 
multidrug resistance protein homologue, SMRP. This protein composed of 946 amino acids, 
represents an N-terminally truncated ABCC5. Its coding sequence is starting from the seventh 
exon of the gene. There are also a number of reports which have demonstrated alternate 
splicing of ABCC family members. The earliest report is for ABCC1 gene, which contains 31 
exons and several alternate spliced forms, which, interestingly, retain their reading frames 
(Grant et al., 1997). ABCC11 and ABCC12 also contain alternate forms, some of which retain 
their reading frame, but have lost certain functional domains (Yabuuchi et al., 2001; Bera et 
al., 2002).  
Length of the exons 5a, 5b and 5c is 152 bp, 75 bp and 1.142 bp, respectively, and 
their splice donor and acceptor sequences correspond to the consensus splice junction 
sequences (Table 8). It has been shown that the usual size of the human exon is 300 
nucleotides with the average internal exon measuring only 145 nucleotides in length (Venter 
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et al., 2001; Lander et al., 2001). Exon recognition in the context of the vastly larger introns is 
guided in part by partially conserved sequence elements at the exon-intron junctions, denoted 
5’ and 3’ splice sites, which is a challenge, given their small size. Usage of the alternative 5’ 
or 3’ splice sites can result in exons of different sizes. In addition, inclusion or skipping of one 
or more exons is a common form of alternative splicing. 
In general, alternative splicing is known as the major source of proteome diversity in 
humans. This is the process by which a single primary transcript yields different mature 
RNAs leading to the production of protein isoforms with diverse and even antagonistic 
functions (Modrek et al., 2003; Johnson et al., 2003). Alternative splicing leading to the 
production of transcripts with different properties from one locus has been proposed as an 
important mechanism underlying the complex phenotypes governed by mammalian genomes 
(Lander et al., 2001; Tupler et al., 2001). Annotation of the human genome has revealed that 
the majority of intron-containing transcripts are alternatively spliced (Modrek et al., 2003; 
Johnson et al., 2003). For example, estimations, based on analyses of expressed sequence tags 
(ESTs), suggested that the transcripts from 35% of human genes are alternatively spliced 
(Hanke et al. 1999; de Souza et al. 2000). However, this number is likely to be an 
underestimate, considering the fact that the human EST collection does not represent all 
protein coding sequences and that many alternative splicing events are very rare and occur 
only in a specific tissue at a specific time in development and/or under certain physiological 
conditions. Another study of 10,000 human genes, which are expressed in more than 50 
tissues and cell lines, concluded that transcripts from at least 74% of all multi-exon genes 
were alternatively spliced (Johnson et al., 2003). These findings confirm predictions that 
majority of transcripts expressed from human genes are alternatively spliced. An extreme 
example of complex alternative splicing events is the gene encoding the Down syndrome cell 
adhesion molecule (Dscam) in flies which may generate more than 38,000 distinct isoforms, 
which is 2 to 3 times the number of predicted genes in the entire organism. There are 12 
different variants of exon 4, 48 variants of exon 6, 33 variants of exon 9 and two variants of 
exon 17. However, each mature Dscam mRNA contains only one variant of these exons. 
Although nothing is known about regulation of the Dscam splicing, there must be some 
degree of control because Dscam transcripts always contain one variant exon at each position, 
yet never more than one variant (Schmucker et al., 2000). 
It has been predicted, using the TMHMM method, that the cDNA sequences of three 
novel isoforms of ABCC5 encode putative protein with one transmembrane helix (Fig. 23). 
This amino acid stretch corresponds to the first transmembrane helix of the first hydrophobic 
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transmembrane domain (TMD1) of ABCC5 transporter. Typically the plasma membrane 
encoded ABC transporters are composed of two nucleotide binding domains (NBDs), also 
known as ATP-binding domains, and two transmembrane domains (TMDs), which contain 6-
11 membrane-spanning α-helices and provide the specificity for the substrate (Dean et al., 
2001). The NBD are highly conserved among species, whereas the membrane spanning 
domains TMDs are much more divergent (Higgins, 1992). However, hydropathy analysis of 
putative proteins encoded by these three isofoms did not predict transmembrane domains, 
suggesting that these transcripts may encode soluble proteins. 
Sequences analysis of the human ABCC5_SV1, ABCC5_SV2 and ABCC5_SV3 
cDNAs showed that only exon 5a is highly conserved among different species including 
bovine, porcine and mouse, whereas for exons 5b and 5c this could not be shown (Fig. 24). 
The nucleotide sequences of functionally neutral alternative exons are not under selective 
pressure and therefore should not be conserved in distantly related species, whereas 
functionally relevant alternative exons may be conserved, which leads to the suggestion that 
exon 5a might be functionally relevant alternative exon of ABCC5 gene.  
Computational analysis of the ABCC5_SV1 nucleotide sequence showed that 
inclusion of exon 5a produces a frame shift which results in introduction of stop codon that is 
located more than 100 bp upstream of the last exon-exon junction (Fig. 16B). Stop codons 
that are not located within the last exon and are followed by one or rarely two exon-exon 
junctions that reside no more than 50–55 nt downstream (Fig. 44) (Nagy and Maquat, 1998) 
are called premature termination codons (PTCs) (Hentze and Kulozik, 1999), whereas normal 
termination codons are usually located within the last exon and are not followed by an exon-
exon junction.  
Eukaryotes possess an mRNA surveillance system, termed nonsense-mediated mRNA 
decay (NMD), which scans newly synthesized mRNAs for faulty open reading frames (ORFs) 
and eliminates “imperfect messages” that contain PTCs, which are coding for nonfunctional 
or even harmful polypeptides (Hentze and Kulozik, 1999).  
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Figure 44. NMD and the ‘position-of-an-exon–exon-junction’ rule (Reproduced from Ref. 
Maquat, 2004). Only the 3'-most exon–exon junction within a generic mammalian mRNA is 
shown. Mammalian mRNAs generally have an average of 7-8 splicing-generated exon-exon 
junctions (Lander et al, 2001; Venter et al., 2001). A premature termination codon (PTC) that 
is located in the region indicated in blue, which is followed by an exon-exon junction more 
than 50-55 nucleotides (nt) downstream, elicits nonsense-mediated mRNA decay (NMD), 
whereas a PTC that is located in the region indicated in green fails to elicit NMD. The normal 
termination codon (Ter) usually resides within the 3'-most exon (Nagy and Maquat, 1998). 
 
 
 
In general, during pre-mRNA processing the splicosome deposits exon-junction 
complexes (EJCs) at sites of intron removal (Fig. 45) (Le Hir et al., 2001). With the 
pioneering first round of translation, the ribosome displaces the EJCs in its path and 
subsequently disassociates from the mRNA at the site of termination (Ishigaki et al., 2001). If 
the ribosome reaches a stop codon which is located more than 50 nucleotides upstream of the 
final exon-exon junction, one or more EJCs will remain bound to the mRNA. Interactions 
between EJC proteins and release factors recruit a decapping enzyme that triggers rapid 
mRNA decay (Lykke-Andersen et al., 2000). Thus, a general rule for specifying whether a 
transcript will be targeted by the NMD pathway has been stated as follows (Nagy and 
Maquat, 1998): if an intron is located more than 50 nucleotides downstream of the stop codon, 
then the termination codon is recognized as premature and the transcript will be down-
regulated by NMD. 
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Figure 45. Nonsense-mediated decay is important surveillance mechanism. Normal 
translation involves displacement of all exon junction complexes (EJCs). Any remaining EJCs 
will trigger NMD (Reproduced from Ref. Green et al, 2003). 
 
 
 
In mammalian cells, NMD was discovered in studies of β-thalassemias which are 
caused by introduction of the premature termination codons (Maquat et al., 1981; Kinniburgh 
et al., 1982). It was also identified that the PTC mutations of the yeast ura3 gene destabilized 
the encoded mRNA (Losson and Lacroute, 1979). These findings led to the suggestion that 
NMD serves as an mRNA surveillance mechanism to eliminate mRNAs encoding truncated 
polypeptides that could act in a dominant-negative fashion or other deleterious mechanisms 
(Hentze and Kulozik, 1999. In addition, NMD also degrades natural substrates such as certain 
selenoprotein mRNAs (Moriarty et al., 1998; Sun et al., 2001). Finding that mouse embryos 
which are inactive in NMD resorb shortly after implantation provides the evidence for the 
importance of NMD (Medghalchi et al., 2001). Furthermore, blastocysts that are isolated 3.5 
days post-coitum and that are inactive in NMD undergo apoptosis in culture after a brief 
growth period (Medghalchi et al., 2001). 
Present study demonstrated that ABCC5_SV1 splice variant is target of NMD by 
using antibiotics puromycin and anisomycin which are interfering with the efficiency of 
translation and thus blocking NMD (Fig. 20) (Noensie and Dietz, 2001; Lei et al., 2001; 
Rajavel and Neufeld, 2001; Carter et al., 1995). Our experiments with human cell lines 
ARPE-19 and Y79 revealed that the SV1 transcript containing PTC increased in abundance 
relative to other isoforms after treatment with protein synthesis inhibitors. Moreover, it was 
shown that the amount of this PTC containing transcript in NMD-inhibited cells was 
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absolutely dependent upon protein synthesis, thus revealing classic characteristics of NMD 
(Carter et al., 1995). These findings suggest that exon 5a plays a role in regulation of ABCC5 
expression facilitating general, conserved regulatory mechanism.  
To confirm the correlation between expression levels of ABCC5 and its various short 
N-terminal isoforms RNAi method was used. Results of RNAi experiments demonstrated that 
reduction in SV1 levels was correlated with increase of ABCC5 mRNA amount in treated A-
RPE 19 cell line, just opposite to the effect obtained by blocking NMD, thus clearly 
confirming correlation between those two transcripts and proposed hypothesis of the 
regulation of ABCC5 expression. For this purpose ARPE-19 cell line was treated with 
synthetic siRNA duplexes and the effect on the induction of RNAi was investigated. Our 
experiments showed that siRNA1 duplexes effectively silenced SV1, SV2 and SV3 isoform 
expression to a level of approximately 20% of normal. Other siRNAs tested were less 
efficient in silencing the various isoforms (Fig. 22). RNAi obtained for SV2 and SV3 
transcripts by using siRNA2 duplexes was 30-50%, whereas inhibition obtained for SV3 
mRNA using siRNA3 was approximately 50%. Silencing was measured between 24 to 48 
hours posttransfection time since the most effective inhibition was observed at these time 
points (Fig. 21). Currently it is not known weather the lower effectiveness of specific RNAi 
duplexes arises from a local secondary structure phenomenon of the mRNA, protection of the 
mRNA by a cellular binding protein, translational silencing through miRNA effect (Doench et 
al., 2003), or an as yet unidentified feature in the sequence of the duplex. Alternatively, a 
minor error in the cDNA sequence or a polymorphism has to be considered, as already a 
single base change will render the duplex ineffective (Harborth et al., 2001).    
Expression analysis of ABCC5 as well as SV1, SV2 and SV3 isoforms performed by 
RT-PCR, virtual Northern blot and quantitative RT- PCR showed high level of expression of 
these transcripts in retina compared to their expression levels in other human tissues, thus 
demonstrating tissue dependent expression of the ABCC5 as well as ABCC5_SV1, 
ABCC5_SV2 and ABCC5_SV3 splice variants (Fig. 18). 
All those data strongly suggest that tissue specific splicing of exon 5a containing PTC 
and the subsequent degradation of the respective message via NMD rather seam to be a 
general mechanism of tissue-specific regulation of ABCC5 expression than just elimination of 
“imperfect” message. This could occur by the 5a exon facilitating regulated unproductive 
splicing and translation (RUST) (Fig.46) (Lewis et al., 2003). Just as the binding of 
transcription factors may turn on (or off) gene expression, the binding of splicing factors can 
turn on (or off) gene expression by splicing productive (or unproductive) isoforms. This mode 
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of regulation has been demonstrated for the splicing factor SC35, which auto-regulates its 
own expression through coupling alternative splicing and NMD (Sureau et al., 2001). 
Additional cases of RUST have been observed for ribosomal proteins in C.elegans (Mitrovich 
and Anderson, 2000).  
 
 
 
 
 
 
Figure 46. Regulated unproductive splicing and translation (RUST). Protein expression is 
controlled by regulated variations in the splice environment, the presence and abundance of 
splicing factors (SF). This determines whether productive or prematurely terminating 
(unproductive) mRNAs are spliced (Figure taken from Ref. Lewis et al., 2003). 
 
 
 
In summary, present study provides an evidence for the importance of a complex 
alternative splicing pattern of ABCC5 gene involved in the regulation of its retina-specific 
expression and suggests NMD to be critical in the translational regulation of a ubiquitously 
transcribed ABCC5 mRNA. Tight regulation of intracellular cyclic nucleotide concentrations 
exported by ABCC5 is important, because excessive cGMP production in cells is toxic and 
may cause neurotoxicity (Li et al., 1997; Montoliu et al., 1999) or retinal degeneration 
(Heasley and Brunton, 1985; Bowes et al., 1990). It can be assumed that cellular environment 
regulates ABCC5 splicing and provides a checkpoint, after translation, for fine tuning and 
selecting the type of ABCC5 required. Although it is unknown at this point, such a checkpoint 
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may serve to allow a cell to determine the amount of ABCC5 transporter that is required and 
then modulate its expression accordingly.  
Complex pattern of alternative splicing in a tissue-specific manner was reported for 
regulation of protein function of the MID1 (Winter et al., 2004). Identified splicing variants, 
which are highly conserved among species, cause loss-of-function effects via negative effects 
of C-terminally truncated proteins. Others carry PTC and are degraded by NMD. Lamba and 
co-workers (2003) showed NMD dependent down-regulation of alternatively spliced ABCC4 
transcripts. Highly conserved exons of ABCC4 bearing PTC are suggested to play a role in 
regulation of the gene expression by facilitating translation re-initiation. A similar regulatory 
mode has been suggested for the expression of the AUF1 gene. Instead of introducing exons 
containing PTCs into the message, alternative splicing of the 3’UTR of the AUF1 gene has 
been shown. While the inclusion of an unspliced intron in the 3’ part of this gene leads to the 
transcription of a stable message, a final exon-exon junction downstream of the termination 
signal is being produced by alternative splicing of this intron (Willson et al., 1999). 
Alternative splicing was also reported for neuronal nitric oxide synthase (nNOS) gene by 
alternate splicing of exon 1, thus regulating tissue and developmental stage-specific 
expression (Wang et al., 1999). Alternate splicing of CYP4F3, with inclusion of either exon 3 
or exon 4, results in enhanced protein diversity to accommodate different substrates as well as 
impact tissue specific expression (Christmas et al., 2001). 
The connection between alternative splicing and NMD seems to be the result of 
inappropriate inclusion or skipping of exons (e.g., FGFR2 transcripts that include both exons 
8 and 9 (Jones et al., 2001)), which is perhaps an unavoidable side effect of the flexibility 
required for regulating splicing (Wagner et al., 2003). Thus, NMD provides surveillance for 
errors in alternative splicing. In other cases, alternative splicing-coupled surveillance can be 
used to downregulate transcript levels by diverting a larger fraction of these to be dispensed 
by NMD. Several alternative splicing factors can regulate their own synthesis by this 
mechanism (Wollerton et al., 2004). 
 
 
6.2.1 Evidence for the coupling of alternative splicing and NMD 
 
Lewis and co-workers recently suggested a genome-wide coupling of alternative 
splicing and nonsense-mediated mRNA decay in humans based on in-silico analysis of 
reliable alternative isoforms of known human genes (Lewis et al., 2003). In total, 16.163 well-
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characterized human coding mRNAs from RefSeq and LocusLink were analysed. To detect 
alternative isoforms, 4.6 million EST sequences from dbEST were aligned to the genomic 
sequence. Application of the 50-nucleotide NMD rule revealed that 35% of alternative 
isoforms are candidates for NMD. Additionally, 35% of alternatively - spliced RefSeq genes 
were found to generate at least one NMD-candidate isoform. They also reported that the 
distribution of predicted polyadenylation signals in NMD-candidate splices is biased against 
regions just downstream of premature termination codons, undermining the likelihood that 
alternative polyadenylation stabilizes many of the NMD-candidate transcripts. 
Though alternative splicing and NMD combine to make RUST a general mechanism 
of gene regulation, the impact of RUST is not yet fully known and the prevalence is still 
hypothetical. Preliminary phylogenetic sequence analyses hint that NMD might have evolved 
before alternative splicing. This allows the speculation that the predominant ancestral role of 
alternative splicing could possibly have been RUST, rather than the generation of protein 
diversity. Initial studies suggest that among the genes with NMD-candidate mRNA isoforms, 
certain functional classes are overrepresented, including chaperone proteins (Lewis et al., 
2003). 
It appears that NMD may function not only as a surveillance complex for the rare 
transcript but also as part of a pathway that controls expression of a large number of genes. 
The importance of NMD is underscored by its potential involvement in degrading many 
disease-linked gene transcripts. More complete understanding of the interplay between 
alternative splicing and NMD will provide insight possibly leading to effective treatments for 
some genetic diseases and a better understanding of gene regulation. 
It seems unlikely that the complexity of an organism can be explained by the one gene 
- one protein hypothesis. Alternative splicing expands the coding capacity of the human 
genome, and in some instances related, diverse or antagonistic functions of alternatively 
spliced isoforms have been determined. This part of the thesis showed the importance of a 
complex alternative splicing pattern for the tissue-specific function of the ABCC5 transporter. 
In the majority of cases, however, the precise function of each isoform is not understood. 
Thus, what some consider noise might actually be crucial in facilitating the development of 
complex organisms from a limited number of genes. Developing a full catalogue of 
alternatively spliced transcripts and determining each of their functions will be a major 
challenge of the upcoming proteomic era. 
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6.2.2 RNA interference (RNAi) for gene knockdown 
 
In general, RNA interference provides a new and reliable method to investigate gene 
function. This technology has many advantages over other nucleic-acid-based approaches, 
and therefore is currently the most widely used gene-silencing technique in functional 
genomics (Dorsett et al., 2004). RNAi is the process of sequence-specific posttranscriptional 
gene silencing triggered by double-stranded RNAs (dsRNAs) homologues to the silenced 
genes. RNAi was originally described in Caenorhabditis elegans (Fire et al., 1998; Timmons 
and Fire., 1998) and Drosophila melanogaster (Kennerdell and Carthew, 2000; Yang et al., 
2000) as a mechanism to protect against invasion by foreign genes and has subsequently been 
demonstrated to be utilized by diverse eukaryotes such as insects, plants, fungi, and vertebrate 
(Agami, 2002; Cottrell and Doering, 2003; Hannon, 2002). The dsRNAs introduced or 
generated in cells are subjected to digestion with an RNase III-like enzyme, Dicer, into 21-25 
nucleotide RNA duplexes, and the resultant duplexes, referred to as short interfering RNA 
(siRNA) duplexes, function as essential sequence-specific mediators of RNAi in the RNA-
induced silencing complexes (RISCs) (Bernstein et al., 2001; Hammond et al., 2000). Elbashir 
et al. (2001) have shown that synthetic 21-nt siRNA duplexes can induce the sequence-
specific RNAi activity in cultured cells without triggering the rapid and non-specific RNA 
degradation and translation inhibition. RNAi induction by synthetic siRNA duplexes appears 
to have paved the way for studying the molecular mechanism of mammalian RNAi, and also 
provided us with a powerful reverse genetic tool for suppressing the expression of a gene of 
interest in mammalian cells (Harborth et al., 2001). 
 
 
6.3 Cloning and characterization of L33, L35 and L38 genes 
 
The cloning and characterization of L33, L35 and L38 genes was initiated after 
expression analysis of the clones from the retina SSH cDNA library, which derived from 
these three genes, showed that their transcripts are expressed abundantly in the human retina 
(Fig. 12). For the identification of the full-length cDNA sequences of these genes full-length 
human retina cDNA library (local library ID: Jelena) was screened, as mentioned above, and 
sequence assembly of the isolated clones together with homologue clones from the public 
databases resulted in identification of the full-length cDNA sequences of the L33, L35 and 
L38 genes.  
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Full-length cDNA sequence of the L33 gene, which was identified as five exon gene 
on chromosome 15q23, is 1.600 bp long. Computational analysis of its full-length cDNA 
sequence predicted that longest identified open reading frames ORF1, ORF2 and ORF3 could 
encode 41, 42 and 43 amino acid residues, respectively (Table 10).  
Full-length cDNA sequence of the L35, four exon gene which was localized to 
chromosome 7p21, was determined as 3.759 bp. Alternatively spliced transcript that lacks 141 
bp long exon was also detected (Fig. 30). In addition, sequencing of the clones isolated from 
the full-length human retina cDNA library suggested generation of the transcript which is 
only 749 bp long due to the usage of an alternative polyadenylation signal. Analysis of the 
complete cDNA sequence of the L35 gene identified four open reading frames, ORF1 to 
ORF4 and of these, ORF4 as the longest one would encode 54 amino acids (Table 12).  
Complete cDNA sequence of the L38 gene, which was localized to chromosome 
12q21 and identified as five exon gene, is 1.164 bp long. Additional three isoforms for the 
L38 gene that are 1029 bp, 893 and 733 bp in size were also identified (Fig 36B). 
Computational analysis of the full-length cDNA sequence of this gene identified one open 
reading frame which encodes 34 amino acids residue (Fig. 40).  
Considering the lengths of the full-length cDNA sequences of the L33, L35 and L38 
genes which are approximately 1.6 Kb, 3.7 Kb and 1.1 Kb long, respectively, lengths of the 
longest open reading frames predicted for these three transcripts, which are 43, 54 and 34 
amino acids, respectively, are very short. Moreover, in silico analysis of the putative proteins 
encoded by these three transcripts did not result in identification of the conserved domains or 
significant sequence similarity to any other known protein. These findings led us to suggest 
that L33, L35 and L38 genes may belong to the growing group of non-coding RNA (ncRNA) 
genes, producing functional RNA molecules rather than encoding proteins.  
In general, for the sequences with short ORFs coding potential is less convincing, 
whereas many genes having long ORFs are obviously coding. Length of the ORF and coding 
potential alone is often insufficient to decide whether a gene is coding or non-coding, thus it is 
difficult to differentiate coding genes with short ORFs from ncRNA genes. For a small gene 
to be called a protein-coding gene, evidence may be that the ORF is significantly conserved in 
other related species. Comparative genome analysis may also provide a tool to clarify whether 
a locus produces ncRNA as opposed to a functional protein. For example, sequence analysis 
of the plant Medicago ENOD40 cDNA did not show significant coding potential, so it has 
been thought that this is ncRNA gene (Crespi et al., 1994). Subsequently, on the basis of 
comparative genome analysis, the ENOD40 transcript appeared to encode two small proteins 
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that consist of only 13 and 27 amino acids (Sousa et al., 2001). Another example is CsrB, 
360-nucleotide bacterial regulatory ncRNA (Romeo, 1998), for which was originally thought 
to encode a 47-amino-acid protein.  
Relatively few ncRNAs have been identified or described in detail.  In most cases such 
RNAs either have not been predicted or, if detected, have been set aside in favour of focusing 
on the study of functional proteins. The ncRNAs have been documented by a number of 
research groups and provide some insight into this largely unexplored facet of coding 
potential in the genomes of higher organisms. Examples of well characterized ncRNAs 
include i) a synapse-associated 7H4 (Velleca et al., 1994), ii) brain-specific cytoplasmic RNA 
1 (BC1), suggested to operate in the regulation of local translation-related processes in 
postsynaptic microdomains (Lin et al., 2001), iii) brain specific repetitive (Bsr) RNA and 
Ntab, which are expressed abundantly in rat brain, respectively (Komine et al., 1999; French 
et al., 2001), iv) Polar granule component (Pgc), required for germ cell formation in 
Drosophila (Nakamura et al., 1996), v)  adapt33, oxidant-inducible RNA (Wang et al., 1996), 
vi) noncoding transcript in T cells (NTT) (Liu et al., 1997), vii) BORG, induced following 
exposure to bone morphogenetic proteins (Takeda, 1998), viii) H19, an abundant hepatic 
fetal-specific ncRNA, suggested to function as a tumor suppressor (Hurst and Smith, 1999), 
ix) roX1 and roX2, Xist and Tsix, which are involved in X chromosome dosage compensation 
in insects and mammals, respectively (Kelley and Kuroda, 2000; Lee et al., 1999), x) 
fibroblast growth factor-2 antisense (FGF-AS), differentially spliced to produce coding and 
noncoding RNAs in different tissues and regulates the expression of fibroblast growth factor-
2 (Li and Murphy, 2000), xi) SCA8, within which an expansion of a CTG trinucleotide repeat 
causes neurodegenerative disorder spinocerebellar ataxia type 8 (Nemes, 2000), xii) DISC2, a 
single-exon noncoding structural RNA gene involved in the molecular etiology of 
schizophrenia (Millar et al., 2000), xiii) brain-specific dendritic BC200, expressed specifically 
in neuronal cells (Kuryshev et al., 2001), xiv) Bic, which is strongly upregulated in come B-
cell lymphomas (Tam, 2001), xv) the Y-chromosome-specific TTY2 family, expressed 
specifically in human testis and kidney (Makrinou et al., 2001) and xvi) ncR-uPAR, which 
regulates human protease-activated receptor-1 gene during embryogenesis (Madamanchi, 
2002). In addition, Scherer and colleagues (2003) showed that one of the loci associated with 
autism encodes a large ncRNA. There are also many ncRNAs documented at imprinted loci in 
animals (Charlier et al., 2001).  
Over the past few years, RIKEN in Tokyo have taken a systematic approach to 
determining the mouse transcriptome by constructing the normalized cDNAs libraries from 
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different tissues. In total, 60.770 full-length cDNAs were sequenced and after computational 
analysis of the nucleotide sequences clustered into 33.409 transcription units. Of these, over 
11.000 did not contain more than 100 coding nucleotide triplets. Since these transcripts do not 
code for a substantial open reading frame it was suggested that they belong to the group of 
ncRNAs, thus indicating that non-coding RNA is a major component of the transcriptome 
(Okazaki et al., 2002). A large number of all transcriptional units are represented by more 
than one independent clone and many have been shown to be differentially expressed in 
different tissues, and thus represent real transcripts. Whole-transcriptome analysis also 
showed that 42 % of the transcripts are spliced. In addition, over 2.400 pairs of overlapping 
sense-antisense transcripts were identified (Okazaki et al., 2002). 
 
 
6.3.1 Non-coding RNA genes 
 
The central dogma of molecular biology is that genetic information flows from DNA 
to RNA to proteins (DNA>RNA>protein). Usual interpretation of this statement is that 
genetic information flows from DNA to proteins via mRNA, which means that genes are 
generally synonymous with proteins and that genetic output is entirely or almost entirely 
transacted by proteins (Mattick, 2004). This statement is actually valid for the prokaryotes, 
whose genomes are almost entirely composed of closely packed protein-coding sequences 
with associated 5’ and/or 3’ cis-regulatory sequences. However, it has recently been found 
that prokaryotes do in fact contain a number of non-protein coding RNA genes, apart from 
those encoding rRNAs and tRNAs and these may number 200 or more in Escherichia coli, but 
account for no more than about 0.5% of the total number of genes and about 0.2% of the 
transcriptional output (Argaman et al., 2001). It is supposed that the same assumption is true 
for the multicellular organisms, although the proportion of protein-coding sequences is only a 
small minority of the genomic programming of complex organisms such as mammals (Fig. 
47).  
More recently, it became obvious that the hypothesis that most genetic information is 
expressed as proteins may be incorrect, at least in the higher organisms, which led to the re-
definition of a gene as a ‘‘transcription unit’’ (Okazaki et al., 2002) or ‘‘a complete 
chromosomal segment responsible for making a functional product’’ (Snyder and Gerstein, 
2003). It has been assumed that a very large proportion of the genome is in fact expressed, 
although protein-coding sequences constitute only about 1.6 % of the human genome (Wong 
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et al., 2001). It is estimated that approximately 97–98% of the transcriptional output of the 
human genome is non-protein-coding RNA (Mattick, 2001), based upon the fact that intronic 
RNA constitutes 95% of primary protein-coding transcripts (pre-mRNAs) (Lander et al., 
2001; Venter et al., 2001) and on the observations which suggest that there is large number of 
ncRNA transcripts that do not contain substantial open reading frames, which may represent 
at least half of all transcripts. For example, detailed analysis of the regions such as β-globin 
cluster and various imprinted loci in mammals show that almost all of these regions are 
transcribed, mostly into ncRNAs (Ashe et al., 1997). Moreover, analysis of the whole 
chromosomes 21 and 22 using oligonucleotide arrays showed that the level of transcription is 
an order of magnitude higher than accounted for by the characterized and predicted exons 
(Kapranov et al., 2002). However, what fraction of the expressed RNAs serves some 
biological purpose is greatly unknown.  
It is predicted that non-coding RNAs might function in the control of molecular 
genetic activity at various levels, which could occur via a variety of RNA–DNA, RNA–RNA 
and RNA–protein interactions (Mattick, 2003). 
There are huge variations in estimates of the number of genes encoded by the human 
genome. An initial estimate of the number of protein-coding genes in the human genome was 
30–40.000, on the basis of genome sequence analysis (Lander et al., 2001; Venter et al., 
2001). In addition, Zhuo and colleagues (2001) suggested that the number of genes or 
transcription units in mammals ranged from 60.000 to 100.000, on the basis of cDNA cluster 
analysis. They also proposed that many, if not most of the genes do not code for protein, but 
rather function directly as structural, catalytic or regulatory RNAs. These estimations are 
based on cDNA cloning and EST sequencing of polyadenylated mRNAs, identification of 
conserved coding exons by comparative genome analysis and computational gene predictions. 
These three methods work well for large and highly expressed protein-coding genes which are 
evolutionary conserved, but they significantly underestimate the number of other genes 
(Eddy, 2001).  
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Figure 47. The ratio of non-coding to protein-coding DNA rises as a function of 
developmental complexity. Prokaryotes have less than 25% non-coding DNA, simple 
eukaryotes have between 25 and 50% non-coding DNA and more complex fungi, plants and 
animals have more than 50%, rising to approximately 98.5% non-coding DNA in humans — 
which also have a genome size that is three orders of magnitude larger than prokaryotes. The 
different colours represent prokaryotes (bacteria and archaea) (blue), simple eucharyotes 
(black), Neurospora crassa (grey), plants (green), non-chordate invertebrates (nematodes, 
insects) (purple), Ciona intestinalis (urochordate) (yellow) and vertebrates (red). ncDNA, 
non-coding DNA; tgDNA, total genomic DNA. Figure taken from Ref. Mattick, 2004. 
 
 
It has been proposed that the actual number of ncRNA genes in mammals is probably 
in the order of tens of thousands (Mattick, 2003). The majority of these genes remain to be 
identified, considering the fact that RNA may be fairly unstable and that most biochemical 
analyses of cell fractions are not designed to detect ncRNAs. It should also be taken into 
account that the protocols for analysing the functions of ncRNAs are not well established so 
far. Non-coding RNAs have begun recently to be studied in systematic ways and it has been 
found that they have been regulated, i.e. expressed in a gender-, tissue- or cell-specific 
manner (Mattick, 2003). In addition, many ncRNAs are expressed at low levels in the cell 
(Kapranov et al., 2002; Okazaki et al., 2002). 
Considering the fact that many transcripts are initiated from alternate promoters with 
alternate splicing and polyadenylation signals, the definition of a gene may need to be 
expanded to include a transcription cluster (defined as a separate locus producing one or more 
related transcripts from the same DNA strand, together with associated cis-acting regulatory 
elements) which may encode one or more related protein products (encoded by alternatively 
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spliced isoforms) and/or one or more different ncRNAs (such as transcripts that specify micro 
RNAs - miRNAs) (Lau et al., 2001) or small nucleolar RNAs (snoRNAs) (Cavaille et al., 
2000; 2002) together with proteins encoded by the exonic sequences (Fig. 48). Even this 
definition is inadequate if we take in account that different mRNAs may be produced by 
trans-splicing between different primary transcripts (Pirrotta, 2002, Fire, 1999) and that 
overlapping transcripts may encode different products or a different repertoire of products 
with different functional consequences (Snyder and Gerstein, 2003). It is also worth noting 
that an overlapping antisense transcript may be involved in the cis-regulation of its sense pair 
and therefore may need to be considered part of the same ‘‘gene’’. The term ‘‘gene’’ is at best 
a concept to describe a sequence of genetic information, expressed either as RNA (per se) and 
/ or protein (via mRNA), that has functional consequences (Mattick, 2003).  
 
 
 
 
 
 
Figure 48. Modified view of the flow of genetic information in the higher eukaryotes. 
Primary transcripts may be (alternatively) spliced and further processed to produce a range of 
protein isoforms and/or ncRNAs of various types, which are involved in complex networks of 
structural, functional and regulatory interactions (figure taken from Ref. Mattick, 2003). 
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The RNA regulatory system might have been the essential prerequisite to both the 
evolution of multicellular organisms and the rapid expansion of phenotypic complexity into 
environments (Mattick, 1994; Mattick, 2001). This also suggests that the principal source of 
the evolutionary diversity of complex organisms is the regulatory architecture, which is 
primarily encoded in non-coding RNA genes and introns, and therefore also indicates that 
most of their genomes are dedicated to developmental programming and are under selective 
influences (Mattick, 2004).   
RNA genes are immune to frameshift or nonsense mutations (Eddy, 2001). These are 
usually small and multicopy genes, which makes them difficult or even impossible targets for 
recessive mutational screens. Ridanpaa and colleagues (2001) provided an excellent example 
for human genetics. Cartilage-hair hypoplasia (CHH), a short-limbed dwarfism, was first 
described by Victor McKusick, almost 30 years ago (McKusick et al., 1965). Positional 
cloning failed to identify the gene linked to this disease, despite accurate genetic mapping. 
Ridanpaa et al. (2001) afterwards increased the resolution of the genetic map by almost an 
order of magnitude and sequenced the entire genomic region. Ten protein-coding genes, 
which were selected as potential candidate genes, were studied in further, but without success. 
Finally, CHH-associated mutations were discovered in the 267-nucleotide RMRP ncRNA 
gene, which produces the essential RNA component of the ribonucleoprotein 
endoribonuclease MRP (mitochondrial RNA processing). Interestingly, the only reason why 
RMRP was considered as a candidate gene was that its RNA has previously been isolated and 
its sequence was deposited in GenBank. Another example of human genetic disorder which 
has been mapped to a nuclear-encoded ncRNA candidate gene by positional cloning is 
autosomal-dominant dyskeratosis congenital. Here again, telomerase RNA was considered as 
candidate gene because its sequence was already deposited in the GenBank database. 
Mutations in telomerase RNA have been found in patients with dyskeratosis congenital 
(Vulliamy et al., 2001). Moreover, this gene was an obvious candidate, since an X-linked 
form of dyskeratosis had already been associated with nucleolar protein dyskerin which is 
known to interact with telomerase RNA. Several other ncRNAs have also links to human 
disease. For example, B-cell neoplasia-associated gene with multiple splicing (BCMS) is 
candidate for the tumor suppressor gene in the leukemogenesis of B-cell lymphoma (Wolf et 
al., 2001), expression of MALAT-1 is associated with early-stage non-small cell lung cancer 
(Ji et al., 2003), overexpression of DD3 gene is identified in prostate cancer (Bussemakers et 
al., 1999), translocation within DGCR5 gene is associated with DiGeorge syndrome 
(Sutherland et al, 1996).  
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The regulatory regions of higher organisms are generally much less conserved than 
protein-coding regions and it has been shown that the majority of human genomic 
polymorphisms occur outside of protein-coding regions (Venter et al., 2000). However, 
mutations or polymorphisms in promoters or other non-coding sequences that have strong 
effects on phenotype are very rare. This may be for the simple reason that, while a single base 
change can have fatal effects on the structure and function of a protein component which is 
critical for the protein function and it may only have subtle effects on cis- and trans-
interactions in regulatory networks (Albert et al., 2000). Sequence differences in this 
controlled architecture probably include a large proportion of the genetic contributions to 
susceptibility to complex diseases (Mattick, 2003).  
 
 
6.4 Cloning and characterization of L40 gene 
 
The L40 gene potentially encodes a protein of 111 amino acid residues. Interestingly, 
the L40 gene locus is overlapping with ZPBP in the same orientation. It was determined that 
the deduced 351-amino acid ZPBP protein has no N-terminal signal peptide (Katoh and Katoh 
2003), but contains an N-terminal transmembrane domain and a long extracellular domain of 
almost 300 amino acids, to which L40 gene overlaps. However, both genes have different 
promoter regions, which suggest that regulation of their expression is not related and that two 
genes have distinct tissue-specific elements required for the restricted expression. Expression 
analysis of L40 and ZPBP revealed that the L40 gene is exclusively expressed in human retina 
while the expression of ZPBP is testis-specific. Previous studies in the ZPBP gene showed 
that it is one of several proteins that are thought to participate in secondary binding between 
acrosome-reacted sperm and the egg-specific extracellular matrix, the zona pellucida 
(McLeskey et al., 1998).  
The gamete interaction, mediated by the molecules specific for the mammalian sperm 
and egg, is crucial for the process of fertilization. The first interaction between sperm and egg 
occurs at the extracellular matrix which is surrounding ovulated eggs, known as zona 
pellucida. The zona pellucida is composed of three separate glycoproteins, zona pellucida 
glycoprotein 1 (ZP1), zona pellucida glycoprotein 2 (ZP2), and zona pellucida glycoprotein 3 
(ZP3), which have different roles in gamete recognition (Brewis and Wong, 1999). 
Galactosyltransferase, sp56, zona receptor kinase and spermadhesins are proposed to interact 
with the zona pellucida proteins and are thought to participate in the exocytotic acrosome 
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reaction, which represents the primary binding between sperm and zona pellucida (Brewis and 
Wong, 1999). Digestion of the zona pellucida by these enzymes enables sperm to cross it, and 
at this time the proteins PH20, proacrosin, ZPBP, and Sp17 are thought to participate in 
secondary binding between the acrosome-reacted sperm and zona pellucida (McLeskey et al., 
1998). Once the sperm passes through the zona pellucida, its plasma membrane is fused with 
egg plasma membrane in a process known to involve the egg integrin alpha 6 beta 1 and the 
sperm proteins DE and fertilin.  
The unusual genomic structure of the ZPBP and the L40 gene and overlap between 
their coding regions indicated a possible link between their function in testis and retina, 
respectively, thus suggesting that L40 gene could be involved in interaction between retina 
cells. 
 
 
6.4.1 Overlapping Genes 
 
Veeramachaneni and colleagues identified over 774 gene pairs sharing a common 
locus in the human genome and 542 in the mouse genome. Although it was expected that 
evolutionary conservation of overlapping regions would be under stronger selection against 
mutations which would cause changes in both genes, reported identity between overlapping 
human and mouse orthologs was not higher than average. Information about identified human 
and mouse overlapping genes are stored in Overlapping Genes Database 
(http://posnania.cbio.psu.edu/research/overlapping_genes.html). The database facilitates the 
search for known overlapping genes by name, accession number, or LocusLink ID. A second 
form allows users to browse the set of overlaps by overlap type (coding-coding, 3’-UTR-
coding, etc). 
Overlapping genes occur frequently in viral and cellular prokaryotic genomes as well 
as in organelles such as mitochondria (Normark et al. 1983), but it was believed that they 
occur less frequently in eukaryotic genomes. Although their presence in human and genomes 
of other species was reported previously (Williams and Fried 1986; Lazar et al. 1989; 
Miyajima et al. 1989; Cooper et al. 1998; Bachman et al. 1999; Shintani et al. 1999; Misener 
and Walker 2000; Morelli et al. 2000; Slavov et al. 2000), until lately very little was known 
about their frequency and genome-wide distribution. Recent reports show that overlapping 
genes do indeed occur relatively frequently in human and other mammalian genomes 
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(Okazaki et al. 2002). Nevertheless, there is still little known about the origin, evolution, or 
cross-species conservation of overlapping genes.  
 
 
6.5 SNP analysis in candidate genes – search for AMD susceptibility genes 
 
Haplotype analysis to investigate associations between disease loci and multiple 
markers could be a valuable tool for the use of SNPs in complex disease such as AMD. In this 
study L33, L35 and L38 genes were selected for the analysis of single nucleotide 
polymorphisms (SNPs) since they are candidates for the retina disease genes concerning their 
retina specific expression. In the present study, the regions selected for the SNP identification 
were within the coding region and exon-intron boundaries of the gene, as well as 5 kb 
upstream and downstream of the 5´ and 3´ UTRs, respectively. Sequencing of 13 Kb long 
region of L33 gene resulted in identification of 25 novel SNPs, of which 7 are of high 
frequency and were identified in 5’ and 3’ UTR and intronic regions (Table 16). The same 
analysis of 13 Kb long genomic region of L35 gene resulted in identification 13 novel SNPs, 
of which 10 are of high frequency (Table 17). Identified SNPs are in UTR and intronic region 
of the gene as well as in exon regions. Sequencing of 25 Kb long region of L38 gene resulted 
in identification of 12 novel SNPs, of which only two are of high frequency and were 
identified in 3’ UTR of the gene (Table 18). It has been suggested that, for identification of 
complex disease loci, SNPs in coding regions may be more useful than those in noncoding 
regions. However, our preliminary analysis showed that there is no clear advantage to SNPs 
in exons rather than in introns.  
The process of performing an association study involves simply determining the 
frequency of a test factor (e.g. an SNP allele) in many patients and age and race matched 
controls (Brookes, 1999). Therefore, in order to determine if the SNPs identified in this study 
are related to the disease, comparison of allele frequencies between patients with AMD 
phenotype and healthy controls is required. If the SNP contributes an increased risk for 
disease occurrence, then its frequency should be found at higher level in individuals with 
disease compared to controls without disease (Brookes, 1999).  
Among the best genetic examples of an association between a genetic marker and a 
complex disorder is that of Alzheimer’s disease, in which the e4 allele of the apolipoprotein E 
gene (APOE) has been strongly correlated with the risk of this disease (Strittmatter and Roses, 
1995). Possession of the e4 allele of apolipoprotein E is neither necessary nor sufficient to 
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cause Alzheimer’s disease, but it represents a single, well defined and substantiated common 
genetic risk factor identified by positional approaches and association studies. Another 
example would be non-insulin-dependent diabetes mellitus (NIDDM) in which at least 16 
common SNPs have been associated with this disorder. The strongest association validated in 
confirmation studies has been reported between a variant of the peroxisome proliferator-
activated receptor-γ gene (PPARG) and diabetes mellitus (Altshuler, 2000). One more 
example would be identification of the polymorphism in the beta 2 adrenergic receptor which 
is associated with the blood pressure level (Bray et al., 2000).  
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Abbreviations  
  
A adenine 
aa amino acid 
acc.no accession number 
AMD Age-Related Macula Degeneration 
Amp Ampicilin 
bp base pair 
BLAST Basic Local Aligmnent Search 
BLAT Basic Local Aligmnent Tool 
BSA Bovine Serum Albumine 
C cytosine 
°C degrees Celsius 
cDNA complementary DNA 
ddH2O double destiled water 
DEPC Diethylpyrocarbonate 
DHPLC Denaturing High Presure Lliquid Chromathography 
DMSO Dimethyl Sulfoxide  
DNA deoxyribonucleic acid 
dNTP deoxyribonucleosid triphosphate 
ds double stranded 
DTT Dithiothreitol 
E.coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
EST Expressed Sequence Tag 
EtBr Ethidium bromide 
ex exon 
FCS Fetal Calf Serum 
g gram 
G guanine 
GUSB β-Glucuronidase 
Hs. Homo sapiens 
hrs hours 
htgs unfinished high-throughput sequences 
IPTG  Isopropyl-beta-D-thiogalactopyranoside 
IVS Intervening Sequences  
LTR long terminal repeat 
M molar 
MaLR mammalian apparent LTR 
Mb Mega base pair 
min minutes 
M.musculus Mus musculus 
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MOPS Morpholinopropanesulfonic acid 
MW Molecular Weight  
NCBI National Center for Biotechnology Information  
NMD Nonsense-Mediated mRNA Decay 
nt nucleotide 
ORF Open Reading Frame 
PBS Phosphate-buffered saline  
PCI Phenol Chlorophorm Isoamyl alcohol  
PCR Polymerase Chain Reaction  
PAA Polyacrylamid 
pfu plaque forming units 
qRT-PCR quantitative PCR 
RNA ribonucleic acid 
Rnase ribonuclease  
R.norvegicus Rattus norvegicus 
RT room temperature 
RT-PCR reverse transcriptase PCR  
RPE Retinal Pigment Epithelium  
SDS Sodium dodecyl sulphate  
sec seconds 
ss single stranded 
SNP Single Nucleotide Polymorphism  
S.scrofa Sus scrofa 
T Thymine 
Ta annealing temperature 
TEMED N,N,N',N'-Tetramethylethylenediamine 
Tm melting temperature 
TM   transmembrane 
UTR untranslated region  
U units 
V volt 
VN virtual Northern blot 
vol volumes 
v/v volume per volume 
w/v volume per weight 
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Table 19. General primers  
   
Gene / Plasmid Primer  Sequence 
   
GUSB GUS B3 ACTATCGCCATCAACAACACACTGACC 
GUSB GUS B5 GTGACGGTGATGTCATCGAT 
GUSB GUS B6 GATCCACCTCTGATGTTCAC 
GUSB GUS B7 CCTTTAGTGTTCCCTGCTAG 
G3PDH G3PDH F ATCGTGGAAGGACTCATGACC 
G3PDH G3PDH R AGCGCCAGTAGAGGCAGGGAT 
λTriplEx2  M13F CGCCAGGGTTTTCCCAGTCACGAC 
λTriplEx2  M13R AGCGGATAACAATTTCACACAGGA 
pmalcxh pmal E GGTCGTCAGACTGTCGATGAAGCC 
pGEX pGEX F GGGCTGGCAAGCCACGTTTGGTG 
pGEX pGEX R CCGGGAGCTGCATGTGTCAGAGG 
All mRNAs 3’-RACE AP GGCCACGCGTCGACTAGTACD(T)25(A,G,C) 
 
 
 
 
Table 20. RT-PCR primers   
Primer Sequence Primer Sequence 
    
L01F TGGAAGATTTGGACCGTTAG L09R  TCTGTCATTTGTAGTGGCTG  
L01R GGTGGCGGTAACATAGGAG L10F TTCCTTCCCTTCAGGTACTG  
L02F AATGAGCGTGTAGAAGAAAG L10R TCCACATTGATATAGGCCAC  
L02F1 GAGCTCCTGCTCTACCTTG L11F CAATGCCTAAGAGACCAGAC  
L02R ATCTTTATGTGCTTCCAATG L11F1 GAGGAGACGGAGCAAATGA 
L02R1 CATCTTCATCAACTGCTCCA L11R TAAGAGCCAGTGAAAGGGTC  
L03F AGACTCAACTCCTCAGCAAC L12F TGTTTGGGATGTTGCTTTA 
L03F1 CCTGCCTGCTATTGGTCAC L12R TATTTATGGTCGCTTTTGTC 
L03R TGAACTCTGGGTCTTTGTAG L13F  TGTTTGGGATGTTGCTTTA 
L04F ACAAGAAACTGAAAAACTCG L13R  TATTTATGGTCGCTTTTGTC 
L04R GGGACCATTCTTCTTTGAG  L14F TGCTGTTTGTAAGGCTGGAG  
L05F GGTTCAGAATTTTCACAGCT  L14R AGCGAATATGGTAGAAGGGA 
L05F1 AGATAGTGCCTTTCAGCCCT  L14F2 CCTTTGAGTTGGTCCTTGAA 
L05F2 CCTCAGCAGATGGTATTGGA  L14R TCTCTTTGATGACACGGCTC  
L05F3 GAGCACTTCATCAGGTTCA L14R1 TCCATCTCTCCATCTTCTGC 
L05R CTGGTGTTTGTGTCCTATTC  L15F GTGATGCTCTGCTTGATAAG  
L05R1 TGACTGAACTGGGAACACTG L15R  TAGAACAGGAATGACTTTGC  
L05R2 TCCAATACCATCTGCTGAGG  L16F TGAGGAAGAGGAAGCAGAAC 
L05R3 CAAAAGTCTCAGTTCCTGTGT L16F1 TGATCAGCGGTCAGCAACTCC 
L06F CAGTTTGAGGAGCGACAGC L16F2 GCGTTTTGTGGTAATGGA 
L06R GCCTCAGTGTATTGGTCGG L16R CTGAACCTATCCATCCCAC  
L07F CACTTCATCCTAAACACAGC  L16R1 CAGTATGGATTAAAACCATTG 
L07R GCTGAATGACTGGAAATGT  L16R2 ATGTGGCGGTAACCTTGTTG 
L08F TATGGTGCCGAGTGGTAAC  L17F GATAGAAGAATAGGGGCAAG 
L08R TACTGCTATGGTCACGGTTC  L17F1 CTTCACCTTCCACTTCAGAC 
L09F AGTCTATGTTCAGTTGTGGC  L17R GAATGGACAACACAAATAGG 
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Primer Sequence Primer Sequence 
    
L18F GTAGAAGAGTTGAAGGCTGC L34F1 TAAGAGAGCAAGGAAGTGTC 
L18R CATACAAGGAGGAAGACTGG L34R AGAATGAAGAGGTTGAGTCC  
L19F GGAGCACTTGGGTTTAGAG L34R1 AGTTCTCCAAGTCTCACCAG 
L19R CCCTCAACACTCTTCACAG L35F ACCTTTGCCTTCTCTTGCTC  
L20F CTGATGGAAACCGCTGAAG  L35F1 CTGGCTTCGGATAGTGTTTG  
L20R CTTCAATGGCTTCCTCTGC  L35R CAAACACTATCCGAAGCCAG  
L21F TTTACTTGCTGTGGTTGTGG  L35R1 CAGTCATTACCCCATTCTCC  
L21F1 CATTCACTGTCTCTGTTGGT L36F TTAGCACATACATCCACTTG  
L21F3 AAGTTACTGAAAAGGAGGTAGAAA L36F2 CAAGCTGCTTTGGTTCTGGA 
L21R TCTGAGGCATAGCAAAACAC  L36R GTTTGGAGATTACTGGATTG  
L21R1 GTGAGAGCCTTTATTCCTGG L37F AACTGGCTACTCTTTCAACG  
L21R2 ATGCAGTAACCTCAGGCTTC L37R CTTCATCCTCATTGTCTTCG  
L21R3 CCCAAAAGAAATGAGAAGCCAA L38F TCCACAACGATGCTTTCTA  
L22F TTCTTGTAGTGTCTGCTTGC  L38R AACAAACCTTCACACAAATC  
L22R AGCCTTATGTCCTTATTCAG  L38R1 AATGAGCAGTGATCTGATCC  
L23F AGTTCTCCTGATGTTGTTCC  L39F TAACACCCCAGCCATTGATT  
L23R GCCCACACATCATAAGGTAC  L39F2 AAGAAAAGGAGATTAGGGTACAG 
L24F TACAGTCCTCCTTTGCTTGG  L39F3 TGTCATGCTAGGAAAGTCGAAC 
L24F1 GTTGTGGGTGACTCTTTTGG L39F4 CAAGGTAGGTGGGAGAAGGTG 
L24R CTGTGCTTTCGTAGGGTTTC  L39R CAGGAGGAGCACAAGCAAG  
L24R1 GTGAGGTCTGTTCCAATAGC L39R2 GGAAGTTTATTAGGAAGAATTGG 
L25F GAAAAGACCCAGAAGGATG  L39R3 CAATACAAGATCCGCATAGCAG 
L25F1 AGAAGAGCTGAATGAAGTTG  L40F AAGAACAAAAAAGAGGATGC  
L25F2 GGTTGTCCTGGAGCAGGG  L40F1 CAGGATATGGAATGAATGTC 
L25F3 AGTGTGAGGGAGAGAACCAG  L40F2 CACATGAAAGGTCAAGAAGC 
L25R AGCCATCTAACAGGTCATC  L40F3 TAATTGTTCTGCACGTCTGC 
L25R1 TTCAATGCCCAAGTCAGTG  L40R TCCACTATGATGTTGAAAGG  
L25R2 GTCTCCGACGGTTGTTTAAC  L40R1 ATCTCACCAAGCTAAGAACA 
L25R4-Mus CTGGAGTACAATGCATCAGG L40R2 AAGGCAGCCACTACAGCTAG  
L25R5-Mus CTGGAGTACAATGCATCAGG L40R3 CCATCCTCCTCTTTATCTCC 
L26F GATTCCAGCCCAACAAACC  L40R4 GCTTCTTGACCTTTCATGTG  
L26R CGGATACCCTTGAGACAGC  L41F CAGGCAATGTCTTCAGCAG  
L27F CAGGCAAGAAGGTGTTAGTG  L41R ACCTCAAATGCCAATACCAG  
L27R  GGTCTGGAATGAATGGAAAG  L42F GTCTACTGGCACAAACCTTC  
L28F GCCCTACAGAATGAATACAC L42R TCCTTGTATCGTCATTCCAG  
L28R TATCATTCACAAGTTTCCCA  L43F AGATAACAAAGGAGCGAGAG  
L29F AGAAAGAGATACAGAATGCC  L43R CCACCTGTTCACTAATGTCC  
L29R TAATCTTTTTGGCTTTGGTG  L44F ATTATGAGAGCCAAAGGAGC  
L30F CTGTTTGTCACCCTTCTTGC  L44R ATCCCAGAGAAAGTGTTGAG  
L30F1 GGCTGCTACCATTAAACAAC L45F GAGGCTGCTGAATAATGTAG  
L30F2 TGGCTATGAAGATGCTGGAGA L45R ACTGGATGCCCTGAATGAC  
L30R1 ACTGGGTTGTAAAGGCATCAT L46F GACCTCACAGACATCGTTTC  
L30R CAGTGAGAAGTGCCATAAGC  L46R CTATGGGTGTGGTGAGTAAC  
L31F TCTGACACCAAATGAGGACC  L47F CAACTTCAGAGACAACCCAC  
L31R GCTCCATTTCTGCTTCCAAC  L47R CCGTATTTATGGAGATTGGT  
L32F GTGATCCAGAAAGTTGATGG  L48F CCATGAAGAAGATGACATTG  
L32R CATTACCAAGACAACCCCTC  L48R AGACAGGATCTCTGTGCTAG  
L33F CTTCCACTTCTTCCATCTGC  L49F TCAGTTCTATGTTCCAGCAG  
L33F1 CCAGGAAAGAAGGGCACAT  L49R TAAGAAGCCAACAACTCCAG  
L33R TGCTGGTTTCACAATACTGC L50F GAGATGAAGGTGAAGGTGTC  
L33R1 TTCTTGTGTCTTCATGTGCC L50R CATAGAAAGGTGAAGTGCTG  
L34F GTCTCCATTTCCATTCACAG  L50R1 GGCCATAGGCAATGAGGGCTC 
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L51F GCTCCCAATGGAGACTTTTG  L74F AAACTTGGCTTGATTGCTTC  
L51R ACAGTGATGGCTTCCTTCTC  L74R AAATACCCAGGCACTTCATC  
L52F CCACTTTGATGTTGCGGAG  L75F TGGAGGACTATTCACAGGAG  
L52R AGAAGCCCAAGAGTCCCTG  L75R TATCCTCTTTCCAACGGGTG  
L52R1 TTCCTCGTCTGTAATGGTGCC L76F TAGAAGGCACAGAGAGAATG  
L53F AAAGTAGGACACGGTTGAGG  L76R CTTGTCTGGGATGGAAACTC  
L53R CCTCCAACACACATACCAC  L77F ATGTTGAAAATACTCCCTGC  
L54F TTATCTGTCCTCCAAAGTGA  L77R CTTGATTGAGAGCTTATTGC  
L54R TGATTGTCGTTGCTGCTTTC  L78F TAAGCTCCCTAACTGCCTTC  
L55F GCCTCTTTCATCTTCCCATC  L78F2 CACCAGGCAGTACTTTGACAC 
L55R GAAGACGGAATCACAGGGAG  L78R AGAAACATCATCCAGGGTCG  
L56F GATTCTTCACAGGCTCAGG  L79F TGGGAGTATCTGGCTTTAGG  
L56R ACCTGGCTAACTCATCCTTC  L79R AGGAAGAGAGCAACAGAAGG  
L56F1 CATGGACGGACATCAAGCCTG L80F AATACCTGCCTGGAGAATGG  
L57F CGTTGATAGGGAGTTTGCTG L80R GGGTCATCAGGGAGAATAC  
L57R GGTTATCCCCAATGTCTTCC  L81F ACAACAAGTCCACAACCTGC  
L58F TAGCAAGAGCCCAACAATCC  L81R AGTGAGGGAGAACAAAGAGC  
L58R CTGATGTTGACTTGGCTGC  L82F TGGAAGATAGATGATAAGCC  
L59F GGACGACAATAATGAGAACG  L82R TAATCCCAAATCAAAGCCAC  
L59F2 GTCTGGCATTGTTGGCTTGTG L83F TTGGAGGGCAAGTACACAGA  
L59R CCAGAGGACCAAGAAATACC  L83R CATCTCTTGTTCCTTGGTTG  
L59R2 GTGCTCAGGACCCGGAAGAAT L84F AGTCTGGGAGTCTTTGGAGT  
L59R3 ACAAGCCAACAATGCCAGACC L84R ACTTTCTTCCTCCTCATTCC  
L60F CACCTGGAAACTGGACTGAT  L85F CCTGGAAGTGAAGTTGTTAC 
L60R ATCCAACAGCATTTCATCTC  L85R CCTTGAGTGCCTGGTGTAG  
L61F GGTAACAGAGGAACAAAGGC  L86F GTTCAGAGCGAAGGAGGAG  
L61R AATCATCCCTCTTTACAACG  L86F2 CTTTTGCCTCACCCACTCCAG 
L62F GTATCACATCAACTCCGTCC  L86R GCTCCAGTCTCCTATCATCC  
L62R TCCTGCTCTGGTTCCTTAC  L86R2 GGCCAGGTGCGGTGGTTCATG 
L63F CCAGAAGCTCCAACATTGTC  L87F GCAACAAGTGGGATTATGTG  
L63R CTAACAAGACAATGAGGCAG  L87R ATCAGCACCAAGTAGAAATG  
L64F ACAGGAAAGTCACAGCAAAG  L88F TATACCACTGGCACAACAAC  
L64R AAGACTCACAAATGCCTCAG  L88F2 AGACAGTTGGGAGCATCAGCA 
L65F AAGTAGAAGTCGCTCAAGGG  L88R ATGATGATGTCCCAACTCCT  
L65R GACTTAGACTTGTGTTTGCG  L88R2 TCATACCGTCTGCTGCCTGCT 
L66F AAACTCCTGCTTATCTCTGC  L89F GCTTCACCTACACCTTCCAT  
L66R CAGGCTCTCAAGTTTCAATG  L89R TCGGAACAACACTCAATGCA  
L67F ATGACTTGTGGGGAGACTTC  L90F GCTAGTTTTCGTCGCTTTGG  
L67R TCACAAAGAGGCACACAAGG  L90R TGGCTTATCCTTGATAGTGG  
L68F CTAAAGAGCCTGATGGGGAC  L91F TCTTGCCAGTAGTCTCAGTC  
L68R CCAGTAGCATCAGAAAGAGC  L91R ATCATCTTCATCCAGTTCAC  
L69F AGACAGAAGCCAATCACATC  L92F2 CAGGAGCGCTGAACCCAGAAC 
L69R GTGCTTCTGGTTGTCTGATG  L92R2 GGTGTGGGTGGAAGTGGGAGA 
L70F GCTGAAACCTGGCTTATCTC  L92F/L53F1 GCTTACTGAGGACTTCTTTC  
L70R AGGAAAAGAGACACCCAATG  L92R/L53R1 TGTTCTCCCTTTCTGTCCTG  
L71F GAAGAACAGAACAGTGAAGC  L93F2 CACTGGAGAAGCTCAAC 
L71R CATTCATTTCACAGCAACAC  L93R2 CGAGGCTGCTGAATAATGTAG 
L72F TCCGTGGTGATGAAGAGTTG  L93F/L45R TGAATGACGCACTGGAGAAG  
L72R TCCCAGGTTCTCACTCTTTC  L93R/L45F1 ATTTACCAAGCAAGTGCAGC  
L73F ACCAGAAGACCAGGATGATG  L94F CTCCAGAAATAAAGCAGGTG  
L73R GGAGCAAGAGAACAAGAGAC  L94R ACACAGGATGACAGCAGAAG  
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Table 21. Primer sequences of clone inserts for L25 gene 
 
Primer  Sequence Purpose Enzyme Cloning vector
     
L25SV2-EcoRI-F1  ATCGGAATTCCGGCTTCAGTGGACCAAATTT 
GST/ MBP-L25SV2 
fusion proteins EcoRI 
pGEX-4T-3 /  
pMal-cxh 
L25SV2-XhoI-R1 CGATCTCGAGTGAAGCAACTCAGTAAGATG  
GST/ MBP-L25SV2  
fusion proteins XhoI 
pGEX-4T-3 /  
pMal-cxh 
 
L25SV3-EcoRI-F 
 
ATCGGAATTCCCCTTCCTTTGGAGACTGCTC 
GST/ MBP-L25SV2  
fusion proteins EcoRI 
pGEX-4T-3 /  
pMal-cxh 
 
L25SV3-XhoI-R1 
 
CGATCTCGAGATGTGGAACTGAGTCACAG 
GST/ MBP-L25SV2  
fusion proteins XhoI 
pGEX-4T-3 /  
pMal-cxh 
 
L25-SV2-NotIF 
 
GCGGCCGCATGAAGGATATCGACATAGG 
Protein taged  
with 1D4 NotI pCEP4 
 
L25-SV2-NotIR 
 
GCGGCCGCTTTCTGACCGCAGAATACAGC 
Protein taged  
with 1D4 NotI pCEP4 
 
L25-SV3-NotIR 
 
GCGGCCGCTCGTGAAGCAACTCAGTAAGA 
Protein taged  
with 1D4 NotI pCEP4 
 
 
 
 
 
Table 22. Primers used for quantitative Real-Time PCR 
 
 
Gene  
 
Primers 
 
Sequence 
 
Fragment 
size 
 
MgCl2 
 
Ta 
 
Plate  
read 
 
ABCC5_SV2 
 
 
 
L25qPCRF1 
L25qPCRR1 
 
5’-CAAGAAGAGCTGAATGAAGT-3’ 
5’-ACAGCACCAAGCAAGTGGTC-3’   
 
147 bp 
 
 
2 mM 
 
64°C 
 
87°C 
 
ABCC5_SV3 
 
 
 
L25qPCRF2 
L25qPCRR2 
 
5’-GGCAAGAAGAGCTGAATGAAGT-3’ 
5’-CAGCCATCCTGAAAATTTGGT-3’   
 
151 bp 
 
 
2 mM 
 
64°C 
 
87°C 
 
ABCC5_SV4 
 
 
L25qPCRF2 
L25qPCRR3 
 
 
5’-GGCAAGAAGAGCTGAATGAAGT-3’ 
5’-CAGTCTCCAAAGGAAGGTGGT-3’ 
 
 
151 bp 
 
 
2 mM 
 
64°C 
 
72°C, 
87°C 
 
ABCC5 
 
 
ABCC5qPCRF4 
ABCC5qPCRR7 
 
 
5’-TGGCTTCAGTGGACCAGCCT-3’ 
5’-AGACCGCACGATTTCCGTCA-3’ 
 
 
124 bp 
 
 
2 mM 
 
66°C 
 
86°C 
 
B2M 
 
B2M F 
B2M R 
 
 
5’-TAAGCAGCATCATGGAGGTTT-3’ 
5’-AGCAAGCAAGCAGAATTTGGA-3’ 
 
70 bp 
 
2 mM 
 
66°C 
 
72°C, 
83°C 
 
TBP 
 
TBP F 
TBP R 
 
 
5’-GGTTTGCTGCGGTAATCAT-3’ 
5’-CTGGACTGTTCTTCACTCTTGG-3’ 
 
106 bp 
 
2 mM 
 
66°C 
 
72°C, 
83°C 
 
SDHA 
 
SDHA F 
SDHA R 
 
 
5’-TGGGAACAAGAGGGCATCTG-3’ 
5’-CCACCACTGCATCAAATTCATG-3’ 
 
86 bp 
 
2 mM 
 
64°C 
 
78°C 
 
HPRTI 
 
HPRTI F 
HPRTIR 
 
 
5’-TGACACTGGCAAAACAATGCA-3’ 
5’-GGTCCTTTTCACCAGCAAGCT-3’ 
 
100 bp 
 
3 mM 
 
65°C 
 
72°C, 
82°C 
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Table 23. Primers for SNP analysis of L33 gene Table 24. Primers for SNP analysis of L35 gene 
    
Primer Sequence Primer Sequence 
    
L33-5’UTR-F4 TGTATGTAAGGCCCAGTGGC L35-5’UTR-F2 AGCTTTCTGAAGGTTGGGAC 
L33-5’UTR-R4 GAGCCAGGTTTACATTTGAC L35-5’UTR-R2 GGGTCTTGCTTGAGGAGTAA 
L33-5’UTR-F3 GAGAGCCCGTGATAGCAAAG L35-5’UTR-F1 AGGAAGAAATGCCAAGACCA 
L33-5’UTR-R3 TATGGAAGCGCTAGCCAAGT L35-5’UTR-R1 TCTAGTAGATGGTGGCCAGA 
L33-5’UTR-F2 AAGAGCATCAAGGGGAAACA L35-5’UTR-F3 ACCCTGAAACTCCAGATCCT  
L33-5’UTR-R2 CTGTAGGAGTTGAGTTGGAG L35-5’UTR-R3 TTGATAAGGTAAGGGAGGAT 
L33-5’UTR-F1 AGCGAAACACTTCCTCCAGA L35-5’UTR-F4 TTACTCCTCAAGCAAGACCC 
L33-5’UTR-R1 GCATGGCTGATGAATCATTG L35-5’UTR-R4 AGGATCTGGAGTTTCAGGGT 
L33Ex1F TGTGGAGTGAGAAAGTGGGT L35Ex1F TTGCATTGGTGTGTGTGTTG 
L33Ex1R GGAGGCAAGAAAACAGGTCA L35Ex1R GAGCAAGAGAAGGCAAAGGT 
L33-IVS1-F1 TGACCTGTTTTCTTGCCTCC L35Ex1F1 GCTGCTGAAACACCTATTGC 
L33-IVS1-R1 TGCTTCGTCTCAACCTACTG L35Ex1R1 TGCATGTTAGTACACAGTAG 
L33-IVS1-F2 CAGTAGGTTGAGACGAAGCA L35-IVS1-F1 GTCCTCCTGCTTCCCACATA 
L33-IVS1-R2 GAAAACCTACCATCAGAGCC L35-IVS1-R1 ATCCCTCTCCCACCTCAATG 
L33-IVS1-F3 TCTCCTGTAGCCTTATGACC L35-IVS1-F2 TACGTGACTAAGCCCAGACC 
L33-IVS1-R3 TGATTGACAGATTCGGGGAC L35-IVS1-R2 GTTGAGCTTCTGAGCATTAC 
L33-IVS1-F4 GGCTCTGATGGTAGGTTTTC L35-IVS1-F3 CATGTCACTGGGGATTCTTG 
L33-IVS1-R4 AAATACTTGCCCTCTGTGTC L35-IVS1-R3 GAGTTCCATTGCTTCATCCT 
L33-IVS1-F5 TGTATTCCCTTTGCCCATCT L35Ex2F GACAAATCAAGCCTCCTCTA 
L33-IVS1-R5 GGTCATAAGGCTACAGGAGA L35Ex2R GGCAGGGCATTTAGTCAAGA 
L33-IVS1-F6 GTCCCCGAATCTGTCAATCA L35Ex3F GCCAAGAGGTGACAATAGTA 
L33-IVS1-R6 GATACCTTTTCTCTCGCTCT L35Ex3R AAGTCAGAGTTTAGGCATCC 
L33Ex2F TGTGTCCTCTGGCATAGCAA L35Ex4F1 CACCTTAGTCATTTTCTTGC 
L33Ex2R TCCTTTACCCTGCAACAACC L35Ex4R1 GTAGAGAGGACAATGGCAAG 
L33Ex3F GGTTGTTGCAGGGTAAAGGA L35Ex4F2 CTTGCCATTGTCCTCTCTAC 
L33Ex3R CATAGGGGTTCTTGGAGAGA L35Ex4R2 TTTCATGGGTCATGAGTGGG 
L33Ex4F TTGTGCATCGTTGTCCTGTAG L35Ex4F3 CCCACTCATGACCCATGAAA 
L33Ex4R GAACTGACTTTGCTGGTGAC L35Ex4R3 GCTTAATTCTCAACTGGCCA 
L33-Rev GGCAAGTCCGAAATCCATAG L35Ex4F4 TGGCCAGTTGAGAATTAAGC 
L33-IVS4-F1 GTCACCAGCAAAGTCAGTTC L35Ex4F5 GACAAGCTACCTCAACAGAC 
L33-IVS4-R1 CTGGATGACGCACTCTGAAC L35Ex4F6  TCAATGTAGCCTATGCAAGC 
L33-IVS4-F2 GCCCAGCACCAGGAATAATA L35Ex4R5  TCCATTTGTGCTCATCTCAG  
L33-IVS4-R2 GTCCATCCATTATTGGCATG L35-3’UTR-F1 GGAGAATGGGGTAATGACTG 
L33Ex5F TTGTCAACACTCCTTGGACG L35-3’UTR-R1 GCGATTTGGGGAGGTAGACT 
L33-3’UTR-F1 GGTGACAGAGGGCAACAAGT L35-3’UTR-F2 AGTCTACCTCCCCAAATCGC 
L33-3’UTR-R1 TAGGGCTGGATGAGGGTGAC L35-3’UTR-R2 AAATCCAGGGTAAAGTCAGG 
L33-3’UTR-F2 CCAACATTCACTGCCATTCTT L35-3’UTR-F3 AGCTCATTCTAAATCCCCAG 
L33-3’UTR-R2 CAGCCCACATTTCTCAACCT L35-3’UTR-R3 ATTCCTTCACCATTCACAGC 
L33-3’UTR-F3 CACTTCCTCCTCCCAAATCA   
L33-3’UTR-R3  AAACACACCAGTAGGAAAGC    
L33-3’UTR-F4 GTCACCCTCATCCAGCCCTA   
L33-3’UTR-R4 CAGGTATTCAGACCACATGC     
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Table 25. Primers for SNP analysis of L38 gene   
    
Primer Sequence   
    
L38-5’UTR-F3 GGCTGTATACCTGAGTCACC   
L38-5’UTR-R3 ATCATCTTCTTCCCCTTCTG   
L38-5’UTR-F2 AAAAGATTGCTCGGTGACAG   
L38-5’UTR-R2 TTTGCTTGCTTTGTGATGAC   
L38-5’UTR-F1 ATTCCTTGCCTGATGAGTTC   
L38-5’UTR-R1 CCTGAAATGTAACCACTGAT   
L38-5’UTR-R4 GCCTTATCTTCCACTACCCA   
L38Ex1F TTGGTGACTGAAGAAAGGTG   
L38Ex1R ATCAAAATCCCTCCCTGGTT   
L38-IVS1-F1 ATGCCTATCTTTGTCTTTCC   
L38-IVS1-R1 GTGAACACAGGGAATTCTGG   
L38-IVS1-F2 CGTGGTGTAAGTGTTTTCCC   
L38-IVS1-R2 GACTTCAACTTTTCCCTAAC   
L38Ex2F AGAGGGCGGTTTTTAGGTTC   
L38Ex2R AAAGCCCTAGATAAGAAGAG   
L38Ex2F1 GCAGGTAGGCCAGTGATTTC   
L38Ex2R1 AGCCTCCATCCTATTTATCC   
L38-IVS3-F1 CCCATCTACTCCTTTGCTTA   
L38-IVS3-R1 CCCACTATCACTTTCTCCTG   
L38-IVS3-F2  TTCTCACAACGACTATGCTG   
L38-IVS3-R2 CACATGAACAAACACACCAT   
L38Ex3F TTGCCATGTAGGCTGGTAGG   
L38Ex3R TAAGCAAAGGAGTAGATGGG   
L38Ex4F ATGGTGTGTTTGTTCATGTG   
L38Ex4R CTCTCCTAAATACTCGGCAG   
L38Ex5F GTATGTCTCCAGTAAGCACC   
L38Ex5R ATGGAAGCTCAGGGATCTGT   
L38-3’UTR-F1 TCTTCCCAAAACATCCCTGC   
L38-3’UTR-R1 GCAATCCACCAAACTTTAAG   
L38-3’UTR-F2 TTCTTTTGGTTAGGGTCTGG   
L38-3’UTR-R2 GCATTTGTCTCTTCCAGGCT   
L38-3’UTR-F3 GGGACTGAAAGATACAATGC   
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